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ABSTRACT 
BACKGROUND Extracellular matrix (ECM) remodelling related to arterial injury and healing 
after stenting contributes to both, in-stent restenosis and thrombosis. Despite its important 
clinical implications little is known about ECM changes post-stent implantation.  
 
METHODS Bare-metal (BMS) and drug-eluting stents (DES) were implanted in pig coronary 
arteries with an overstretch under optical coherence tomography guidance. Stented 
segments were harvested 1, 3, 7, 14 and 28 days post-stenting for proteomics analysis of 
the media and neointima. 
 
RESULTS A total of 151 ECM and ECM-associated proteins were identified by mass 
spectrometry. The composition of the neointimal ECM was more diverse than of the 
media, and proteins involved in regulating calcification were upregulated in the neointima 
of DES. After stent implantation the earliest changes in the media were proteins involved 
in inflammation and thrombosis, followed by changes in regulatory ECM proteins. By day 
28, basement membrane proteins were reduced in DES compared with BMS. In contrast, 
the large aggregating proteoglycan aggrecan was increased. Aggrecanases of the 
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family 
contribute to the catabolism of vascular proteoglycans. An increase in ADAMTS-specific 
aggrecan fragments was accompanied by a notable shift from ADAMTS1 to ADAMTS4 
expression after stent implantation. Immunostaining in human stented coronary arteries 
confirmed the presence of aggrecan and aggrecan fragments, in particular at the contacts 
of the stent struts with the artery. Further investigation of aggrecan presence in the human 
vasculature revealed that aggrecan and aggrecan fragments were more abundant in 
human arteries compared to veins. Also, aggrecan synthesis was induced upon grafting a 
vein into the arterial circulation, indicating an important role for aggrecan in vascular 
plasticity. 
 
CONCLUSIONS Significant differences were identified by proteomics in the ECM of 
coronary arteries after BMS and DES implantation, most notably an upregulation of 
aggrecan, a major ECM component of cartilaginous tissues that confers resistance to 
compression. The accumulation of aggrecan coincided with a shift in ADAMTS 
expression. This study provides the first evidence implicating aggrecan and aggrecanases 
in the vascular injury response after stenting. 
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1.1 Vascular biology, stent implantation and consequences 
1.1.1 Coronary artery disease and atherosclerosis: a clinical perspective 
Coronary artery disease (CAD) also known as ischemic heart disease is the most 
common cardiovascular disease and the leading cause of death worldwide.1, 2 It is 
characterized by an imbalance between myocardial oxygen supply and demand due to 
restricted blood flow to the myocardium. The chronic and common manifestation of CAD 
is stable angina pectoris resulting from coronary stenosis, which usually manifests with a 
characteristic chest pain upon exercise. The acute forms of the disease are the acute 
coronary syndromes (ACS), including unstable angina, ST-elevation myocardial infarction 
(STEMI) and non-STEMI (NSTEMI).  
Atherosclerosis is the underlying cause of CAD. While it was previously 
considered as a mere cholesterol storage disease3, atherosclerosis is now understood as 
a chronic progressive inflammatory disease. Atherosclerotic lesions start with early intimal 
thickening, progress to ‘fatty streaks’ as the correlate for infiltrating lipid-laden 
macrophage foam cells and gradually evolve into fibroatheromas, the characteristic 
plaques. Acute rupture or erosion of such a ‘vulnerable plaque’ is by far the most common 
cause of an ACS. Subsequent platelet activation and aggregation results in thrombus 
formation with the partial or complete occlusion of the coronary arterial lumen.  
Numerous landmark studies, with the Framingham Heart Study leading the way, 
have identified several risk factors for developing CAD, with dyslipidaemia and current 
smoking being the most influential ones.4 Thus, the prevention of modifiable risk factors 
remains the first-line measure against CAD. However, primary prevention with drugs is 
indicated in patients with higher risk for developing cardiovascular events to prevent 
progression of atherosclerosis.5 These include lipid-lowering drugs such as statins or the 
recently approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in case 
of insufficient statin therapy6, 7, as well as angiotensin converting enzyme (ACE) inhibitors. 
Antiplatelet therapy with low-dose aspirin is effective for the secondary prevention of 
cardiovascular events. The cornerstone therapy for symptomatic disease are antianginal 
drugs, i.e. cardioselective b-blockers reducing myocardial oxygen demand, nitrates and 
calcium channel blockers and additional dual antiplatelet therapy in ACS. Nevertheless, 
coronary revascularization is indicated for severe disease. Though surgical 
revascularization is primarily chosen for patients with multivessel disease, the less 
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invasive coronary angioplasty/percutaneous coronary intervention (PCI) has emerged as 
the standard of care for coronary revascularization in recent years. 
1.1.2 Pathophysiology of native atherosclerosis 
The substrate for coronary angioplasty is generally an atherosclerotic plaque in the vessel 
wall. For comparison, the wall structure of a physiologic coronary artery is shown in Figure 
1A. It consists of three layers: intima, media and adventitia. The intima comprises an 
inconspicuous monolayer of endothelial cells (ECs) with an underlying basal lamina, 
which lines the arterial lumen and is therefore crucial for an integral vessel. The intima is 
separated from the underlying media, which consists of multiple layers of smooth muscle 
cells (SMCs) and elastin, by the internal elastic lamina. The media is separated from the 
adventitia by the external elastic lamina. Finally, the adventitia is mainly composed of 
fibroblasts and loose extracellular matrix (ECM). The vascular ECM content is explained 
in chapter 1.2.2 in detail.  
Atherosclerosis is a progressive inflammatory disease in the vessel wall8, 
predominantly affecting the intimal layer. Though a systemic vascular disease, 
atherosclerotic plaques are not uniformly distributed.9 This is likely due to the local 
biomechanical forces acting within the artery. Arterial regions that are exposed to 
disturbed blood flow e.g. curvatures and bifurcations result in low shear stress, which 
induces plaque development and progression. Regions of disturbed flow are associated 
with both increased EC proliferation and apoptosis, higher permeability, increased 
expression of inflammatory mediators and production of reactive oxygen species (ROS).10 
Atherogenesis comprises the four stages of adaptive intimal thickening, intimal xanthoma 
(fatty streak), pathological intimal thickening and fibroatheroma (modified AHA 
classification) (Figure 1B).11 The first stage is often observed in atherosclerosis-prone 
arteries and is considered as rather physiological. It describes the natural accumulation of 
SMCs in the absence of lipid or macrophage foam cells. The actual atherosclerotic lesion 
formation is commonly triggered by endothelial dysfunction and subendothelial lipoprotein 
retention usually at vascular regions with disturbed blood flow.12 The highly negatively 
charged glycosaminoglycan (GAG) side chains of proteoglycans are postulated to interact 
with lipoproteins and contribute to their retention, initiating and maintaining 
atherosclerosis.13, 14 Recruited blood monocytes differentiate into macrophages and 
eventually into foam cells upon internalization of the retained lipoproteins, resulting in so 
called ‘fatty streaks’ (stage two). Lesion progression involves SMC proliferation and 
phenotypic switching with the accumulation of ECM and lipid material (stage three or 
pathological intimal thickening). The ECM is mainly composed of hyaluronan, collagen 
type III and proteoglycans (biglycan, versican, decorin) with a lipid pool and free 
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cholesterol. Eventually these lesions develop into fibroatheromas and characteristic 
plaques (stage four). Fibroatheromas are characterized by an acellular necrotic core with 
a fibrous cap. The necrotic core is generated by macrophage infiltration into lipid pools 
and their apoptosis and necrosis, hence it coined the term ‘grave yard of macrophages’. 
Based on the composition of the core it can be divided in an early and late stage, as the 
necrotic core develops and expands. The necrotic core of late fibroatheromas is large and 
poor in ECM, probably due to degradation by metalloproteinases (MMPs) and ADAMTS 
proteases (a disintegrin and metalloproteinase with thrombospondin motifs). Furthermore, 
the late core exhibits extensive cellular debris and sometimes also calcification and 
intraplaque haemorrhage. 
The fibrous cap above the necrotic core is the critical component of a 
fibroatheroma, which determines its stability. Thick fibrous caps are usually ECM-rich 
interspersed with SMCs, which at this stage are regarded to have plaque-stabilizing 
properties. On the other hand, thin-cap fibroatheromas (TCFA) or ‘vulnerable plaques’ are 
more prone to rupture and predominantly infiltrated by macrophages with potential 
protease release but have hardly any SMCs. However, recent studies suggest that this 
concept may be too simplistic as it postulates a homogenous population of SMCs within 
the plaque.15 On the contrary, recent genetic lineage tracing studies have demonstrated 
that SMC phenotypic switching may also result in macrophage-like-cells.16 These SMC-
derived cells lack the classical set of SMC markers, but express macrophage markers, 
which is why traditional methods such as immunostaining have failed to identify their 
origin. The protective role of SMC in the cap is attributed to their ability to repair 
subclinical plaque rupture by proliferating and synthesising ECM. Indeed, episodes of 
plaque disruption and subsequent healing have been observed on plaques.17 Thus, 
plaque progression has also been suggested as a result of such episodes of silent rupture 
and healing. Similarly, plaque evolution is not always a linear process as depicted above. 
A serial intravascular ultrasound study showed that while some plaques transformed into 
advanced lesions with thin fibrous caps, others regressed and healed over time.18 Thus, 
prediction of a plaque rupture from imaging alone remains challenging. A recent tissue-
based proteomics study from our group identified a 4-biomarker signature, including 
matrix metalloproteinase 9 (MMP9), S100A8/S100A9, lysosomal cathepsins and galectin-
3-bining protein), with differential expression between symptomatic compared to 
asymptomatic plaques.19 This 4-biomarker signature was subsequently measured in 





Figure 1. Vascular wall in health and disease (A) Coronary artery wall structure. The physiologic 
arterial wall structure is depicted. Adapted from Blausen.com staff in Medical gallery of Blausen Medical 
2014. (B) Atherosclerotic lesion morphologies. Atherosclerosis is a progressive inflammatory 
disease of the vessel wall comprising the four stages of adaptive intimal thickening, intimal xanthoma 
(fatty streak), pathological intimal thickening and fibroatheroma. Adapted from Yahagi et. al in Nature 
Reviews Cardiology, 2016.11 
1.1.3 PCI: from plain balloon angioplasty to biodegradable coronary stents 
PCI has become the reperfusion treatment of choice for CAD, representing one of the 
greatest therapeutic advances in medicine. Since the introduction of coronary angioplasty 
by Andreas Grüntzig et al. in 1977 the techniques and equipment used for PCI have been 
widely refined.20 The general principle, however, remains the same: an inflatable balloon 
catheter is inserted through a peripheral artery under local anaesthesia and is gradually 
expanded to dilate an obstructed coronary artery, thus restoring blood flow and ensuring 
myocardial blood supply. In the early days of PCI, restenosis of dilated vessels occurred 
in 30-60% of cases and has limited the use of plain balloon angioplasty.21 Restenosis in 
these days was a result of contractive recoiling, as well as neointima and constrictive 
remodelling22, 23, which required a further revascularization procedure. In order to prevent 
acute recoil, stents have been introduced. Stents are usually metallic scaffolds placed into 
the stenosed artery segment to hold it open (Figure 2).24 The earliest form of stents were 
INTRODUCTION 
 17 
bare-metal stents (BMS). Stent implantation has significantly reduced the incidence of 
restenosis as demonstrated by randomized clinical trials by the mid 1990s and largely 
obviated the need for emergency bypass surgery.25, 26 With the widespread use of stent 
implantation, the restenosis frequency decreased to 15-30%.27 By the late 1990s, stents 








Figure 2. Coronary artery stenting. (A) In PCI, an inflatable 
balloon catheter surrounded by a compressed stent is inserted into 
the stenosed coronary artery through a peripheral artery. (B) The 
balloon is gradually inflated, which compresses the plaque against 
the vessel wall and expands the stent. (C) The balloon is then 
deflated and the catheter can be removed. (D) The stent remains at 




Although stent implantation has become a standard of care for coronary revascularization, 
in-stent restenosis (ISR) due to neointimal hyperplasia as well as subacute thrombosis 
emerged as complications associated with stents.29 Neointimal hyperplasia involves 
luminal narrowing due to SMC proliferation and ECM deposition.30 To overcome stent-
mediated neointimal proliferation, drug-eluting stents (DES) have been developed and 
resulted in a further reduction of restenosis and repeat-revascularization compared with 
BMS.31-33 However, long-term safety and efficacy studies on these so called first-
generation DES (sirolimus- and paclitaxel-eluting stents) have revealed that DES are 
linked to an increased late stent thrombosis (LST) rate and demonstrated failure to 
improve mortality.34, 35 LST has been associated with impaired re-endothelialisation, as 
well as induction of inflammation due to durable polymer coatings on stents, resulting in a 
need for prolonged dual antiplatelet therapy. Continuous development in stent design with 
regards to eluted drugs, stent platforms as well as polymer coatings lead to the 
introduction of second-generation DES (zotarolimus- and everolimus-eluting stents). 
These stents are characterized by thinner struts, more deliverable novel anti-proliferative 
agents and biocompatible polymers aiming at minimizing the vascular inflammation and 
accelerating vessel re-endothelialisation. Indeed, restenosis and thrombosis rate with 
these newer generation DES were lower in the first two years of use.36, 37 Another 
development in stent technology introduced biodegradable polymers as well as fully 
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biodegradable scaffolds on the basis of poly-L-lactic acid (PLLA) or magnesium alloys.38-40 
The rationale behind biodegradable stents is to provide initial mechanical support as the 
vessel heals but to dissolve over time to restore native vessel integrity. Thus, 
biodegradable stents may address some of the caveats associated with metallic DES, 
such as LST, restenosis and impaired vasomotion of the stented segment.41 Their safety 
and efficacy profile is still being evaluated in large randomised clinical trials. However, the 
result of the first meta-analyses of current generation biodegradable scaffolds compared 
with metallic everolimus-eluting stents was not in favour of biodegradable scaffolds.42 As 
these are only the first generation biodegradable stents further research is required for 
this technology.43  
1.1.4 DES characteristics 
Since SMC proliferation with subsequent ECM accumulation is critical to neointimal 
hyperplasia, the design of DES focused on inhibiting SMC proliferation. Moreover, the 
drugs have immunosuppressive effects as they also inhibit the proliferation of immune 
cells. This concept has been a key advance in restenosis reduction, as previous attempts 
of systemic anti-inflammatory treatment have failed in humans.27, 44 Compared with BMS, 
which are simply a metallic stent platform, DES consist of three components: usually a 
metal stent platform, a polymer coating and an antiproliferative agent. Most stents are 
made of stainless steel or cobalt chromium alloys releasing the drug over a period of 
weeks or month.45 In Xience Vâ, the everolimus-eluting coronary stent system of Abbott, 
80% of the drug is delivered within the first month.46 The maximum time to everolimus 
disappearance from blood is seven days47, ensuring a predominant local rather than a 
systemic effect. 
The potent antiproliferative DES agent sirolimus and its analogues zotarolimus and 
everolimus act by inhibiting the activation of the mammalian target of rapamycin (mTOR), 
eventually causing cell cycle arrest. On the other hand, paclitaxel acts by inhibiting the 
disassembly of microtubules, which form the mitotic spindle during cell division, thereby 
inducing mitotic arrest.48 
1.1.4.1 Molecular basis of mTOR regulation and inhibition 
Cell growth and proliferation depends on the availability of sufficient amino acids and 
energy metabolites for protein synthesis.49 The mTOR signalling pathway is crucial for this 
regulation (Figure 2). mTOR in complex controls protein synthesis and cell division in 
response to resources availability and mitogenic stimuli. The mTOR complex 1 (mTORC1) 
contains the highly conserved protein kinase mTOR, raptor (regulatory associated protein 
of mTOR) and LST8. mTORC1 targets components of the translation machinery, such as 
eukaryotic translation initiation factor 4E-binding protein (4E-BP). Its phosphorylation and 
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release by mTORC1 allows the initiation of translation. Besides nutrients such as amino 
acids, growth factors activate mTORC1, mainly via the phosphatidylinositol 3-kinase 
(PI3K) / AKT pathway. AKT activates mTOR in complex 1 indirectly by phosphorylating 
other upstream proteins in the cascade. The Ras/ERK signalling pathway has also been 
shown to activate mTORC1 signalling. Everolimus and its analogues are inhibitors of 
mTOR signalling pathway. The drug forms a complex with the cytoplasmic protein FKBP-
12 (FK 506 binding protein).47 The generated complex is a highly potent and specific 
inhibitor of mTOR, through direct binding to mTORs FRB (FKB12-rapamycin-binding) 
domain. Eventually the inhibition of the mTORC1 results in cell growth and proliferation 
inhibition.  
 
Figure 3. Simplified schematic representation of mTORC1 signalling. Mammalian target of 
rapamycin complex 1 (mTORC1) is stimulated in response to nutrient and energetic resources 
availability, as well as by growth factor signalling. Upon phosphorylation and release of eukaryotic 
translation initiation factor 4E-binding protein (4E-BP) by mTORC1 translation is initiated, allowing cell 
growth and proliferation. Everolimus and its analogues are inhibitors of mTOR signalling pathway.  
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1.1.5 Biology of restenosis and stent thrombosis 
Stent implantation causes mechanical vascular injury, disrupting the endothelial layer in 
the arterial wall, which is generally previously impaired by the presence of a coronary 
atherosclerotic plaque. This may heal adequately over time or in case of inadequate re-
endothelialisation result in restenosis or occasionally in thrombotic occlusion (LST).  
Despite continuous development and improvement in stent technology, LST and 
especially ISR remain a considerable cause of treatment failure after PCI.50 Large-scale 
angiographic surveillance studies with over 10, 000 patients estimated the restenosis rate 
at approximately 12% with newer generation DES.51, 52 On the other hand, very recent 
randomized trials without angiographic surveillance showed rates of clinically relevant 
restenosis of <5% at 1 year post-stenting.53 However, despite low ISR rates in relative 
terms, the absolute number of patients presenting with stent failure is still significant since 
stenting has become a very common procedure and their management is challenging. 
Overall rates of early and late stent thrombosis are even lower with 1.5%, owing to 
adequate antithrombotic therapy.54 
1.1.5.1 In-stent restenosis 
Angiographic restenosis is defined as luminal area narrowing of more than 50% by 
neointimal tissue.50 Using intravascular ultrasound (IVUS) or optical coherence 
tomography (OCT), restenosis is defined as re-narrowing of more than 75% of the vessel 
area in cross-section, as these modalities acquire data in three-dimensions. Restenosis 
upon PCI is well characterized as a distinct pathophysiological process of its own entity 
rather than an accelerated form of atherosclerosis.50 The contributing factors are divided 
in five categories: 1. prolapse of the disrupted plaque, 2. elastic recoil of the vessel wall, 3. 
constrictive vascular remodelling, 4. neointimal hyperplasia and 5. neoatherosclerosis. 
While the first three factors were mainly prevented by the introduction of stents, the latter 
two largely evolved due to stent-induced vascular injury with or without drugs, playing the 
major role in ISR development. Thus, according to the current understanding the 
substrate of ISR ranges from neointimal hyperplasia to neoatherosclerosis. However, 
stent underexpansion is also a common cause for restenosis. Finally, restenosis between 
BMS and DES is considerably different, not only in composition of the neointimal tissue55, 
but also in the time-course of the appearance of ISR.56 
 
Mechanisms of neointimal hyperplasia 
Vascular stent injury with inadequate re-endothelialisation and healing results in 
neointimal hyperplasia. Neointima formation involves the interaction between platelets, 
inflammatory cells, ECs and SMCs. It can be divided into an early (days to weeks) and a 
INTRODUCTION 
 21 
late phase (weeks to months): the early phase is characterised by platelet activation and 
inflammation; the late phase by SMC migration and proliferation resulting in ECM 
remodelling.57 Under physiologic circumstances, the intact endothelial monolayer 
maintains an antithrombotic and anticoagulant surface, which is crucial for vessel patency. 
This monolayer is established by intercellular junctions regulating endothelial permeability. 
Besides the linkage of ECs with each other by transmembrane proteins such as occludin 
and claudin, integrins are responsible for the adhesion of the ECs to the subendothelial 
ECM proteins such as fibronectin and vitronectin. Both interactions are equally important 
for vascular integrity. Further, the endothelial surface is maintained by the production of 
molecules with antithrombotic properties, including but not limited to nitric oxide (NO), 
prostacyclin, tissue plasminogen activator, thrombomodulin, heparin-like molecules and 
tissue-factor pathway inhibitor.58 As explained above, the underlying pathology for 
stenting, atherosclerosis per se is accompanied by EC dysfunction, not only in disease 
initiation but also in lesion progression.59 However, upon balloon dilatation and vascular 
stenting the endothelial integrity is severely disrupted (complete to partial denudation of 
the EC layer) and the antithrombotic surface is impaired. This results in crushing and 
lifting of the plaque from the underlying arterial wall with subsequent exposure of the 
subendothelial matrix, but also in tearing and stretching of the medial wall.60  
Thus, the initial response to mechanical damage with endothelial denudation and 
matrix exposure is fibrin and platelet deposition. Platelets adhere due to exposure of 
collagens. Histologic studies have identified fibrin-rich thrombi around stent struts one day 
post BMS implantation.60 Platelet activation is accompanied by recruitment of circulating 
leukocytes reacting to stent struts. Their interaction is crucial for the initiation and 
progression of neointimal formation. Endothelial adhesion molecules such as VCAM-1, 
ICAM-1 and E-selectin are expressed on regenerating ECs upon pro-inflammatory 
cytokine release such as interleukin-1 (IL-1) or tumor necrosis factor-a (TNF-a) via the 
nuclear factor-kB (NF-kB) pathway.59 These adhesion molecules induce their attachment 
and transmigration across surface-adherent platelets eventually aggravating vascular 
inflammation.30 Notably, in stented human vessels vascular inflammation is already 
present due to the underlying atherosclerotic lesion. Besides platelets, leukocytes 
contribute to the secretion of growth factors and cytokines and induce SMC proliferation. 
These factors include fibroblast growth factor (FGF), insulin-like growth factor (IGF), 
transforming growth factor beta (TGF-b) platelet-derived growth factor (PDGF) and 
vascular endothelial growth factor (VEGF). Activated by growth factors/cytokines, SMC 
migrate from the media towards the intima and their subsequent proliferation initiates the 
remodelling phase. These changes require a phenotypic switch of SMCs from a 
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contractile to a synthetic phenotype producing excessive ECM, eventually resulting in 
neointimal hyperplasia.60 A schematic illustration of the mechanisms of thrombosis and 
restenosis upon stent implantation is provided in Figure 4. The precise role of ECM in 
restenosis will be elucidated in section 1.2.4.2.  
 
Figure 4. Mechanisms of thrombosis and restenosis upon stent implantation. Stent implantation 
inevitably causes mechanical vascular injury and endothelial denudation. Consequent exposure to 
subendothelial matrix induces platelet activation, which may result in thrombotic occlusion. At the same 
time excessive local inflammation is triggered, which stimulates SMC proliferation and ECM deposition 
leading to neointimal proliferation, thus restenosis. Antiplatelet therapy and antiproliferative agents on 
DES are used as preventive measures. 
 
1.1.5.2 DES thrombogenicity  
The substantial reduction of restenosis rates with DES came at the expense of increased 
risk for late (30 days up to 1 year) and very late (after 1 year) stent thrombosis.35, 61 Stent 
thrombosis is defined as an abrupt thrombotic occlusion of a previously patent stent. It is a 
rare but a serious complication that can cause sudden death or acute coronary 
syndromes. Thus, the application of prolonged dual antiplatelet therapy following DES 
deployment is indicated and improves long term safety of DES as demonstrated in large 
clinical trials.62 Overall rates of early and late stent thrombosis are currently low with 1.5%, 
owing to adequate antithrombotic therapy.54 Premature discontinuation of antiplatelet 




Mechanisms of thrombogenicity of DES 
The thrombogenicity of DES has been explained with delayed/impaired re-
endothelialisation.64, 65 The antiproliferative agents inhibit the proliferation of both SMCs as 
well as ECs, thus delaying re-endothelialisation and arterial healing. Vessels with 
incompetent endothelial cells, which are characterized by poor cell-to-cell junctions and 
reduced secretion of antithrombotic molecules, are more prone to thrombosis and 
neoatherosclerosis development.58 Besides EC dysfunction and impaired re-
endothelialisation, stent-induced shear stress increases thrombogenicity and 
inflammation.66 Uncovered stent struts protruding into the vessel lumen alter blood flow 
and result in spatiotemporal changes in local shear stress distribution. High shear can 
activate platelets through the release of thromboxane A2 and ADP. Additionally, durable 
DES polymer coatings can induce excessive inflammation and hypersensitivity reactions, 
which have been suggested as another cause for thrombogenicity.65 Furthermore, 
recently rupture of neoatherosclerotic plaques have been associated with very LST.56 
 To overcome the limitations of ISR and LST, new DES technologies focus on 
development of drugs that can selectively inhibit SMC proliferation while allowing re-
endothelialisation.67, 68 Common and unique environmental cues that regulate EC versus 
SMC proliferation need to be explored. ECM proteins are likely to impact these processes. 
1.1.5.3 In-stent neoatherosclerosis 
In recent years in-stent neoatherosclerosis has been increasingly recognized as an 
important substrate for late stent failure for both BMS and DES, especially in the extended 
phase.69, 70 Initial evidence for neoatherosclerosis came from intravascular imaging71, 72 
and histopathologic studies.56 Neoatherosclerosis is the development of atherosclerosis in 
stented vessels. It is defined as the accumulation of lipid-laden macrophage foam cells 
within the neointima of stented arteries, with or without necrotic core formation or 
calcification or thrombosis.73 Notably, the development of in-stent neoatherosclerosis has 
been considered independent from the underlying native atherosclerosis, as there is no 
communication between the neointima and the underlying lesion.69 Furthermore, it was 
shown that neoatherosclerotic plaques originate and remain within the stented area and 
are less likely to be an extension of native disease from proximal or distal non-stented 
segments.69 In a recent study, however, neoatherosclerosis was found to be more 
common in patients with concurrent progression of native atherosclerosis, as 
demonstrated with angiographic evidence during a 5 year follow-up period.74 This finding 
suggests that similar pathophysiological mechanisms are at work for native and de novo 
atherosclerosis. The main difference between native coronary atherosclerosis and in-stent 
neoatherosclerosis is the time-course for lesion development. While native atherosclerosis 
INTRODUCTION 
 24 
takes decades to develop, neoatherosclerosis is seen over a period of months to only a 
few years. 
There are major differences in neoatherosclerosis formation between BMS and 
DES with regard to its incidence and temporal onset. Neoatherosclerosis seem to occur 
more rapidly and frequently in DES than BMS.69 The first indication for neoatherosclerosis 
is considered as the accumulation of lipid-laden foam cells frequently around the stent 
struts. In an autopsy study the earliest time-point for their detection was four months after 
implantation of first generation DES (sirolimus-eluting-stent, SES), but occurred only after 
two years in BMS and remained a rare phenomenon up until 4 years.56 The order for the 
appearance of a fibroatheroma with necrotic core was similar in both types (1 year SES 
vs. 2.5 years for BMS). Beside the accelerated onset in DES, the incidence of 
neoatherosclerosis was also significantly greater in DES (31%) than in BMS (16%).56 
Surprisingly, however, there was no difference in the incidence of neoatherosclerosis 
between first and the second-generation everolimus eluting stent, though the latter 
demonstrated a later onset with 9 months after implantation.75 
 These findings suggest a triphasic luminal response after BMS implantation, with 
an early restenosis due to neointimal hyperplasia, an intermediate regression upon 
complete healing and a late luminal re-narrowing likely due to neoatherosclerosis beyond 
four years.70 On the other hand, DES show a continuous neointimal growth during long-
term follow-up, after an initial suppression of intimal growth, coined the “late catch-up” 
phenomenon.70 
 
Mechanisms of neoatherosclerosis   
The precise mechanisms of neoatherosclerosis formation, and especially their accelerated 
onset in DES remains unknown to date and is likely to be multifactorial. However, the 
delayed and incomplete re-endothelialisation with impaired EC function is thought to be 
crucial in this process. It is suggested that the impaired barrier function is responsible for 
an excessive entrance of lipoproteins and subsequent macrophage infiltration into the 
subendothelial layer.69, 73 Furthermore, the greater accumulation of ECM proteoglycans in 
DES55 is likely to contribute to lipoprotein retention due to interactions with their GAG side 
chains.14 Moreover, shear induced EC phenotype changes (mechanotransduction) with 
expression of adhesion molecules might further allow inflammatory cell attachment.56 
Polymer associated chronic inflammation is likely to be another contributing factor. 
Furthermore, the established link between platelet activation and inflammation might 
contribute to accelerated neoatherosclerosis in DES, since thrombogenicity is increased in 
DES for the reasons highlighted above. Finally, clinical risk factors have been identified for 
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increased neoatherosclerosis risk, such as younger age, longer implant duration and 
stenting for acute myocardial infarction.56  
1.1.5.4 miRNAs in restenosis 
Recent studies have shown that miRNAs are also critically involved in neointimal 
hyperplasia upon vascular injury.76, 77 miRNAs are small, highly conserved noncoding 
RNAs, which are around 22 nucleotides long.78 They are involved in the 
posttranscriptional regulation of protein expression. miRNAs act by binding to the 
untranslated region of mRNAs (3’UTR) with their seed region, which either induces 
degradation of the target mRNA or silences its translation dependent on the base 
complementarity. They originate from primary transcripts (pri-miRNAs) of either introns of 
protein coding genes, or noncoding genes, which are then processed by the 
endonucleases Drosha and Dicer.79 The primary transcript is folded to a double-stranded 
hairpin structure, called pre-miRNA, in the nucleus and is then cleaved and unwinded to 
two single strands (the guide and passenger strand) upon transport in the cytoplasm. The 
mature miRNA strand is loaded into the RNA-induced silencing complex (RISC), which is 
directed to its target mRNA preventing its translation. The fact that a single miRNA can 
supress multiple target genes, and again the same gene can be supressed by different 
miRNAs, presents a challenge in untangling miRNA functions.  
 The importance of miRNAs in neointimal hyperplasia is mainly supported by their 
association with the phenotypic modulation of SMCs.80 miR-21 induces neointimal growth 
through proliferative and antiapoptotic effects on SMCs.77 miR-221 and miR-222 were 
also found to regulate SMC phenotype.81 miR-143/-145 promote differentiation and 
repress proliferation of SMCs, thus inhibit the switch from contractile to the synthetic 
phenotype.82 Similarly, endothelial miRNAs were shown to be modulated after vascular 
injury. miR-126, which is highly enriched in ECs, is involved in VEGF signalling and EC 
dysfunction.83 A recent clinical study found that transcoronary gradients of miR-126 and 
miR-145 correlated with the extent of TCFAs, suggesting that instable plaques might 
affect the local uptake or degradation of these miRNAs.84 
1.1.6 Animal models of coronary stenting 
For coronary stenting different animal models are available including rabbit, sheep, dog 
and pig. While in large animals the coronary artery itself is used for stenting, in smaller 
animals, such as mouse and rabbit, generally the aorta is stented. The pig coronary 
stenting model is a gold-standard for evaluating safety, but is also useful to gain insight 
into biology of stenting, as it most closely simulates human disease.60 It is the most useful 
and practical model.85 However, its major limitation is the absence of atherosclerosis, 
which can be addressed by using genetically modified pigs with lipid alterations. The 
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porcine PCI model is performed in a similar way to the clinical procedure. All three arteries 
(the anterior descending artery, the circumflex branch and right coronary artery) can be 
used for stent deployment. Generally, disease-free juvenile animals weighing between 20-
30kg are used for reasons of practicality, availability and cost. The nature and severity of 
the injury determines the vessel response.85 For example, with balloon denudation, a 
superficial endothelial injury can be created or a focal deep tear with asymmetric healing 
and formation of a neointima. On the other hand, stent implantation imposes a long-lasting 
stretch upon the artery, with a more symmetrical neointima. By using deep injury with 
metal wire coils with an oversized high-pressure balloon a model of proliferative human 
restenosis is mimicked.86 Generally, the neointima formation in the porcine model is 
complete by 28 days.  
1.1.7 Optical Coherence Tomography 
Optical coherence tomography (OCT) is a real-time intravascular imaging modality based 
on near-infrared light.87 It has an excellent resolution allowing an accurate characterization 
of coronary artery morphology revealing vascular pathology, such as plaques and 
response to coronary stents. OCT image resolution (axial 10 µm, lateral 20 µm) is an 
order of magnitude greater than the commonly used intravascular ultrasound (IVUS) (100-
200 µm), as it uses light as energy source instead of sound. However, its tissue 
penetration (1-2.5 mm) is lower compared to IVUS (10 mm). Currently OCT is rather 
utilized for research than for routine clinical practice.  
Images are generated by directing a low-coherence, near-infrared light of 1.3 µm 
wavelength at the target tissue. Light is emitted from a distal tip of an optical fibre located 
within the imaging catheter and images are acquired, as the catheter is sequentially pulled 
back. The interferometer splits the light beam into a sample and a reference arm.88 While 
the reference arm is directed to a mirror, which reflects the light directly back to the 
interferometer, the light of the sample arm is absorbed, refracted or reflected from the 
sample tissue because of its varying optical impedances. The scattered/reflected light 
travels back to the interferometer and interacts with the reference light. The interaction 
between these two light waves are then measured by the detector and determine the OCT 
image (Figure 5A). OCT requires a blood-free zone for imaging, because erythrocytes 
strongly scatter light, thus attenuate the image. Current instruments utilize a non-occlusive 
contrast flushing method to create a blood-free zone, inducing a transient ischemia. 
Overall, it is a safe technique with 0.2% incidence of vessel dissection due to the imaging 
system.87 Also coronary spasms appear to be less than 1% when intracoronary 
nitroglycerin is administered prior to image acquisition.  
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1.1.7.1 OCT image features 
The normal coronary artery is visualized with its three layers on OCT: The intima and 
adventitia appear as a signal-rich band with the media as an area of low signal intensity 
in-between. The internal and external elastic lamina can be distinctly defined as signal-
rich thin bands within the dark band of the media (Figure 5B). OCT assessment of intimal 
thickness is highly accurate, allowing to detect intimal thickening due to lipid deposition as 
an early indication for atherosclerosis. Coronary plaques are detected by focal thickening 
and loss of the normal vessel architecture. While fibrous plaques produce a relatively 
homogenous and highly backscattering signal, calcified plaques appear signal poor with 
sharply delineated borders.88 The fibrous cap is typically a homogenous signal-rich band 
overlying the signal-poor lipid core. The minimal thickness of the fibrous cap is relevant to 
determine TCFA. OCT plaque characterization of atherosclerotic arteries in autopsy 
samples and additional histology characterization as the gold standard revealed a high 
correlation in terms of sensitivity and specificity (overall agreement kappa=0.83).89 
However, false-negative diagnosis of lipid pools was frequent, which was attributed to the 
limited penetration of OCT. Thus, lipid pools were misinterpreted as fibrous plaques. Also 
OCT is prone to artefacts.88 
1.1.7.2 OCT and restenosis 
Due to its high-resolution OCT is a powerful tool for the long-term follow-up of stenting, to 
assess stent strut apposition, tissue coverage and neointimal growth and composition. 
Metal stent struts are highly reflective and generate a strong signal with shadowing behind 
the stent strut (‘blooming’), while this is not seen in bioabsorbable stents.87 Beyond 
assessing the extent of tissue coverage (neointima measure from the inner stent strut 
surface to the luminal surface), OCT can be utilized for the diagnosis of ISR and therapy 
guidance. It is well-suited to primarily distinguish precisely between the two principal 
causes of restenosis: stent underexpansion (for example due to undersizing or low 
deployment pressure) and neointimal hyperplasia.50 This distinction is helpful to guide the 
therapy, as the latter is treated by repeat stenting or drug coated balloon angioplasty, 
while aggressive non-compliant balloon angioplasty is required for stent 
underexpansion.51 Due to lower tissue penetration of OCT compared to IVUS external 
elastic lamina is not always well imaged hampering accurate vessel sizing. On the other 
hand, its better resolution allows accurate characterization of neointimal tissue, including 
neoatherosclerosis, which is limited with IVUS. Restenotic tissue is categorized into three 
main groups by OCT: homogenous, heterogeneous or layered.90, 91 Homogenous 
describes the uniform high signal intensity with low back scatter, typical of areas of high 
SMC composition. This pattern was found to be typical for BMS restenosis. 
INTRODUCTION 
 28 
Heterogeneous displays a mixed signal intensity, which may represent proteoglycan-rich 
neointimal, granulation tissue or early neoatherosclerotic plaques. Layered is seen as 
superficial high signal intensity and deep low signal intensity often in peristrut areas. A 
fourth category, ‘attenuated’ is likely indicative of lipid-core plaques. The last three 
patterns are more commonly seen in DES restenosis and may represent delayed vessel 
healing or neoatherosclerosis. Although systematic OCT deployment sounds attractive for 
ISR intervention, there is no clinical trial evidence supporting its clear advantage.50 




Figure 5. OCT principles. (A) The principles of OCT image acquisition are illustrated. (B) OCT image of 
normal coronary artery. (a) OCT catheter in overview image is marked with arrow. * indicates shadow 
artefact of guide wire. (b) The three arterial layers are revealed in the magnified image. Adapted from 
Abtahian et al. in Cardiovascular Intervention, 2016.87 
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1.2 Vascular ECM 
1.2.1 Basic ECM features 
The ECM is the highly interactive and dynamic network of non-cellular components 
present within all tissues. It consists of structural and regulatory proteins and is constantly 
remodelled to control tissue homeostasis.92 Its composition is unique to every tissue and 
contributes significantly to the tissue properties. For example, the vascular ECM mainly 
defines the mechanical and physical properties of the vasculature. It is designed to 
provide elastic recoil.93 The ECM is well known for its ability to provide structural support 
to tissue and organs. However, beyond their physical functions for tissue integrity, the 
ECM proteins play important non-structural roles in cell differentiation, proliferation, 
survival and migration, as well as cell-to-cell communication.94 Importantly, the ECM is 
involved in binding and retention of soluble bioactive molecules including lipoproteins, 
growth factors, cytokines, proteases and protease inhibitors. Thus, matrix signalling 
regulates the microenvironment, in which the cells are embedded in. 
The importance of the ECM is illustrated by the numerous pathologies related to 
ECM dysfunction. For the vasculature, the loss of ECM integrity is associated with 
weakening of the vessel wall and can even lead to its rupture in the case of aneurysms.  
The ECM is constantly remodelled through synthesis, degradation and chemical 
modification.92 Maintaining the appropriate balance of ECM synthesis and degradation is a 
continuous process and needs to be tightly regulated in the vasculature. Increased ECM 
deposition is associated with neointimal hyperplasia and restenosis. On the other hand, 
excessive matrix degradation is linked to plaque rupture and aneurysm formation. 
1.2.2 Composition of the vascular ECM 
The vascular ECM is predominantly produced by SMCs in the vessel media, though the 
cells of the remaining vascular layers, namely ECs and fibroblasts also produce ECM.95 
The vascular ECM is composed of elastin, collagens, proteoglycans and glycoproteins. 
ECM proteins are characterized by their multidomain structure. Domains are defined as 
homolog sequence units and are highly conserved.96 Individual domains may have distinct 
functions, and exert their function even after fragmentation. Thus, the combination of 
different domains provides multiple functions to ECM proteins. Moreover, due to the 
domain interactions the formation of fibres and other large ECM protein assemblies are 
favoured. Enzymatic processing of ECM proteins for example by MMPs, can release 
proteolytic ECM fragments with biological activity, so called ‘matrikines’.97, 98 The 
functional properties of ECM proteins are further altered by glycosylation (Table 1), the 
most complex post-translational modification. Beside the role of glycosylation in correct 
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protein folding and degradation protection, glycosylation significantly contributes to the 
biological functions of proteins. Glycoproteins are proteins with short glycans attached, 
mainly N- (asparagine) or O-linked (serine, threonine, hydroxyproline or hydroxylysine) 
branched oligosaccharides. On the other hand, proteoglycans consist of a core protein 
with large polysaccharides attached, namely GAGs.  
The vascular ECM is divided into the basement membrane (BM) and the interstitial 
matrix. The BM is deposited underneath the ECs forming a sheet-like barrier between the 
endothelium and the underlying vascular layers. It is involved in cell adhesion, regulation 
of permeability as a selective barrier, control of cell growth, differentiation and migration 
as well as angiogenesis.99 The BM components are mainly produced by ECs and are self-
assembled on competent cell surfaces through binding interactions among its proteins.99, 
100 Collagen type IV is the most abundant BM protein, representing about 50% of its total 
protein content.101 Type IV collagens assemble to a flexible, felt-like network, giving the 
BM its tensile strength.102 Further BM components include collagens XV and XVIII, as well 
as laminins, perlecan, agrin and nidogen, which are linked in the network via their 
interactive domains. Remarkably, perlecan has the largest core protein of all 
proteoglycans (600 kDa). Notably, endorepellin, a C-terminal proteolytic perlecan 
fragment103, and endostatin, a C-terminal fragment of collagen XVIII98 inhibit 
angiogenesis.  
The interstitial matrix mainly determines the mechanical properties of the vessel 
and consists largely of the fibrillar collagens type I and III, together with elastic fibres and 
proteoglycans - all of which will be discussed in the following section. 
 
 
Table 1. Classification of glycosylated ECM proteins.  
The cardiovascular ECM consists of structural proteins, including fibrillar collagens and elastin (grey), 
and ECM proteins with non-structural functions (orange). The majority of ECM proteins are capable of 
both functions (green). SPARC denotes “secreted protein acidic and rich in cysteine”. Adapted from 




Elastic fibres in the vascular media enable vessels to recoil upon transient stretch. They 
consist mainly of elastin and are surrounded by a sheath of microfibrils, including the large 
glycoprotein fibrillin and fibulin.105 Mutations in the fibrillin gene result in Marfan’s 
syndrome, a condition linked to aortic aneurysms. Elastic fibres are deposited and 
organized early in development and have long half-lives (50-70 years in human 
arteries).105 Since they cannot be re-organized in adulthood, their mechanical damage or 
proteolytic degradation results in irreversible changes. This is best demonstrated in the 
ageing-induced arterial stiffening, which involves the loss of the elastic fibres by normal 
degradation. Tropoelastin is the biosynthetic precursor of elastin and is soluble compared 
to elastin itself. Upon secretion, the lysine residues of the tropoelastin molecules are 
highly cross-linked to each other, resulting in the elastin insolubility.106 It is this cross-
linking process which confers elastin its elasticity. The ability of the large arteries to 
respond to the pulsatile cardiac output with an even and smooth flow is attributed to their 
elastic ECM composition.93 This phenomenon, of storing a portion of the stroke volume in 
systole and releasing it with diastole is known as the ‘Windkessel effect’. Besides 
providing an even flow it also helps to decrease the cardiac afterload.  
1.2.2.2 Collagens 
Collagens are the most abundant proteins in mammals.102 To date there have been 28 
different collagen types described.107 Among those, type I (60%) and III (30%) collagen 
are the major fibrillar collagens of the vessel, constituting 90% of the vascular 
collagens.106 The remaining 10% include the collagens type V (fibrillar), XII, XIV (non-
fibrillar) IV and VIII (BM). Collagen fibres provide the vessel its tensile strength, which is 
attributed to their structure. Collagen fibre formation is a hierarchical process: in essence, 
individual polypeptide chains are assembled to collagen molecules, then to fibrils and 
eventually to fibres (Figure 6). 
  Fibrillar collagens are characterized by their triple helix structure, consisting of 
three polypeptide chains, known as a-chains. The chains are either identical forming 
homotrimers (e.g. collagen type III) or different resulting in heterotrimers (e.g. collagen 
type I). Each chain consists of the repeating amino acid motive Glycine-X-Y, where X and 
Y can be any amino acid but are often proline and hydroxyproline.107 Collagens are 
produced as procollagens – a precursor form with additional C- and N-terminal propeptide 
extensions to prevent a premature assembly into large collagen fibrils within the cell.102 In 
addition, the procollagen chains undergo extensive post-translational modifications, i.e. 
enzymatic hydroxylation of proline and lysine residues. Proline hydroxylation helps to form 
hydrogen bonds between the a-chains that stabilizes the triple-helix. The consequences 
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of instable triple helix formation, due to lack of proline hydroxylation is demonstrated in 
scurvy, a disease caused by vitamin C deficiency. Vitamin C is required for adequate 
hydroxylation as it is a co-factor for enzymatic hydroxylation. Upon secretion, the 
propeptides are enzymatically cleaved, and the collagen triple-helices aggregate into 
larger collagen fibrils. In addition, the collagen molecules are cross-linked (inter- and 
intramolecular) by the enzyme lysyl oxidase (LOX), increasing their tensile strength. 
Through the cross-linking, the collagen fibres also become increasingly insoluble. Finally, 
these fibrils are packed together in even thicker mature collagen fibres. The fibres are 
additionally stabilized via interactions with fibril-associated collagens with interrupted triple 
helices (FACIT), such as collagen type XII and XIV.107 FACITs have a different structure to 








Figure 6. Fibrillar collagen structure. Collagen 
fibre assembly is a hierarchical process, taking place 
intra- and extracellularly. (a) Each a-chain consists 
of the repeats Glycine-X-Y and has additional 
propeptides. (b) 3 a-chains form a triple helix in the 
endoplasmatic reticulum initiated by their C-terminal 
propeptide. (c) The resulting procollagen is secreted 
into the extracellular space. (d) Propeptides are 
cleaved enzymatically to form mature collagen. (e) 
Collagens then self-assemble into collagen fibrils 
and finally these are organized into (f) collagen 
fibres. Adapted from Mouw et al. in Nature Reviews 
Molecular Cell Biology, 2014107 and Alberts et al. in 
Molecular Biology of the Cell, 2008.102 
 
1.2.2.3 Proteoglycans 
Proteoglycans are distributed within the vascular interstitial matrix as well as the BM and 
have multiple regulatory functions within the vessel wall ranging from involvement in 
collagen fibril assembly108 to growth factor binding94. Proteoglycans are characterized by a 
core protein with variable GAGs attached, which can be a single one as in case of decorin 
or many dozens as found in the lectican family members. They are usually attached at 
serine residues within the core protein through O-linked glycosylation.102 GAGs are large 
unbranched polysaccharides consisting of repeating disaccharide units. Depending on the 
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disaccharide structure, four main types of GAGs are distinguished: (1) hyaluronan, (2) 
chondroitin sulfate / dermatan sulfate, (3) heparin sulfate and (4) keratan sulfate. GAGs 
are highly negatively charged molecules, due to their sulfate or carboxyl groups on their 
sugars. Thus, they attract counter-ions and draw water into the tissue, which enables the 
matrix to resist compressive forces. For example, this mechanism provides the basis for 
the viscoelastic properties of cartilage, which is enriched with the proteoglycan 
aggrecan.109 Also, the negatively charged GAGs allow numerous interactions with other 
ECM components. Hyaluronan is the largest GAG and the only one not attached to a core 
protein as a side chain.104 It is known to form non-covalently linked aggregates with 
proteoglycans such as aggrecan and versican. The proteoglycans within the vessel wall 
are the large aggregating proteoglycans (i.e. versican with hyaluronan), the small leucine-
rich proteoglycans (SLRPs) and the cell surface proteoglycans (i.e. syndecan, fibroglycan 
and glypican).106 The latter are relevant for anchoring and signalling between cells and the 
ECM mediating cell-matrix interactions.110 
Versican is one of the principal vascular ECM components and present in all three 
wall layers, though prominently found in the intima and adventitia.111 It is a large 
chondroitin sulfate proteoglycan (CSPG) and as such a member of the lectican (also 
known as hyalectin) family together with aggrecan, neurocan and brevican. Aggrecan is 
predominantly found in cartilage, while neurocan and brevican are mainly distributed in 
the central nervous system. Versican consists of two globular domains at either end of the 
protein and an interglobular region carrying the chondroitin sulfate attachments.112 Due to 
alternative RNA splicing versican exists in at least four different isoforms (V0-V3), which 
differ in size and the amount of chondroitin sulfate chains. The V3 isoform lacks the 
interglobular domain, thus has no GAGs at all. Elucidating functional differences of the 
various isoforms are subject to ongoing research. Via its N-terminal G1 domain versican 
binds to hyaluronan stabilized by the link protein to form large aggregates. These 
aggregates build a reversibly compressive compartment and provide a swelling pressure 
within the vascular ECM.111 Though versican plays important roles in the healthy 
vasculature, i.e. for cell adhesion and ECM assembly including elastic fibre assembly112, it 
is substantially increased in vascular disease.111 Accumulation of versican has been 
associated with restenosis and in atherosclerosis it has been implicated in lipoprotein 
retention.13, 113 In contrast, a proteomics study analysing the ECM content of abdominal 
aortic aneurysms revealed a reduction in versican, possibly due to degradation.114 A 
decrease in versican, especially its V0 isoform had been reported previously in abdominal 
aortic aneurysms.115 It remains subject to debate, whether versican is the culprit in 
pathogenesis of vascular disease or its increased expression represents a counter-
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regulatory, thus protective mechanism. Nevertheless, there is sufficient evidence for its 
key role in vascular pathology.111 
SLRPs are small molecules with a core protein size of around 40 kDa. They 
feature leucine-rich repeats flanked by cysteine-rich domains, hence their name.116 Based 
on parameters such as gene organization and sequence homologies, SLRPs are divided 
in five classes (Table 1). Prominent vascular SLRPs include decorin, biglycan and 
lumican. Decorin and biglycan are crucially involved in collagen fibril formation. However, 
they have also important matricellular functions influencing cellular proliferation, 
differentiation, survival and adhesion, as they interact with numerous proteins.117 Decorin 
is an important anti-fibrotic agent, as it inhibits TGF-b and interacts with connective tissue 
growth factor (CTGF).118  
1.2.2.4 Integrins 
Integrins, although not regarded as ECM proteins per se, are important ECM-associated 
glycoproteins, as they connect the matrix to the cell cytoskeleton.119 Integrins are a 
diverse family of heterodimeric transmembrane cell adhesion receptors with at least 24 
members, composed of an a- and b-subunit.120 The extracellular domains of integrins are 
connected to the ECM glycoproteins laminin, fibronectin and vitronectin as well as 
collagens. However, integrins are not simply adhesion molecules, but act as true 
signalling receptors. Upon binding their ligands, they can transmit signals in both 
directions, and impact many aspects of cell behaviour from survival to migration and 
proliferation. Further, integrin-mediated adhesion is involved in transmitting physical 
forces into intracellular biochemical signals, a process known as mechanotransduction.121 
Besides ECM proteins, other ligands for integrins include members of the immunoglobulin 
superfamily such as ICAM-1 on ECs, which are expressed upon pro-inflammatory 
cytokine release. Thus, through this earliest induction of inflammation, integrin signalling is 
also involved in the pathogenesis of atherosclerosis.122 Notably, integrin aIIbb3, which 
binds to fibrinogen, is involved in platelet aggregation and as such acts as a prominent 
anti-thrombotic drug target, inhibited by the antibody fragment abciximab.123  
1.2.3 ECM degradation 
Vascular cells constantly remodel their surrounding ECM for migration, proliferation or just 
adaptation to external stimuli. Moreover, ECM degradation is required for the release of 
biologically active molecules such as growth factors.94 The turnover of the vascular ECM 
is usually a slow, continuous process, as mature collagen and elastic fibres are degraded 
only in small amounts.106 However, in processes such as tissue repair or in vascular 
diseases the ECM is rapidly degraded. Degradation is achieved by extracellular 
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proteolytic enzymes (proteases), most notably the family of matrix metalloproteinases 
(MMPs) or adamalysins, a family of proteases comprising the a disintegrin and 
metalloproteinases (ADAM) and a disintegrin and metalloproteinases with 
thrombospondin motifs (ADAMTS). But also other proteases such as the cathepsins 
contribute to ECM degradation.  
Naturally, ECM degradation needs to be tightly regulated to prevent increased and 
uncontrolled ECM loss consequently compromising tissue integrity. Besides 
transcriptional control of proteases, one control mechanism includes the secretion of 
inactive precursor proteases – so called zymogens, which are locally activated when 
needed. Another mechanism is to specifically inactivate the proteases with inhibitors, such 
as tissue inhibitors of metalloproteases (TIMPs).  
1.2.3.1 MMPs 
MMPs are supposed to be the major protease family involved in ECM degradation.92 
Collagenases and elastases mainly belong to the MMP family. To date 23 MMPs have 
been described, each generally specific for multiple target substrates. For example, 
MMP9 not only cleaves the collagens type IV, V, VII and X, but also elastin and 
fibronectin. MMPs are multidomain enzymes containing a pro-peptide, a catalytic domain 
and a C-terminal haemopexin-like domain, involved in substrate specificity. For their 
activity MMPs depend on zinc as a cofactor, hence belonging to the superfamily of zinc-
based proteases, the metzincins. Commonly MMPs are secreted as zymogens and are 
activated upon proteolytic cleavage of the propeptide, which reveals their zinc bound 
catalytic domain. MMPs are either soluble or attached to the cell membrane such as 
MMP14. Upon secretion the inactive MMPs can bind to their substrates, forming a 
reservoir that can be activated upon demand by their catalytic activation.110 The relevance 
of MMPs for ECM remodelling is underpinned by the finding that circulating MMPs may 
identify patients at greater risk of developing ISR following DES deployment.124 Significant 
elevations in MMP-9 levels at baseline and MMP-2 and MMP-9 levels 24h post-PCI were 
associated with ISR development. 
1.2.3.2 Adamalysins 
Adamalysins are another family within the zinc-based proteinases and include the ADAMs 
and ADAMTS, which have additional thrombospondin motifs. ADAMs are largely cell 
membrane-associated metalloproteinases and about half of the known 21 human ADAMs 
possess proteolytic activity. They play a relevant role in cell signalling, as they cleave 
transmembrane protein ectodomains releasing cytokines and growth factors.125 Moreover, 
ADAMs are involved in cell-adhesion, as their disintegrin domains can interact with 
integrins and syndecans on neighbouring cells.126 They also contribute to cell-matrix 
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interactions, by binding fibronectin or laminin (e.g. ADAM13). However, certain ADAMs 
(e.g. ADAM10, ADAM15) also exhibit collagenase activity, thus degrade the ECM. 
 In contrast, the ADAMTS are secreted metalloproteinases and the ADAMTS family 
comprises 19 members to date.127 Their common domain organisation includes a signal 
peptide, a propeptide, a zinc bound catalytic domain, a disintegrin-like domain, a central 
thrombospondin repeat, a cysteine-rich domain and a spacer domain (Figure 7). 
Moreover, all ADAMTS, except ADAMTS-4 have additional thrombospondin motifs. Like 
MMPs, the cleavage of the ADAMTS propeptide is required to gain enzymatic activity. 
Convertases such as furin or furin-like enzymes are involved in this activation process. 
ADAMTS-13, however, cleaves von Willebrand factor and has been shown to be 
enzymatically active even without the cleavage of its relatively short pro-domain.128 
ADAMTS-1, -4, -5, -8, -9, -15 and -20 are the proteoglycan degrading enzymes. 
Degradation of proteoglycans, including the large aggregating proteoglycans, appears to 
be their major ECM-related function. Due to their cleavage of aggrecan, ADAMTS-1, 
ADAMTS-4 and ADAMTS-5 are also referred to as aggrecanases, with the latter two 
showing the highest activity. Furthermore, ADAMTS-2, -3 and -14 are involved in 
processing of procollagen to collagen by cleaving the N-terminal propeptide of 
procollagen.129 
Figure 7. Domain structure of the ADAMTS family. Also phylogenetic analysis of the family members 
is shown. Adapted from Stanton et. al in Biochimica et Biophysica Acta, 2011.127 
1.2.3.3 TIMPs 
TIMPs are specific metalloproteinase inhibitors allowing control of protease activity. Four 
TIMPs (TIMP-1 to 4) have been identified in human to date.130 They are relatively small 
molecules that bind to the activated enzymes blocking their activity. TIMPs inhibit all 
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MMPs with various specificity. It has been shown that SMCs of normal arteries 
constitutively produce MMP-2 (specific for collagens, elastin and fibronectin), but also 
TIMP-1 and TIMP-2. However, no enzymatic activation is detectable, suggesting its tight 
control by the inhibitors.131 Notably, TIMP-3 is a better inhibitor of ADAMTS than for 
MMPs. 
1.2.4 ECM remodelling in vascular disease 
As stated in the introduction, in physiological conditions ECM degradation and re-
synthesis is in a steady-state to maintain vessel wall integrity. It is obvious, that 
metalloproteinases are important in vascular repair processes, but excess activity is 
harmful for vascular integrity.132 On the other hand, increased ECM deposition is the 
vessel wall is associated with neointimal hyperplasia. Thus, ECM dysregulation is 
implicated in almost every vascular disease including atherosclerosis, aneurysms133, 
varicose veins134, diabetic vasculopathy135 and restenosis, which is of particular interest 
for this study.  
Inflammatory cells, including lymphocytes, monocytes/macrophages but also 
neutrophils, infiltrate the vessel wall upon vascular injury. They are an important source of 
proteases degrading the vascular ECM.136 Also, cytokines and growth factors released by 
inflammatory cells, such as TNF-a, IL-1 or PDGF have been shown to stimulate MMP 
synthesis in SMCs137, 138, which is likely associated with the secretory switch in SMCs. In 
general, in vascular pathology and healing there is an interplay of ECM proteins and 
inflammation, as ECM components modulate immune reactions. For example, upon injury 
low molecular weight fragments of hyaluronan are generated, which are known to induce 
proinflammatory signalling in macrophages via Toll-like receptor (TLR) 4 and TLR2.139 
Thus, their clearance through a CD44-dependent signalling contributes to resolution of 
inflammation. On the other hand, proteases released by inflammatory cells or activated 
SMCs generate active ECM fragments, with impact on chronic inflammation.140 
 
Regulation of SMC differentiation and ECM synthesis 
As mentioned above (section 0), vascular SMCs de-differentiate upon injury, thus 
undergoing a phenotypic switch.141, 142 Usually SMCs in the blood vessel are quiescent 
cells with low proliferation rate and low ECM synthetic activity. Their main function is to 
contract and regulate the blood vessel tone, also in response to EC-derived NO. They are 
characterized by the expression of contractile SMC makers, such as smooth muscle a-
actin (SMA), myosin heavy chain (MYH11), calponin (CNN1) and transgelin (TAGLN). 
However, unlike skeletal or cardiac myocytes, SMCs are not terminally differentiated and 
are highly plastic cells. In response to environmental cues they can de-differentiate to 
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become migratory, hyper-proliferative and synthetic. This change plays a relevant role in 
the pathophysiology of atherosclerosis15, 143 or restenosis60 and is associated with ECM 
accumulation. However, SMC differentiation is not only limited to two states. The SMC 
phenotypic switch includes also an osteoblast-like phenotype, as seen in vascular 
calcification144, but also a macrophage-like phenotype, as described in recent lineage 
tracing studies and mentioned above (section Error! Reference source not found.).145, 
146 The mechanisms, which control SMC plasticity are not entirely understood. However, 
there is evidence that factors such as PDGF, TGF-b as well as MMPs are actively 
involved in this process.142 In addition, MMP2 can release and activate TGF-b itself from 
its inactive complexed form with the latency associated peptide (LAP) and latent TGF-b 
binding protein (LTBP).147 Downstream involved factors include myocardin and Kruppel-
like factor 4 (KLF4). Recent studies, have also implicated a role for microRNAs in the 
control of SMC de-differentiation as described above.  
1.2.4.1 ECM remodelling in atherosclerosis 
ECM remodelling in early atherosclerosis contributes to lipid retention, as described above 
for proteoglycans, especially versican.13 This is further supported by a study which 
showed that SMCs expressing the versican V3 isoform, hence lacking GAGs, are forming 
a matrix, which is resistant to lipid deposition and macrophage accumulation despite 
hyperlipidemia.148 However, plaque stability in advanced atherosclerosis is also strongly 
influenced by ECM remodelling.149 Fibrillar collagens, particularly type I, are the major 
components of the fibrous cap.150 As they provide tensile strength, they seem to be crucial 
in stabilising the plaque. Thus, local MMP overexpression in the vulnerable shoulder 
regions derived from macrophages and SMCs provides a potential explanation for plaque 
destabilization through weakening of the ECM.131, 136 Notably, MMP 9 in particular, has 
been linked to acute coronary syndromes.151 Moreover, ADAMTS-1 has been implicated 
in atherosclerosis.152 ADAMTS-1 expression was reported to be upregulated in plaques of 
a mouse model of atherosclerosis. The authors concluded that ADAMTS-1 may be 
involved in atherogenesis by promoting SMC migration through the cleavage of ECM 
proteins, such as versican. Further evidence for an involvement of ADAMTS-1 in plaque 
destabilization, came from a histopathological study investigating coronary atherectomy 
specimens obtained from patients with acute myocardial infarction (AMI) or stable 
angina.153 ADAMTS-1 was more strongly expressed in AMI plaques than in stable plaques 
and co-localized with macrophages, suggesting its role in plaque instability. No 
differences were detected for ADAMTS-4 and 5 between the two groups. Finally, 
ADAMTS-4 and ADMATS-8 were shown to be expressed in macrophage-rich areas of 
human atherosclerotic plaques.154 This suggests, that macrophages are a major source of 
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these two proteases in plaques. Their expression was found to be inflammatory regulated 
and induced upon monocyte to macrophage differentiation. In addition, ADAMTS-4 
expression was strongly upregulated during atherosclerosis development in mice. 
However, the exact role of the ADAMTS enzymes in atherosclerosis, especially their 
impact on the development of atherosclerosis is still unclear and needs to be further 
elucidated. 
1.2.4.2 ECM remodelling in restenosis 
The ECM accounts for >50% of the neointimal volume in restenotic lesions as shown in 
stented human coronary arteries in histopathological studies.155 Despite this large portion, 
the ECM composition and organization is not well characterized, especially not using a 
holistic approach at the protein level. Within the developing stent-induced neointima, ECM 
proteins modulate crucial processes including cell adhesion, proliferation and migration, 
as well as growth factor expression resulting in vascular remodelling. Farb et al. found that 
in the early neointima, a thin provisional ECM is formed consisting of fibrin, fibronectin and 
water entrapping matrix proteins such as versican and hyaluronan as an initial response 
to stent injury. This initial ECM environment allows inflammatory cells to adhere and begin 
the repair process. Further secretion of proteoglycans by SMCs stabilize the fibrin-
enriched ECM, providing viscoelasticity to the healing tissue and allowing more SMCs to 
bind and proliferate. Therefore, the initial neointima remains hypercellular and rich in type 
III collagen, versican and hyaluronan. Increased versican accumulation during the initial 
period of one – three months upon coronary angioplasty has also been reported in 
previous studies156, thus supporting the findings of Farb et al. Further, Farb et al. revealed 
that over time, MMPs released by inflammatory cells progressively degrade hyaluronan. In 
addition, partial reabsorption of type III collagen and synthesis of type I collagen, decorin 
and biglycan allow wound healing with cross-linking of type I collagen. Cross-linked 
collagen inhibits SMC proliferation, resulting in a cell-depleted, but collagen- as well as 
proteoglycan-rich ECM.60, 155 Similarly Chung et al. found, again using histopathological 
methods, that neointimal lesions beyond two months upon stent implantation, consist 
primarily of large amounts of proteoglycan-rich ECM and are rather cell poor.157 However, 
a more recent study comparing the neointimal characteristics in restenotic DES vs. BMS 
beyond one year implant duration revealed greater proteoglycan content and less SMCs 
over time in DES, while BMS showed a greater cell density and collagen deposition.55  
Moreover, the study of Chung et al. found 80% TGF-b1 positive staining in the in-
stent restenotic tissue157, which is likely to influence the ECM accumulation in restenotic 
lesions158 – TGF-b1 is known to regulate the synthesis and turnover of various ECM 
components such as proteoglycans, hyaluronan, fibronectin and collagen. Thus in a 
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pharmacological animal study, Backes et al. intended to target TGF-b induced matrix 
deposition to prevent restenosis using pirfenidone.159 The exact mechanism of action for 
pirfenidone is not fully understood yet, however it has been demonstrated to inhibit 
primarily TGF-b induced collagen synthesis. Indeed, neointima formation in rats treated 
with pirfenidone upon balloon injury of the carotid artery was strongly reduced compared 
to controls. Cell proliferation was unaffected by the drug (as indicated by PCNA staining), 
however collagen deposition (picrosirius red) was markedly reduced, suggesting a primary 
effect on ECM synthesis. Indeed, the FDA has only recently (October 2014) approved 
pirfenidone (Esbriet) for the treatment of idiopathic pulmonary fibrosis160, upon positive 
effects in randomized, placebo-controlled phase III trials.161 However, despite promising 
results in this preclinical study of Backes et al., a current PubMed search (September 
2016) did not reveal any follow-up studies using pirfenidone on coronary stents. The same 
is true for dichloroacetate, that has also been shown to reduce neointima formation by 




1.3.1 Introduction into proteomics 
1.3.1.1 Proteomics as part of systems biology 
Biological processes are by no means linear systems, but rather represent dynamic 
networks with crosstalks of their components at multiple levels. This concept is best 
expressed in the research field of systems biology or the omics technologies. Systems 
biology uses a systematic, holistic, rather than the traditional reductionist approach 
studying one gene or protein at a time, to reveal the mechanisms and interactions in 
biological systems in an unbiased way. Omics experiments has only become feasible with 
the advent of high-throughput technologies to analyse vast amounts of data. Particularly 
genomics with the Human Genome Project paved the way to systematic high-throughput 
sciences.162 Proteomics, aiming to deliver a “protein complement of the genome” evolved 
as an essential part of systems biology.163 Since its introduction proteomics research has 
grown rapidly, also reflected in the increasing number of publications (currently >6000 
publications each year164) and establishment of journals serving this research field such 
as Proteomics, Journal of Proteomics, Journal of Proteome Research or Molecular and 
Cellular Proteomics.  
1.3.1.2 Proteomics – Definition and challenges 
The term “proteome” was first introduced in the mid 1990s in analogy to the term 
“genome” and refers to the entire set of proteins produced by an organism, tissue or cell 
at any given time.165, 166 Proteomics is the large-scale study of the entire proteome 
including protein isoforms and modifications, their abundance and structure as well as the 
interactions between them.167 Thus, the overall aim of proteomics is to contribute to a 
comprehensive description of cellular function. Proteomics is particularly suited for this, 
since proteins are the major effector molecules in every biological process ultimately 
determining the phenotype of a cell. Therefore, by systematically analysing proteins, 
proteomics bears great potential for the identification of novel prognostic and diagnostic 
targets (biomarker discovery). Also, it holds promise towards better patient stratification.19, 
168 
Previous achievements of genomics were essential for progress in proteomics, 
providing the ‘blueprint’ of potential gene products. Unlike genomics studies however, 
proteomics is characterized by a higher degree of complexity and dynamics.163 The 
relationship between the genome and proteome is not linear, i.e. the concept that one 
gene encodes one protein does not apply. Post-transcriptional control such as RNA 
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editing and alternative splicing results in a greater protein diversity. Moreover, only a 
certain set of genes are transcribed in a cell at a given time point in response to 
environmental cues. Further complexity is added by post-translational modifications 
(PTM), such as glycosylation or phosphorylation, as well as protein degradation. In 
addition, what renders proteomics most challenging are the detection of very low 
abundant proteins which have to be quantified in the excess of other proteins. The 
dynamic range of protein concentrations in a sample often exceeds the resolution 
capacities of proteomics technologies (currently 4-6 orders of magnitude). Especially the 
plasma proteome represents a major challenge, spanning ten orders of magnitude.169 
Unlike PCR, proteomics techniques lack the ability to amplify their targets upon detection. 
Thus, proteomics strongly relies on enrichment and subfractination of complex samples. 
For example, extracellular matrix (ECM) proteins, which are less abundant than cytosolic 
or mitochondrial proteins in the heart are less likely to be identified when whole tissue 
lysates are analysed. Thus, methods enriching for ECM proteins can overcome this 
issue.114, 170 Therefore, appropriate sample preparations are essential for reproducible 
proteomics experiments. Another example is the depletion of the highly abundant plasma 
proteins albumin or the immunoglobulins.171 (Another approach to tackle the great 
dynamic range of the plasma proteome is to shift biomarker discovery approaches from 
plasma to tissue-based proteomics. In the affected tissues, the potential biomarkers are 
less dilute and their cellular origin is less uncertain.172 Finally, technological advances in 
proteomics instrumentation, mainly mass spectrometers (MS) and analysis techniques are 
contributing to overcome these difficulties, such as targeted proteomics or data-
independent analysis (DIA) methods which will be discussed in the subsequent sections.  
1.3.1.3 Proteomics vs. traditional biological research 
Traditional biochemistry approaches using the workhorse techniques such as Western 
blotting or microscopy focus on single known proteins at a time highlighting only a limited 
part of interconnected protein networks.173 Notably, these techniques are based on a priori 
assumptions on the proteins of interest and rely on the availability of antibodies. Though 
antibodies usually exhibit great specificity, their use is associated with notorious limitations 
such as epitope masking, non-specific binding or cross-reactivity between species. In 
contrast, untargeted proteomics research is not constrained by a priori assumptions but 
provides an unbiased comprehensive analysis of the protein composition in a sample. 
Thus, untargeted proteomics is less a hypothesis-driven but rather a discovery-based 
approach. On the contrary, the unbiased findings of proteomics studies often trigger the 
formulation of new hypotheses, consequently being also referred as “hypothesis-
generating” strategies.174 Taken together, proteomics does not replace, but is highly 
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complementary to traditional biological research, providing an opportunity for genuine 
progress in biological research. 
1.3.2 Proteomics applications 
1.3.2.1 Proteomics experiments 
Three major types of proteomics analysis exist.  
Firstly, proteomics is used for compositional analysis, which simply aims to identify 
all proteins present in a sample. 
Secondly, proteomics enables characterization of protein-protein interactions. This 
is mainly accomplished by affinity purification coupled to mass spectrometric (AP-MS) 
identification. For this purpose, the protein of interest (“bait protein”) together with its 
interaction partners is captured with a ligand coupled to a solid-phase support and 
subsequently analysed by proteomics techniques.175 As targeting ligands often antibodies 
(immunopurification) or epitope tags are used, after the tag of choice, such as a His-Tag 
or FLAG is fused to the protein of interest on the DNA level. Main limitation of this 
application is the co-purification of non-specific interactors, so called “background 
contaminants”, due to their unspecific binding to the solid phase, antibody or epitope tag. 
Thus, appropriate controls are necessary: such as utilizing the same isotype antibody, an 
antibody recognizing a different epitope or AP in the absence of the bait. A contaminant 
repository, the “CRAPome”, a freely accessible database containing common background 
contaminants for the scoring of true protein-protein interactions has been established.176  
Lastly, the main area of application for proteomics is differential protein expression 
profiling in response to biological perturbations. In this approach, quantitative protein 
changes between two or more different, well-defined conditions, such as control and 
diseased samples, are compared. However, differential regulation is not only reflected in 
protein abundance, but might also be expressed in differential post-translational 
modification. This type of proteomics experiments are the typical settings for discovery 
projects such as biomarker discovery. For example, a protein found increased in diseased 
samples may serve as a useful diagnostic marker or a drug target. In a second step, after 
identifying the significantly differential expressed proteins, these putative candidates are 
mostly validated in larger sample cohorts to assess their reproducibility in larger 
populations. 
1.3.2.2 Proteomics workflow 
A typical proteomics study involves the following steps (Figure 8):  
1. As any other study also proteomics starts with a well-conceived experimental 
design (sample size, group balance, degree of biological variation, etc.). It would be 
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wrong to assume that proteomics experiments can be implemented with a premature plan, 
since untargeted proteomics is a hypothesis-generating approach. On the contrary, 
proteomic analysis are very laborious and expensive and most notably they generate vast 
amounts of data. Thus, without a precisely formulated question, the data interpretation 
can be very cumbersome and conclusions may not be drawn reliably.  
2. Sample preparation is paramount for accurate and reproducible proteomics 
analysis. This already starts with appropriate sample collection, handling and storage 
conditions. For example, immediate sample freezing upon collection or treatment with 
protease inhibitors upon thawing is crucial to prevent protein degradation. Protein 
extraction from a biological sample can be managed in a single step or subfractination 
methods can be applied. This is performed for better protein solubility as well as reducing 
sample complexity or to study a specific subproteome as described above.177-180 Further 
sample preparation requirements such as protein labelling, denaturing, reduction or 
enzymatic digestion are dependent on the method chosen for protein analysis and will be 
discussed throughout the respective sections.  
3. Due to sample complexity further sample separation steps are required prior to 
analysis. This is necessary to overcome undersampling of low-abundant 
peptides/proteins, because failing that, the analysers are dominated by high-abundant 
peptides/proteins. This can be achieved by methods such as one- or two-dimensional gel 
electrophoresis (1-DE, 2-DE) or high-performance liquid chromatography (HPLC). Due to 
rapid advances in MS technology, laborious gel electrophoresis methods are more and 
more receding, even though 2D gels have a very high resolution capacity. On the other 
hand, HPLC separation is standard procedure in proteomics, mainly because of the switch 
from protein to peptide-based proteomics. The most commonly applied chromatography 
for proteomics is reversed-phase LC using C18 columns. The separation is based on 
physico-chemical interactions of the proteins/peptides with the C18 residues on the 
stationary phase, the column. Depending on their hydrophobicity level and the gradient of 
the mobile phase with increasing organic content the peptides/proteins elute at different 
time points from the column, resulting in different retention times for each peptide/protein. 
4. Separation is followed by mass spectrometric analysis, the actual 
measurement of the sample. MS is the workhorse of modern proteomics and brought the 
most significant breakthrough in proteomics research. Current MS have exceptional mass 
accuracy, resolution and detection sensitivity (dynamic range), reaching to attomole 
amounts.181 However, as explained above the true sensitivity of MS is determined by the 
nature of the sample.182 Moreover, MS analyse multiple proteins at the same time and 
offer automation, thus high throughput.183 The mass spectrometer determines the mass-
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to-charge ratio (m/z) of an ionized molecule generating large amounts of MS spectra. A 
detailed description on MS principles and instrumentation will be given in section 1.3.4.1 
5. Next step in the workflow is data analysis for protein identification and 
quantification. After all, MS simply measures the m/z of a protein/peptide. So how is the 
protein sequence retrieved ultimately? The unambiguous identification of the actual 
protein occurs after correlation of the MS spectra to a database with the assistance of 
software tools and scoring algorithms.184 Considering the amount of generated data, this 
is only possible with automated software solutions. Even though the single spectra are not 
manually matched anymore, this is still a very time-consuming part of proteomics analysis 
together with the subsequent data interpretation. The exact sequence determination 
process as well as quantification will be discussed in section 1.3.5.3 
6. Validation is the final workflow step, which especially applies to differential 
expression proteomics studies. It is important to realize that a proteomics experiment 
does not finish with the identification of differentially expressed proteins, but requires 
extensive validation. First of all, a major challenge in data interpretation is to discern those 
proteins with functional relevance from the many other differentially expressed proteins. 
Thus, a solid biomedical knowledge is beneficial to select the target proteins for follow-up 
studies. Usually independent techniques, such as Western blotting or 
immunohistochemistry, are applied to validate the proteins of interest. Targeted 
proteomics is also gaining importance as a robust system to validate findings from 
discovery based approaches, as will be explained in section 1.3.8. Moreover, results of 
discovery projects can be validated by analysing larger sample cohorts. Finally, detailed 
physiological analysis is needed to decipher the role of a putative candidate in biological 
processes. These analyses can range from in vitro studies to the generation of knock out 
animals. However, this may not be easily manageable for a single laboratory but might 
require collaborations with specialized laboratories all around the world to provide 




Figure 8. Proteomics workflow. Proteomics analysis involves multiple progressive steps. (A) A well-
conceived experimental design is crucial for proteomics experiments, especially for reliable data 
interpretation later. (B) Protein extraction is critical as subfractination is required to detect low abundant 
proteins.  (C) Sample complexity and undersampling is further reduced by sample separation (gel 
separation, LC), prior to MS analysis (D). (E) Detected proteins are identified upon computational 
spectrum matching. (F) Finally proteins of interest are validated by independent techniques, such as 
immunoblotting or immunohistochemistry.  
 
1.3.3 Two-dimensional gel electrophoresis 
Even though advances in mass spectrometry are widely replacing gel-based proteomics 
techniques, 2-DE is still in use, owing to its unique separation power. It allows the 
resolution of more than 10 000 proteins on a single gel.185 Since its introduction in 
1975,186, 187 the technique has been widely refined, the general principle however is the 
same: proteins are separated in two dimensions, first based on their isoelectric point and 
second by their molecular mass using SDS-PAGE. Due to the use of 2 separation 
dimensions, 2-DE gels have a higher resolving capacity than 1-DE (SDS-PAGE). In the 
first dimension proteins are separated by the concentrating technique of isoelectric 
focusing (IEF). The sample is loaded onto a strip with an immobilized pH gradient (IPG). 
These strips consist of acidic and basic buffering groups covalently linked to the gel matrix 
generating a pH gradient. Wide pH gradients of 3-10 are used for an overview of protein 
composition, while narrow-range IPF strips of 3 pH steps provide a better resolution for 
unambiguous protein identification.188 Upon application of an electric field, proteins 
migrate according to their intrinsic charge until they reach the pH at which their overall 
charge is neutral – their isoelectric point. This migration results in focused, discrete protein 
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bands on the strip. This strip is then placed on a large SDS polyacrylamide gel for 
separation in the second dimension. Proteins now migrate orthogonally to their previous 
movement according to their molecular mass. Thus, 2-DE gels produce a complete map 
of intact proteins in form of multiple “spots”. The spots are visualized by Coomassie, zinc, 
silver or fluorescent staining, with silver being the most commonly applied. 
Immunodetection or radiolabelling are also used. Following staining, gel images are 
digitalized and the spots are detected and directly quantified using densitometry. Spot 
patterns between multiple gels are compared for differential expression with the help of 
image analysis software, providing automated spot-detection.189 However, visual 
inspection is still essential. Spots of interest are excised and the proteins are identified by 
mass spectrometry. Same proteins can be detected in different spots, since post-
translational modifications, isoforms or degradation products cause a shift in isoelectric 
point and molecular weight. Unlike other proteomics techniques, quantitation with 2-DE is 
performed directly on the gel at the protein level and not after identification by mass 
spectrometry.   
1.3.3.1 2D DIGE 
Technical irreproducibility due to gel-to-gel variation remains the main limitation of 2-DE 
gels. A significant improvement was achieved with the introduction of the more 
sophisticated two-dimensional difference gel electrophoresis (2D DIGE) technique.190 This 
technique allows the comparison of two or three protein samples simultaneously on the 
same gel, thus limiting experimental gel-to-gel variation. This is achieved by labelling the 
proteins of each sample with a different fluorescent Cy-dye (Cy2, 3 and 5), which are 
designed not to interfere with the migration properties of the labelled proteins. The 
differently labelled samples are then mixed together in equal amounts and run on the 
same gel in two dimensions. Often a differently labelled pool of all experimental samples 
is included serving as an internal standard for normalization. Proteins common to both 
samples appear as spots with a common fluorescent signal due to overlay, while the 
differentially expressed proteins emit the signal of their own labelled fluorescent dye. The 
gel is analysed using a fluorescent gel imager (scanner- or camera-based system) 
detecting the emission wavelength of each Cy-dye, which can have an integrated spot-
picking robot. Again, software packages such as DeCyder are deployed to determine the 
differential spots to be picked. DIGE is capable of reliably quantifying protein differences 
as low as 15% over a protein concentration range of over 4 orders of magnitude.191 
However, despite its high sensitivity and improved reproducibility the limited resolution of 
hydrophobic proteins such as transmembrane proteins (causing precipitation during IEF) 
and very large or small proteins remain a caveat of this technique. Interference from high-
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abundant proteins is a further limitation. Last but not least, image analysis and spot 
picking can be a very tedious process representing a bottleneck in the entire process. 
1.3.4 Mass spectrometry based proteomics 
1.3.4.1 MS principles and instruments 
MS is the main driver of proteomics research. It determines the m/z of an ionized 
molecule. The measurement is carried out using electromagnetic fields in a vacuum. 
Thus, peptides/proteins first need to be transferred from the liquid into the gas phase 
(volatized) and electrically charged (ionized). This is accomplished using matrix-assisted 
laser desorption ionization (MALDI) or especially electrospray ionization (ESI).192, 193 It was 
the advent of these techniques that MS became applicable for proteomics analysis, and 
for which (ESI) John B. Fenn and Koichi Tanaka were awarded the Nobel Prize in 
Chemistry in 2002. MALDI sublimates and ionizes the samples out of a dry, crystalline 
matrix via laser pulses.194 Surface-enhanced laser desorption ionization (SELDI) is a 
variation of MALDI, where proteins are bound to a surface with a substrate, which allows 
contaminants being washed away.195 In contrast, ESI ionizes proteins/peptides directly out 
of a solution by application of high voltage to the liquid and is therefore readily interfaced 
with LC. Thus, ESI-MS coupled to LC is the method of choice for the analysis of complex 
samples. Peptides are typically doubly protonated by ESI. 
In simple terms, mass spectrometers consist of 3 parts: (1) an ion source as 
explained above, (2) the mass analyser(s) and (3) a detector. The mass analyser is the 
central part of an MS in determining the m/z. While the ions are accelerated through an 
electric or magnetic field in vacuum they undergo a deflection according to their mass and 
charge state, which is reflected in the m/z ratio. The stream of sorted ions reaches the 
detector, such as an electron multiplier. The detector registers the intensity of ions of the 
same m/z, thus their relative abundance, which is displayed as spectra. There are 
different type of mass analysers using either static or dynamic and magnetic or electric 
fields, each with its own strength and weakness. In many mass spectrometers, especially 
in newer types, several analysers are put together to take advantage of the strengths of 
each. In proteomics four basic types of mass analysers are used: In brief, these are time-
of-flight (TOF), ion trap (including the orbitrap), quadrupole mass filters and Fourier 
transform ion cyclotron resonance (FTMS) analysers. For a detailed technical review on 
MS instrumentation see review by Aebersold and Mann.194 The mass analysers are 
characterized by the key parameters such as sensitivity (dynamic range), resolution and 
mass accuracy. A high resolution allows the MS to distinguish many different 
proteins/peptides of slightly different m/z from each other and display them as single 
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peaks. This is required for their accurate identification. The mass accuracy is the ratio of 
the m/z measurement error to the true m/z and is measured in ppm.  
1.3.4.2 Overview of MS methods 
Advances in proteomics are tightly linked to the development of mass spectrometry 
technology, which is in a constant state of flux. Due to the rapid development of MS 
technology at all levels there is no straightforward classification of MS based proteomics. 
MS approaches can be categorized from various viewpoints: Firstly, it can be divided in 
gel-based (2-DE or Gel-LC-MS/MS) or gel-free (shotgun proteomics) methods. In terms of 
quantification it can be distinguished between label-free and isotopic labelling (SILAC, 
iTRAQ, TMT) techniques. These quantification techniques are relative, while absolute 
quantification can be achieved with stable-isotope labelled standards in targeted 
proteomics. Finally, depending on the method of protein analysis, proteomics is 
subdivided into a “top-down” and “bottom-up” approach. The bottom-up strategy means 
the identification of a protein via its peptides after its proteolytic digestion (relies on 
tandem MS) and is by far the most commonly applied strategy. Within the field of bottom-
up proteomics, there is still a great variety of MS strategies and acquisition modes (MS 
operating modes for data acquirement), which can be overwhelming when first introduced 
to proteomics. Currently there are three main strategies used in this field.196 The first and 
most widely used strategy is known as shotgun or untargeted discovery proteomics with 
the MS operated in data-dependent acquisition (DDA) mode. The second strategy is 
targeted proteomics, carried out by multiple reaction monitoring (MRM) (also called 
selected reaction monitoring, SRM). The final approach is the newly emerging data-
independent acquisition (DIA) mode. Both, DDA (biased) and DIA (unbiased) are 
discovery based methods, which globally profile the proteome of a given sample, while 
MRM is a targeted method only identifying preselected proteins of interest. Further, these 
 three approaches differ with regards to their analytical performance in terms of sensitivity, 
reproducibility, limit of detection and resolving power.197 Limit of detection refers to the 
minimal quantity of an analyte that can be confidently detected. In the following sections 
all these introduced methods and MS acquisition modes will be discussed in detail. A 








Figure 9. Overview of proteomics approaches. Using gel-based methods fractionation of protein 
extracts is accomplished on protein level. Separated proteins are excised and subjected to in-gel 
digestion. Upon alternative fractionation gel-free proteomics approaches directly proceed to in-solution 
digestion and LC-MS/MS analysis. There are three data acquisition modes in bottom-up proteomics: 
DDA, DIA and MRM, whereas MRM is a targeted approach, while DDA and DIA are discovery-based. 
 
1.3.4.3 Top-down vs. bottom-up proteomics 
Two different methodologies are used for protein analysis by MS.  
 In the less-used top-down approach intact proteins without prior digestion are 
analysed by MS. It starts with the ionization and measurement of the whole protein, which 
is then fragmented in the MS, mostly using a Fourier transform MS.198 This approach has 
the advantage that it provides a high protein sequence coverage and accurate PTM 
localization. Furthermore, unlike in the bottom-up approach, protein isoforms and 
degradation products can be unambiguously determined. Yet, top-down proteomics 
remains technically challenging, because of separation and quantification difficulties of 
whole proteins.  
 In contrast, in the bottom-up approach a peptide-to-protein sequence is followed 
for protein identification, which is based on the mass spectrometric measurement of 
peptides. The mass range and fragmentation characteristics of peptides, rather than that 
of intact proteins are better suited to MS capabilities, which is why the bottom-up 
approach has become the method of choice for protein analysis. However, at the same 
time protein identification became more challenging, since the identified peptides had to 
be reassigned back to the original protein using a method called protein inference.199 The 
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problem was tackled with the development of efficient computational methods and 
software tools.200 Nevertheless, the problem is aggravated by the fact that the same 
peptide sequence can be found in multiple different proteins, making an unambiguous 
protein identification difficult. Especially the identification of protein isoforms or protein 
degradation products is not trivial as they generate a large set of identical peptides. Thus, 
generally a protein is considered to be confidently identified with at least two unique 
peptides. 
1.3.5 Liquid-chromatography tandem mass spectrometry 
1.3.5.1 Sample preparation 
Protein analysis with the bottom-up approach relies on liquid chromatography tandem 
mass spectrometry (LC-MS/MS), which is the current gold standard technique for 
proteomics analysis. It provides a robust method for large-scale, high-throughput protein 
analysis. Upon denaturation (mostly urea), reduction (mostly DTT) and alkylation (mostly 
iodoacetamide), proteins in a sample are digested into peptides in-solution, usually with 
the protease trypsin. In case of gel-separated proteins digestion is performed directly in 
gel (often robotic in-gel digestion), followed by elution of the resulting peptide mixture 
(Gel-LC-MS/MS). Trypsin usually generates peptides between 0.5 to 3 kDa, which is an 
optimal mass range for chromatographic separation and ionization.196 Enzymatic cleavage 
with trypsin occurs at the carboxyl side of the amino acids lysine or arginine, except when 
either is directly followed by proline. Thus, peptides found without a lysine or arginine 
residue – so called “non-tryptic” peptides - often indicate their endogenous cleavage as 
degradation products. Trypsin is most commonly used, since it has a high cleavage 
specificity and is robust and cheap. However, missed cleavages with trypsin are common 
and need to be considered for the subsequent database search.201 
1.3.5.2 MS analysis 
Following enzymatic digestion, peptides are purified mainly using C18 reversed-phase 
resins and separated by reversed-phase LC according to their hydrophobicity. LC is 
directly coupled to the MS, so that eluted peptides are immediately ionized by ESI and 
enter the MS. Despite high resolving capabilities of LC, simultaneous co-elution and co-
ionization of peptides cannot be fully prevented, which has an impact on the subsequent 
analysis performance. The peptides are identified in two steps, hence the term tandem 
MS or MS/MS: in the first step, MS1 or survey scan, the m/z and intensity of the intact 
ionized peptide (precursor ion) is determined. To identify its sequence, in addition to its 
exact mass, the peptide is isolated and fragmented along its backbone, usually by 
energetic collision with an inert gas such as helium, nitrogen or argon, in a process called 
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collision induced dissociation (CID).202 In a second mass analyser the m/z ratios of the 
generated fragment ions are measured, resulting in the MS2 or MS/MS spectrum. Figure 
10A illustrates the LC-MS/MS approach from digestion to protein identification. The 
following example gives an idea of the amount of the collected data in the above 
described analysis platform: an MS1 spectrum is obtained roughly every two seconds. 
From this, in a typical shotgun approach up to 15 peptides are selected for fragmentation 
and their MS/MS spectrum is recorded simultaneously with the MS1 spectrum. Thus, in a 
usual two – four hours chromatography run this adds up to an enormous amount of 
collected data.173 
1.3.5.3 Protein identification algorithms 
Upon obtaining the MS2 spectra there are two ways of identifying the protein sequence: 
database search or de novo sequencing.184, 203 
In de novo sequencing the sequence is directly retrieved from the spectra, 
independently of pre-existing protein databases.204 Fragmentation at the peptide bond 
generates peptides of increasing size: b-ions containing the N-terminus or y-ions with the 
C-terminus. Fragments are numbered depending on the amino acids they contain. For 
example, a fragment containing the N-terminus with 3 amino acids is called a b3 ion, while 
a fragment with the C-terminus and 2 amino acids is termed a y2 ion. Thus, the sequence 
information can be deduced from the mass difference between two consecutive fragment 
ion spectra, each corresponding to an amino acid, for each of which the mass is known 
(Figure 10B). This approach is particularly useful for peptide precursors which are not 
present in a sequence database. For example, a sequence carrying unexpected 
modifications with an altered mass profile or for the identification of proteins from species 
with incompletely sequenced genomes. However, de novo sequencing is quite an intricate 
process, since a complete fragmentation ladder is very rarely provided and because of the 
presence of noise peaks. Also high-throughput experiments generating an enormous 
amount of peak data are ill-suited for this approach.  
Thus, the much simpler database search is more commonly applied for protein 
identification.205, 206 In this approach, the measured fragment spectra are matched against 
a protein database with a search engine, such as Mascot200, SEQUEST207 or 
X!Tandem.208 The databases contain theoretical fragment spectra of in silico digested 
peptides according to the known cleavage patterns of the used proteases, most 
commonly trypsin. The match between an actual measured fragment spectrum and a 
theoretical database spectrum is given a score. Thus, the peptides with the highest 
matching scores are selected and lead to highly confident protein identification. Since 
mass shifts can result from PTMs or artificial modifications while sample preparation such 
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us a cysteine modification due to alkylation with iodoacetamide, these alterations need to 
be considered and set for search algorithms. Thus, matching occurs within a pre-set mass 
tolerance. Ultimately, accurate identification relies on the availability of complete and 
accurately annotated sequence databases.199 This approach fails to recognize peptides 
not present in the database. While for human and mice mainly complete sequence 
databases exist this is more challenging for other species. However, complete software 
packages such as PEAKS, which contains features of both approaches, de novo 
sequencing as well as database search options are available to alleviate disadvantages of 
both methods.209 Pig and human proteins share high sequence homologies due to their 
phylogenetical similarity210 (e.g. >90% similarity for decorin as scored in BLAST). Thus, for 
example, pig insulin was historically used to treat human patients with diabetes.211 Though 
this similarity allows protein identification using human databases for porcine proteins, the 
protein quantification and identification can be further improved with a porcine database. 
Thus, for our study we have generated a custom-made porcine database for ECM 
proteins. Finally, to quantify confidence in correct peptide identification or false positive 
identification respectively, false discovery rate (FDR) estimation can be used.212 The most 
common method of estimating FDR is by searching the data against a decoy database. A 
decoy database contains randomized non-natural peptide sequences for example by 
reversing the genuine amino acid sequences of all database entries. Thus, a match 
against a decoy database is random and per definition false. FDR can be estimated by 
comparing distributions of randomized and non-randomized matches. 
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Figure 10. Protein identification by LC-MS/MS.  (A) (a) Tryptic digestion of protein mixtures is 
followed by LC separation of the resulting peptides to reduce sample complexity (b). Separated peptides 
are ionized and directly injected into the MS (c).  (d) In a survey scan the m/z and relative abundance of 
ionized peptides are determined by the first mass analyser. (e) Peptides are selected for fragmentation 
by CID on the basis of their abundance. The m/z of the resulting fragment ions is measured by tandem 
MS (MS/MS). (f) Protein identification is commonly accomplished by database searching, which contains 
all theoretical MS/MS spectrum patterns resulting from in silico fragmentation of all known protein 
sequences.  (B)  De novo sequencing. Using this method protein sequence is directly retrieved from 
the spectra, independent of protein databases. (a) Fragmentation at the peptide bond generates b-ions 
containing the proteins N-terminal end and y-ions with the C-terminus.  (b) The sequence information is 
deduced from the mass difference of two consecutive fragment ion spectra, as the mass for each amino 
acid is known. By analysing both, b and y ions the sequence is determined. Here, generically only b-ions 
are shown. 
 
1.3.6 Shotgun proteomics 
The term shotgun proteomics simply refers to the application of LC-MS/MS to globally 
profile proteins in a complex sample in a high-throughput manner. In this method peptide 
identification is usually accomplished by database matching as described above. Shotgun 
proteomics relies on the DDA method. “Data dependent” in this context refers to the 
selection criteria of peptides for fragmentation in MS2. That means in complex samples, 
where multiple peptides are simultaneously ionized, it is not possible to select all peptides 
in the survey scan for fragmentation, as this would overwhelm the sequencing capabilities 
of most instruments.  Instead, a deliberate peptide selection for fragmentation is required, 
which is based on predefined criteria, hence data dependent. These are: protein 
abundance, signal intensity and charge state. Selection is made real time by the MS 
software during the survey scan and newer MS are able to select the 15 most abundant – 
“top 15” – proteins. Thus, a fixed number of precursor ions is selected in every MS1 
survey scan and analysed by MS2. Charge state preselection is used to exclude singly 
charged ions, which are mostly contaminants.196 In addition, the acquisition parameter 
“dynamic exclusion” is enabled to prevent repeated selection of the same peptide, thus 
overcoming interference from high abundant proteins and also allowing low abundant 
proteins to be identified. Nevertheless, under sampling of low abundant peptides is not 
completely eliminated and remains a bias, not even in newer instruments with increased 
sequencing speed. Precursor selection is a stochastic and irreproducible process, which 
will never be exactly the same between two runs of an identical sample due to variability 
of chromatographic separation. Thus, reproducible quantification, especially of low-
abundant peptides remains a challenge. However, the run-to-run variability remains within 
an accepted range for most discovery based proteomics studies, especially with extensive 
prefractionation, making shotgun proteomics a robust platform for global protein analysis. 
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1.3.7 Quantitative proteomics 
In biological studies, especially in differential expression studies, it is not only of interest to 
identify a protein in a sample but also to obtain its quantity. Yet, mass spectrometry itself 
is not truly quantitative due to sequence-specific differences in ionization efficiency of 
peptides (and ion suppression). However, MS-based quantification strategies are well 
suited for relative quantification between samples run under the same MS conditions. 
Absolute quantification can be achieved by using internal standard peptides with targeted 
proteomics as will be discussed in section 1.3.8.2. Generally, quantification with MS can 
be divided in label-free and stable isotope-labelling methods.213 
1.3.7.1 Label-free quantification 
Label-free quantification became possible with advances in computing power. There are 
two different approaches for label-free quantification using either mass spectrometric 
signal intensity or spectral counting.214 The latter is based on the obvious rationale that 
more abundant peptides generate more MS2 spectra. Therefore, relative quantification is 
achieved by counting the number of MS2 spectra assigned to a protein across the 
samples. However, this approach is still controversial, since it does not take the direct 
physical peptide properties into account assuming a linear response for every peptide.215 
The second approach uses spectral ion currents for relative quantification. Advanced 
pattern comparison software is applied to align ion intensities of the same peptide on MS1 
and MS2 level in different samples. The main advantages of label-free quantification are 
that it is cost-effective, achieves higher proteome coverage and it does not require 
laborious labelling workflows. Thus, making it the preferable method for large sample 
analysis. 
1.3.7.2 Stable isotope-labelling 
This approach is based on the incorporation of stable isotope tags into peptides or 
proteins either by a chemical reaction, a metabolic or enzymatic process. Stable heavy 
isotopes have the same physico-chemical properties as their light counterparts, meaning 
they behave identically on chromatography. However, due to their slight mass difference, 
they generate distinguishable signals in the MS, making them ideal for quantification 
purposes. Compared to label-free methods, the labelling approach provides a higher 
quantitative accuracy and consistency. This is due to near equal ionization efficiencies of 
the isotope tags. The most commonly used labelling methods are stable isotope labelling 
by amino acids in cell culture (SILAC), tandem mass tags (TMT) and isobaric tagging for 
relative and absolute quantification (iTRAQ) (Figure 11).  
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Stable isotope labelling by amino acids in cell culture  
SILAC is an in vivo metabolic labelling approach on the protein level (Figure 11A).216 This 
means proteins are already labelled during their synthesis in cells. This is achieved by 
growing cells in a medium containing isotopically labelled amino acids, which are 
incorporated in the proteins. Mostly arginine and/or lysine are heavy labelled with 13C 
isotope (instead of 12C) or 15N isotope (instead of 14N) to ensure that all tryptic peptides 
contain a labelled isotope. Lysine has the additional advantage of being an essential 
amino acid, which cannot be produced de novo. At the same time cells of the other 
experimental condition are grown in normal medium, containing the normal or “light” 
amino acids. Eventually both samples are multiplexed and analysed in the same MS run, 
which reduces experimental variability. The heavy and light labelled protein pairs co-elute 
on chromatography. Due to the characteristic mass shift in their MS1 spectra (for example 
6 Da for 13C lysine) the relative quantity for each protein can be calculated. An equal ratio 
between both samples indicates no difference in abundance. If the heavy labelled peptide 
exhibits a higher peak intensity, than the protein was more abundant in the labelled 
sample and vice versa.  
Application of SILAC goes beyond cells in culture, but is also used for mice without 
affecting their development, growth or behaviour217 – as the proteins are chemically 
identical except for their mass difference. However, SILAC diet is expensive, thus limiting 
its use to small animal models. SILAC is also a very useful tool to assess protein 
turnover.218, 219 Upon feeding a SILAC diet to animals the amino acids are gradually 
incorporated into the newly synthesized proteins and are clearly distinguishable from pre-
existing proteins. Thus, the ratio between heavy and light peptides indicates the protein’s 
synthesis rate and can be compared across different proteins.  
Isobaric tagging 
In the mass tagging approach proteins or peptides are chemically tagged with a stable 
isotope-containing molecule in vitro. Thus, unlike SILAC this approach is also applicable 
to human samples. The most commonly used tags are TMT220 and iTRAQ221, both 
belonging to the category of isobaric mass tags. The tags are available with different 
isotopic substitutions (reporter regions) creating distinct mass differences to allow 
multiplexing of currently up to ten samples with TMT (10-plex) and eight with iTRAQ (8-
plex). Again multiplexing offers the advantage of reducing experimental error. Each tag 
consists of three functional regions (Figure 11B). The amine-reactive region is equal in all 
tags and allows the binding to the N-terminus and side chain amines of peptides. In 
addition, they have a mass reporter and a balance region, which are different and unique 
to each tag, due to isotopes substituted at various regions. As the name indicates the 
function of the balance region is to compensate the variable mass of the reporter region, 
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so that the intact tag has the same mass in all samples, hence the term “isobaric”. Thus, 
after mixing of all differently labelled samples the peptides remain undistinguishable 
during chromatographic separation and MS1. Only upon fragmentation in MS2, the 
different reporter regions are released enabling the distinction and quantification of the 
peptide in different samples. 
Cysteine-reactive mass tags are also available (iodoTMT), to specifically label 
cysteine-containing peptides, commonly applied in the field of redox-proteomics. In 
comparison to the isotope coded affinity tags (ICAT), multiplexed quantification (up to 6-
plex) is possible. ICAT, also with specificity towards sulfhydryl groups, contains an 
additional biotin affinity tag.222 This tag enables purification by avidin affinity 
chromatography. Thus, it allows further reduction of sample complexity by targeted 
labelling and enrichment, but only to identify proteins with cysteinyl residues. 
The downside of isobaric mass tagging is that labelling occurs at the peptide level, 
thus late in the experimental workflow. Therefore, potential experimental variations before 
labelling cannot be prevented. In comparison SILAC provides a very accurate 
quantification with minimal experimental error, since the introduction of isotopes occurs as 
early as possible during synthesis. A further caveat associated with this method is that a 
complex background can lead to inaccurate quantification. Mixed MS/MS spectra resulting 
from the simultaneous fragmentation of more than one peptide from different proteins, can 





Figure 11. Stable isotope-labelling. (A) The SILAC approach allows an early metabolic labelling 
already at the protein level during protein synthesis by incorporation of heavy or light amino acids. 
Proteins are mixed, digested and analysed by LC-MS/MS. Due to their characteristic mass shift in MS1 
their relative quantity can be determined. (B) In contrast, using iTRAQ or TMT labelling is performed 
only at the peptide level. Different tags allow multiplexing and reduce experimental error. Upon individual 
labelling of each sample, peptides are mixed. Both iTRAQ and TMT are ‘isobaric’ tags, meaning that the 
peptides co-elute in chromatography and cannot be distinguished in MS1 due to their balance region. 
Only in MS2 peptides can be relatively quantified due to the mass shift in the reporter regions. 
 
18O labelling 
Another labelling method is the enzymatic incorporation of stable isotopes, such as 18O 
instead of 16O.224 In this approach isotopic labelling occurs during the proteolytic digestion 
of proteins. The cleavage of peptide bonds requires the addition of H2O. If the reaction is 
performed in the presence of 18O labelled water (H218O), the generated peptides have 
either a 2 or 4 Da mass shift compared to their natural counterparts, depending on 
cleavage occurring at either one or both ends. Though it is highly specific and universally 
applicable a major limitation of this method is the enzyme-mediated back-exchange of 18O 
with 16O, resulting in complicating data analysis.225 However, by using immobilized trypsin 
which is removed upon digestion/labelling, the back-exchange can be widely 
prevented.213, 226 Also software tools for efficient quantitative analysis of complex samples 
have been developed.227 
INTRODUCTION 
 59 
 Further, this principle is also applied for PTM studies, namely for the identification 
of N-linked glycosylation sites on proteins.228 During enzymatic deglycosylation of N-linked 
glycans under incorporation of H2O, the enzyme PNGase-F converts asparagine to 
aspartic acid via a deamidation reaction causing a mass shift of 0.984 Da. Thus, if H218O 
is used, it leads to a mass shift of 2.99 Da, which leads to increased search specificity and 
indicates the former presence of glycosylation at that position. 
1.3.8 Targeted proteomics 
In contrast to discovery or shotgun proteomics as extensively discussed in section 1.3.6, 
targeted proteomics allows the precise identification of specific proteins of interest. Thus, 
it provides a hypothesis-driven proteomics strategy,229 which is often deployed to validate 
and complement the findings obtained from discovery approaches. The focus on 
predetermined target proteins offers a significantly higher sensitivity, quantitative accuracy 
and reproducibility than the DDA approach. Indeed, due to these highlighted 
characteristics together with its advantages over conventional antibody detection, targeted 
proteomics has been appreciated as the method of the year 2012 by the journal Nature 
Methods.230 
The typical MS method for targeted proteomics is selected reaction monitoring 
(SRM) mainly carried out on triple quadrupole instruments (QQQ). Due to the multiplexed 
analysis capability the method is also called multiple reaction monitoring (MRM), which is 
used synonymously with SRM.231 In SRM, the first mass analyser (Q1) selects precursor 
ions within a mass range around the mass of the predetermined targeted peptides, which 
are then fragmented by CID in the collision cell (Q2). The specific fragment ions of the 
targeted peptide are then selected and measured by the second mass analyser (Q3) 
(Figure 12 A). A specific precursor – fragment ion pair is termed a transition. The high 
selectivity and specificity of this method is given by the two levels of mass selection in Q1 
and Q3 acting as a two-stage mass filter. In principle, the instrument is preprogramed to 
consistently monitor the same set of predefined transitions (Q1/Q3 pairs) and record their 
intensities over the entire chromatography run. This is considered as the basis for its high 
reproducibility in repeated samples. Thus, analysis time is optimally used on the peptides 
of interest, largely eliminating interference from high abundant/ contaminant peptides. On 
the other hand, its use is only limited to preselected peptides, as no full mass-spectra are 
recorded. Currently the number of peptides that can be monitored in a single run without 
compromising performance is limited to around 100 peptides. Multiplexing up to 1000 
proteins is possible, however at the cost of reduced quantification accuracy.232 
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1.3.8.1 MRM assay generation 
A selective transition/inclusion list needs to be generated to set the instrument and start 
the experiment. This strongly depends on the knowledge of the MS characteristics of a 
peptide and its fragmentation products. The required MRM transition data for a given 
protein is called an MRM assay. This information is mostly derived from previous 
untargeted MS experiments or alternatively the MRM assays can be retrieved from an 
online compendium (see below).  
Firstly, a number of rules need to be considered when selecting the optimal 
peptides.233 In essence, the selected peptides need to be unique for the protein of 
interest, or proteotypic as it is also called. Preferably, the peptide should be of medium 
length, fully tryptic and should not contain abundant PTMs or amino acids prone to 
variable chemical modifications such as asparagine (N) deamidation or methionine (M) 
oxidation. In terms of their MS parameters peptides with the most intense transition peaks 
are selected. In addition to their m/z values, the optimal collision energy and the 
chromatographic retention times are retrieved. The latter is used to monitor the expected 
transitions close to their corresponding elution time.234 Due to these timed ion selection 
windows in the so called “scheduled MRM” approach more transitions can be 
monitored/multiplexed in one run. All these considerations together contribute to the 
unprecedented sensitivity of this method. Although initially laborious, once the assays are 
established, they can be used in a highly multiplexed manner with great reproducibility 
across different sample sets. Indeed, the extensive effort required to develop MRM 
assays has been considered as the main reason for MRM becoming only lately popular in 
the field of proteomics,232 even though it has been widely applied to the measurement of 
small molecules such as drugs or metabolites in the past decades. Thus, great effort is 
put to improve the situation for example by the introduction of freely-accessible validated 
online transition lists, such as the SRMAtlas (http://www.srmatlas.org/) to retrieve the 
MRM assays needed. This is a compendium of highly specific MRM assays that has 
enabled the quantification of 99.7% of the > 20 000 annotated human proteins.235 The 
assays are developed and validated by the wider proteomics community.236  
Parallel reaction monitoring (PRM) is a newer targeted proteomics development, 
where Q3 of a triple quadrupole is substituted with a high-resolution accurate mass 
analyser such as TOF or orbitrap.237 This allows the accurate detection of all fragment 
ions due to higher resolution, while in MRM the transitions are usually restricted to a 
maximum of 5. Thus, PRM requires less time for assay development, since it monitors all 
transitions and obviates the need for preselecting target transitions. 
INTRODUCTION 
 61 
1.3.8.2 Database search and absolute quantification using MRM 
For analysis of targeted proteomics data, mainly the open-source software Skyline is 
deployed. Even though the software offers an automatic selection of the best transition 
matches for each peptide, the correct attribution/identification needs to be visually 
matched and the peak areas manually integrated, making the data analysis a 
cumbersome process.  
Most importantly, SRM is the prototypical MS quantification method, as it is highly 
consistent and accurate. It allows absolute quantification, by spiking-in heavy labelled 
reference peptides of known concentrations. Additionally, iRT standards are used for 
retention time calibration. Briefly, the fragment ion intensities of peptides of interest are 
related to corresponding signals of isotopically labelled peptides with the same sequence 
(Figure 12B). Finally, due to the above highlighted characteristics of targeted proteomics 
without the constraints of antibody based protein detection and quantification, MRM is 
emerging as a promising alternative to traditional protein quantification methods such as 
ELISA. By applying this method, commercially available kits such as PlasmaDiveTM, allow 
the absolute quantification of up to 100 proteins in human serum or plasma.238 The 
increasing importance of targeted MS technologies for clinical application is reviewed by 
Carr et al.239 
 
Figure 12. SRM/MRM analysis on a triple quadrupole (QQQ) MS. (A)  Most co-eluting peptides are 
filtered by the first quadrupole (Q1) based on a predetermined list of targeted precursor – fragment ion 
pairs (transitions). The selected peptides are subjected to fragmentation by CID in Q2 and their fragment 
ions are selected and measured by Q3. (B) Heavy labelled reference peptides of known concentration 




1.3.9 Data independent analysis 
1.3.9.1 DIA in comparison with DDA and MRM 
Neither the untargeted discovery nor the targeted proteomics approach on its own is able 
to quantify every single component of a proteome. Each method is a compromise that 
improves analytical performance at some level, while reducing it at another. DDA is 
biased due to its random selection of peptides for fragmentation. Thus, reproducible 
quantification, especially of low-abundant peptides remains its major limitation. On the 
other hand, MRM is limited to the detection of preselected peptides requiring a priori 
knowledge. Therefore, it is not suitable for a discovery-based approach. Additionally, it 
has a limited multiplexing capacity. To overcome the limitations of both methods and 
combine their advantages the unbiased data-independent acquisition (DIA) mode was 
adopted for proteome analysis. This method aims to obtain the MS2 spectra of every 
single precursor ion regardless of its abundance or its prior knowledge, hence the term 
“data independent”. Therefore, DIA provides an unbiased discovery approach for 
reproducible and accurate quantification of the entire proteome in a sample without being 
restricted to predefined peptides. A comparative summary on the data acquisition mode in 




Figure 13. Comparison of data acquisition using the MRM, DDA or DIA method.  Both DDA and 
DIA are discovery based approaches, while MRM allows targeted identification of only preselected 
peptides (A, Figure 12). (B) In the DDA mode, peptides for fragmentation are selected on the basis of 
their abundance upon a survey scan in Q1. Top 6-20 ions (a fixed number depending on the 
instruments’ capacities) are fragmented in Q2 and their complete fragment ion array is measured in Q3 
resulting in the full-scan MS/MS spectrum. Due to the biased selection, reproducibility is a limitation of 
the DDA mode, especially of low abundant peptides. (C) In contrast, in the unbiased DIA approach all 
peptides within a defined isolation window are subjected to fragmentation (Q2) and detected by a high-
resolution TOF analyser. This results in highly multiplexed fragmentation maps which are analysed by 
targeted data extraction based on established spectral libraries. 
 
1.3.9.2 Data acquisition in the DIA mode 
The key to achieve a complete MS2 spectrum is the sequential isolation window 
acquisition principle.240 More precisely, the MS triggers fragmentation of all precursor ions 
within a predefined m/z isolation window.  Due to seamlessly adjacent isolation windows 
the entire precursor m/z range expected for tryptic peptides can be covered in a single 
duty cycle. What is more, the width of a cycle is adjusted to be shorter than the 
chromatographic elution time of a peptide. Eventually, while the instrument repetitively 
cycles through the consecutive isolation windows fragmenting each peptide, MS2 spectra 
of all possible precursors are recorded in real time. This results in the generation of 
complete, but complex fragment ion maps. However, due to this multiplexed recording of 
MS2 spectra originating from multiple precursors, the relationship between the fragment 
ion and its precursor is lost. For comparison, in the DDA method the MS2 spectrum is 
generally well associated with the MS1 spectrum. Thus, the uncoordinated record of 
precursors and their fragment ions immensely complicates the data analysis. Therefore, 
the main challenges of the DIA mode are data processing and interpretation of 
multiplexed MS2 spectra. 
1.3.9.3 SWATH-MS and DIA data analysis 
The DIA strategy of unbiased MS2 data acquisition is not new, several DIA methods with 
various isolation window widths have been proposed previously.241-245 However, recent 
improvements in MS instruments regarding their resolution power, mass accuracy and 
scan speed have greatly contributed to the maturation of the DIA strategy. Currently the 
most advanced DIA strategy in applied proteomics is SWATH-MS (sequential windowed 
acquisition of all theoretical mass spectra).246 SWATH-MS experiments are typically 
performed on high resolution quadrupole TOF instruments. In this setup 32 fixed 
precursor isolation windows (swaths) with a width of 25 m/z each are used to cover a 
mass range of 400 – 1200 m/z (allowing an overlap of 1 Da between two adjacent 
windows). With a dwell time of 100 msec for each window, the total cycle time adds up to 
3.2 sec. The data from all windows is compiled together in a single map, termed the 
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SWATH map. The reason for SWATH-MS’s success lies in the novel data analysis 
strategy, which is fundamentally different from the standard database searching tools 
applied in previous DIA methods. Though a discovery based approach, the data analysis 
is accomplished using a targeted data extraction strategy for confident scoring. The data 
in generated fragment ion maps are mined using fragment ion spectral libraries supported 
by software such as OpenSWATH or Skyline. The spectral or assay libraries contain the 
exact MS coordinates for each targeted peptide including the precursor m/z, the fragment 
ion m/z, their intensities and their chromatographic retention time. Thus, peptides in the 
map can be uniquely identified with MRM-like reproducibility and quantification accuracy. 
However, currently as a developing MS technique, DIA cannot compete with MRM in 
terms of sensitivity, especially for low abundant peptides.240, 247 Moreover, for successful 
data analysis, availability of high-quality assay libraries as complete as possible is 
crucial.248 Any possible peptide of interest (including isoforms, degradation products or 
PTM carrying forms) can be queried in DIA maps. Since the SWATH map is a permanent 
digital record of fragment ion spectra for all peptides in a sample, it is possible to 
reanalyse the data as new targets of interest arise. The permanent nature of SWATH 
maps has also compelled researchers to convert tissue biopsy samples into permanent 
digital maps that can be perpetually queried in silico.249 
Notably, the query of DIA data is quite a recent strategy compared to DDA, which 
has been optimized over the past two decades. Thus, facilitation of DIA data analysis by 
optimized protocols for spectral library generation, automated data extraction or scoring 
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2 HYPOTHESIS 
Despite continuous improvements in stent technology, stent failure still occurs. In-stent 
restenosis and neoatherosclerosis are the major causes. Coronary artery stent 
implantation induces vascular injury resulting in ECM remodelling. Modulating ECM 
deposition might be a promising approach for preventing restenosis after stent 
implantation without interfering with re-endothelialisation. 
 
3 AIM 
The aim of the study is to obtain temporal profiles of ECM changes following implantation 
of BMS and DES, thus characterising ECM proteins contributing to vascular healing in 
response to stent injury. Our current understanding of ECM remodelling upon stent 
implantation is based on histopathological studies, investigating the role of only few 
selected ECM proteins. In comparison, proteomics provides a more holistic approach to 
profile ECM changes post-stenting, rather than just individual ECM proteins by antibody 
staining. By applying proteomics to a large animal model of vascular stent injury, this 
study aims to identify changes in key regulatory ECM proteins after stent-induced vascular 
injury. 
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4 MATERIALS AND METHODS 
4.1 Porcine experiments 
4.1.1 Porcine model of stent injury 
All procedures in pigs were approved by the local ethical committee for animal 
experiments, Institute of Pharmacology Polish Academy of Sciences, Cracow, Poland. For 
this study PCI was performed in 12 healthy male and female Polish domestic swine 
(Polska Biala Zwisloucha), which are a crossbreed of the European and the German 
domestic swine. All animals were obtained from the same supplier Institute of 
Zootechnology, National Research Institute, Experimental Centre in Grodziec Slaski. By 
the time of intervention all animals were between 3-4 months old and weighed between 
28-48 kg. Pigs were premedicated with intramuscular atropine sulfate (0.05mg/kg) and 
anaesthetized by intravenous (i.v.) injection of ketamine hydrochloride (20 mg/kg), 
xylazine (2 mg/kg) and propofol (20-40 mg/kg) followed by intubation. Anaesthesia was 
maintained with continuous i.v. propofol infusion (2-4 mg/kg/h). Anticoagulant therapy with 
heparin (5000 IU) was administered prior to the procedure and additional i.v. bolus 
injections of heparin (2000 IU) were administered every 30 min during interventions 
lasting longer than 60 min. To prevent the risk of in-stent thrombosis pigs received a 
loading dose of 150 mg aspirin and 150 mg clopidogrel bisulphate orally 1 day prior to 
coronary intervention and remained on dual anti-platelet therapy with 75 mg each orally 
once daily until termination. 
PCI was performed through femoral access by an experienced interventional 
cardiologist in accordance with equal guidelines applied to humans: sterile conditions, 
activated clotting time > 250 sec, use of sterile disposable equipment and ECG-, O2 
saturation- and blood pressure monitoring. The coronary arteries of each animal, i.e. the 
left anterior descending artery (LAD), the left circumflex artery (LCX) and the right 
coronary artery (RCA) were either stented with a BMS (MULTI-LINK cobalt chromium 
stent, Abbott Vascular, US) or everolimus-eluting DES based on the same cobalt-
chromium platform (XIENCE PRO Everolimus Eluting Coronary Stent System, Abbott 
Vascular, US) or had balloon angioplasty alone without stent implantation (plain old 
balloon angioplasty - POBA). Stents were supplied free of charge by Abbott Vascular. Full 
strut expansion was achieved for each deployed stent. Intracoronary nitroglycerin (1 mg-
wise) was given when intracoronary spasms occurred. Further medication included the 
application of prophylactic post-interventional single dose i.v. wide spectrum antibiotics 
lincomycin hydrochloride (5 mg/kg) and spectinomycin sulfate (10 mg/kg) (Linco-Spectin, 
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Pfizer, US), as well as the antiparasitic agent ivermectin (10mg) (IVOMEC, Merial, 
France). Quantitative coronary angiography and OCT were performed on follow-up 
procedure 1, 3, 7, 14 or 28 days post-stent implantation, followed by harvesting of the 
coronary arteries. These procedures were performed by a team around Prof. Wojtek 
Wojakowski from the 3rd Division of Cardiology, Medical University of Silesia, Katowice, 
Poland.  
4.1.2 OCT image analysis in pigs 
OCT imaging was performed at stent implantation and at follow-up using the 
ILUMIEN OPTIS imaging system (St. Jude Medical, US). The OCT probe (mid marker of 
the OCT Dragonfly catheter) was positioned 5 mm distally to the analysed stent. All OCT 
imaging was performed using automated pullback triggered by hand injection of contrast. 
Every 1 mm of the stent was scrutinized by OCT to assess minimal lumen area, stent strut 
apposition, stent strut coverage and neointimal volume. Also, qualitative analysis of the 
neointima was performed classifying the neointima into heterogeneous, layered or 
homogenous with peristrut attenuation or ring. If peristrut attenuation was visible in the 
whole circumference of the stent at the single OCT cross-sectional frame, the peristrut 
ring was recognized. The data was analysed using the OCT image analysing system 
CAAS IntraVascular (version 1.1, Pie Medical Imaging). This procedure was performed by 
a team around Prof. Wojtek Wojakowski from the 3rd Division of Cardiology, Medical 
University of Silesia, Katowice, Poland.  
4.1.3 Porcine sample collection and processing  
Upon harvest, the arteries including the stents were immediately snap frozen with liquid 
nitrogen and subsequently kept therein until shipment in dry ice. Perivascular tissue and 
stent struts were carefully removed from the arteries under a dissecting microscope. Non-
stented artery segments were removed and a piece of the dissected stented/POBA 
treated artery sections were used for proteomics analysis. Another piece of the same 
artery was used for RNA extraction for validation studies. In the tissue used for proteomics 
analysis the neointimal tissue, that had developed in stented arteries at day 28 were 
dissected from the media and analysed separately. In total, 31 samples were analysed for 
the media by LC-MS/MS (n=3 BMS and n=3 DES at each time-point 1, 3, 7 and 28 days; 
n=4 POBA early [day1-day3] and n=3 POBA late [day 14 - day28]). For the neointima a 
total of 14 samples were analysed (n=7 BMS, n=7 DES at 28 days) including the 
neointima of arteries of a second cohort with 4 samples each for BMS and DES day 28. In 
addition, six coronary arteries of 4.5 months old healthy, untreated pigs were harvested as 
unstented controls and used for validation studies.  
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4.2 Mice experiments 
4.2.1 Mouse model of venous bypass graft  
Mice experiments were performed by authorized researchers (Dr. Ursula Mayr) in the 
Cardiovascular Division at King’s College London. Housing and animal care were in 
accordance with the UK Animals (Scientific Procedures) Act 1986. An established mouse 
model of venous bypass graft was used by grafting isogeneic venae cavae to common 
carotid arteries of C57BL/6J mice, as described previously.250 Mice were anaesthetised by 
intraperitoneal injection of ketamine (75 mg/kg) and medetomidine HCL (1 mg/kg). A 
segment of vena cava of approximately 1 cm from a donor animal was grafted end-to-end 
to carotid arteries using a cuff technique. Briefly, this technique involves, that the ligated 
ends of the dissected artery are passed through a cuff over which a segment of the artery 
is everted and fixed with a suture. The harvested vena cava segment is then grafted 
between the two ends of the carotid artery by pulling the ends of the vein over the artery 
cuff and suturing them together. Upon detection of vigorous pulsations in the grafted 
vessel, the skin incision was closed.  
Vessels of SILAC fed mice for targeted proteomics analysis 
Post-surgery 9 mice were fed a SILAC diet containing heavy lysine (Lys+6) ad libitum to 
label the newly synthetized proteins upon surgery. SILAC feed was obtained from 
Silantes, Germany. Mice were euthanized by anaesthetic overdose 28 days 
postoperatively. The vein grafts were harvested by cutting the implanted segment from the 
native vessel at the cuff end, together with the native vena cava and the aorta. The 
vessels were processed for targeted proteomics analysis using the three-step extraction 
method as described below. 
Grafts for histology 
Additional mice (i.e. 2 per group) were fed a normal diet upon surgery and the grafts 
together with vena cava were harvested at time point 3, 7 and 28 days post-surgery for 
histological characterization. 
4.3 Human tissue collection 
All procedures involving use of human tissues were approved by a local Research Ethics 
Committee of St. George’s Hospital London, United Kingdom. Formal written consent was 
obtained from all patients prior to surgery. Normal saphenous vein specimens were taken 
by surgical resection in patients undergoing coronary artery bypass surgeries; the 
segment of the saphenous vein near the knee level was collected for analysis from each 
patient. Control aortic samples from patients without connective tissue disorder were 
obtained upon aortotomy performed during routine aortic valve replacement from positions 
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of the ascending aorta that were free of macroscopically evident vascular pathology. All 
samples were snap frozen following surgical removal. There were no known potential 
confounders during sampling of clinical specimens and tissues. The tissues were 
collected by a team around Prof. Marjan Jahangiri of St. George's Healthcare NHS Trust, 
London, United Kingdom. ECM extracts of these tissues were used for targeted 
proteomics and immunoblot analysis. The aorta was also used for immunofluorescence 
analysis.  
4.4 Protein extraction  
4.4.1 ECM protein enrichment 
To enrich ECM proteins in samples, the proteins of the porcine media as well as human 
and SILAC mice tissues were extracted in a three-step manner, using a method 
previously developed in our laboratory.114 For this purpose, the samples were partially 
thawed, diced into smaller pieces to enforce protein extraction and weighed. On average 
approximately 50 mg tissue per porcine media sample, 30-40 mg per human and around 
10 mg per mouse sample were placed in ice-cold phosphate-buffered saline (PBS) to 
remove plasma contaminants. A mixture of commercially available protease inhibitors 
(Sigma-Aldrich) was added according to the manufacturer’s guidelines to inhibit broad 
range proteinase activity and consequently prevent ECM protein degradation. In addition, 
25 mM EDTA, a chelator binding metal ions, was included to ensure metalloproteinase 
inhibition. In total the tissue was washed 3 times with PBS supplemented with protease 
inhibitor to ensure effective removal of plasma contaminants.  
After the wash-steps the proteins were stepwise extracted: first in salt (NaCl)-, 
followed by sodium dodecyl sulphate (SDS)- and finally in guanidine hydrochloride 
(GuHCl)- buffer. For the first extraction step, the diced samples were incubated with 0.5 M 
NaCl buffer, pH 7.5, further containing 10 mM Tris, 25 mM EDTA and proteinase inhibitors 
(Sigma-Aldrich). Buffer volume to tissue weight ratio was adjusted to 10:1 (µl/mg) and the 
samples were mildly vortexed for 1.5 h at room temperature. Subsequently the NaCl 
solution was removed and stored frozen at -80 °C for later use. The rationale behind the 
NaCl treatment is to induce displacement of polyionic interactions between proteins 
through the salt ions, thus facilitating the extraction of loosely bound extracellular proteins. 
These include newly synthesized ECM proteins and degradation products providing an 
overview of tissue turnover. Next, after a brief wash with distilled water, the samples were 
incubated with 0.08% SDS (buffer volume to tissue weight 10:1) supplemented again with 
protease inhibitors and 25 mM EDTA. The sample buffer mixture was mildly vortexed for 
1.5 h at room temperature and subsequently the SDS solution was stored frozen for later 
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use. The SDS is used to solubilize cell membrane lipid bilayers, therefore removing the 
cellular material while preserving the ECM and its associated proteins. Finally, 4M GuHCl 
buffer, pH 5.8, including 50 mM sodium acetate, protease inhibitors and 25 mM EDTA 
was added to the washed tissue samples in a 5:1 ratio of buffer volume to tissue weight. 
Incubation was performed for 48 h at room temperature with vigorous vortexing to 
enhance solubilisation of the ECM components. GuHCl is an effective buffer to solubilize 
most of the strongly bound ECM components, as it induced disaggregation of ECM 
components by destabilizing the ionic, disulphide-dependent protein conformation. 
Proteins of the more fragile porcine neointima samples (average tissue weight 25 mg) 
were extracted only in a single step in GuHCl buffer for 48h. 
Protein concentration of GuHCl and NaCl extracts were determined using a 
spectrophotometer at 280 nm (NanoDrop, Thermo Scientific). Protein concentration in 
SDS extracts were measured using the PierceTM BCA protein assay kit (Thermo Fisher, 
cat. no. 23227) according to the manufacturer’s protocol for more accurate results, as the 
SDS buffer interferes with the NanoDrop measurement. For proteomics analysis an 
aliquot of 15 µg protein of each GuHCl sample was mixed with 100% ethanol (10:1 
volume ratio) and stored at -20 °C overnight to remove guanidine, which otherwise would 
interfere with further processing steps. Precipitated proteins were pelleted by 
centrifugation (12 000 rpm for 50 min at 0 °C) and upon removal of ethanol the pellets 
were dried using a concentrator (SpeedVac Plus SC110 A, Savant) and kept at -20 °C 
until further use.  
4.4.2 Deglycosylation of ECM extracts 
After extraction and precipitation, proteins were deglycosylated for two reasons: first to 
facilitate the amino acid sequence determination of proteins by MS and second to improve 
epitope recognition by antibodies. Removal of the oligo- and polysaccharides was 
achieved using specific deglycosylation enzymes. Protein pellets of GuHCl extracts after 
ethanol precipitation were resuspended in 1x deglycosylation buffer (25 mM EDTA, 50 
mM sodium acetate, 50 mM Tris, pH 6.8) supplemented with deglycosylation enzymes 
and incubated at 37 °C in agitation (200 rpm) for 24 h in the first step. The deglycosylation 
enzymes included: chondroitinase ABC (1:100), keratinase (1:500) and heparinase II 
(1:500) (all from Sigma-Aldrich) for the removal of GAG side chains; 2 different 
debranching enzymes including α2-3,6,8,9-neuraminidase (1:200) and ß-N-
acetylglucosaminidase (1:200) as well as O-glycosidase (1:200) for the removal of the 
remaining O-linked sugars (all from Merck-Millipore). After the initial incubation samples 
were speed-vac dried. To identify N-linked glycosylation sites by isotopic mass-differences 
later in the mass spectrometer, PNGase F (1:200, from Merck-Millipore) was added 
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together with 18O water (Sigma-Aldrich). Removal of N-linked sugars requires the 
incorporation of an –OH group from H2O molecule, which converts the asparagine into 
aspartic acid and alters the mass of the remaining peptide. When isotopically labelled 
water is used, the mass difference is +2.99 Da instead of +0.98 Da with normal water. The 
higher mass shift is easier identified by the MS and also reduces false positive 
identifications of N-linked glycosylation sites due to a spontaneous deamidation. Further 
48 h of incubation followed after adding of PNGase F. When samples were 
deglycosylated for immunoblot analysis, no 18O water was used, and deglycosylation was 
accomplished in a single step including all enzymes or only the GAG removing enzymes 
in 48 h.  
4.5 Proteomics workflow for pig samples 
4.5.1 In-solution protein digestion 
Deglycosylated proteins were subjected to in-solution digestion to be analysed by a 
bottom-up proteomics approach with LC-MS/MS. 15 µg of deglycosylated protein was 
denatured with 6M urea and 2M thiourea in each sample. Next, samples were reduced 
with dithiothreitol (DTT) (final concentration 10mM) and incubated at 37 °C for 1 h in 
agitation (200 rpm). For alkylation iodoacetamide (IAA) was added (final concentration 50 
mM) followed by incubation at room temperature for 1h in the dark. Proteins were then 
precipitated with ice-cold acetone (6x the reaction volume) overnight at -20 °C, followed 
by centrifugation at 13000 rpm for 30 min at 4 °C. The protein pellets were speed-vac 
dried and resuspended in 30 µl of 0.1 M tetraethylammonium bromide (TEAB) buffer, pH 
8.2, containing trypsin at a trypsin:protein ratio of 1:50. The samples were left for digestion 
at 37 °C in agitation at 200 rpm overnight and 10% trifluoroacetic acid (TFA) was added to 
stop the reaction (final concentration 1% TFA). 
4.5.2 Peptide clean-up using C 18 
For purification of the peptide samples C18 clean-up was performed using a 96-well C18 
spin plate (Harvard Apparatus). The resin was initially wetted and activated in 200 µl 
methanol (100%) and centrifuged at 1000 x g for 1 min. Next, the resin was equilibrated in 
200 µl cleaning solution (80% acetonitrile and 0.1% TFA) and washed 3 x with 200 µl of 
washing solution (1% acetonitrile and 0.1% TFA) with centrifugation after each step. Only 
then samples were loaded onto the resin and centrifuged at 1500 x g for 1 min; the flow 
through was reloaded onto the resin to maximise peptide binding and centrifugation was 
repeated. The resin was then washed with 200 µl of washing solution for 3 times and 
centrifuged after each step. Eventually, the samples were eluted in 170 µl of elution 
solution (50% acetonitrile and 0.1% TFA) twice and collected in the same plate. The 
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eluted samples were frozen in -80 °C for 4 h and immediately lyophilised in a freeze dryer 
(Christ Alpha 1-2 LD Freeze Dryer) at -55 °C overnight. The lyophilised peptides were 
resuspended in 30 µl of 2% acetonitrile, 0.05% TFA in HPLC-grade H2O resulting in a final 
peptide-concentration of 0.5 µg/µl. Samples were kept frozen at -20 °C until LC-MS/MS 
analysis. 
4.5.3 Untargeted LC-MS/MS analysis 
The tryptic peptides of the porcine media and neointima were separated using a nanoflow 
HPLC system (UltiMate 3000 RSLCnano, Thermo Scientific) with subsequent MS/MS 
analysis on an orbitrap MS (Q Exactive Plus mass spectrometer, Thermo Scientific). 
Peptides were separated on a reversed-phase HPLC column (AcclaimÒ, PepMap 100 C18 
peptide column, 3 µm, 100 Å, 50 cm x 75 µm, Thermo Scientific) at a flow rate of 300 
nl/min and eluted with a 240 min gradient using a mobile phase solvent composition with 
increasing acetonitrile content. The following gradient was set: 2-10% B from 0-10 min; 
10-30% B from 10-200 min; 30-40% B from 200-210 min; 99% B from 210-220 min and 
eventually 2% B from 220-240 min; the mobile phase solvent compositions were as 
follows: A = 0.1% formic acid (FA) in HPLC grade H2O; B = 80% acetonitrile, 0.1% FA in 
HPLC grade H2O). The sequentially eluted peptides were directly analysed by an orbitrap 
mass analyser using a full ion scan mode over the m/z range of 350 – 1600 and a 
resolution of 70,000 at 200 m/z. Data-dependent MS/MS analysis was performed using 
higher-energy collisional dissociation (HCD) on the 15 most abundant ions in each full MS 
scan with dynamic exclusion enabled for 30 sec. 
4.5.4 Database search 
Spectral raw files were searched using Proteome DiscovererTM software (version 1.4, 
Thermo Scientific) against a custom-made hybrid database using Mascot (version 2.3.01, 
Matrix Science). The custom-made database contained a comprehensive porcine ECM 
protein list with a human proteome background (UniProtKB/Swiss-Prot, release 2014_06, 
20220 protein entries) (see section 4.5.5 for its generation). The mass tolerance was set 
at 10ppm for the precursor ions and at 20 mmu (0.02 Da) for fragment ions. 
Carbamidomethylation of cysteines due to alkylation with IAA was chosen as a fixed 
modification. Oxidation of methionine, lysine and proline, since hydroxylysine and 
hydroxyproline are common modifications on collagens as well as deamidation of 
asparagine with 18O water (+2.99 Da) were defined as variable modifications. Only tryptic 
peptides were included in the analysis. Two missed cleavages were allowed. Scaffold 
(version 4.3.2, Proteome Software Inc., US) was used to validate MS/MS-based peptide 
and protein identifications and quantification.251, 252 Peptide identifications were accepted if 
they were established with greater than 95% probability as specified by the Peptide 
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Prophet algorithm.251 Protein identifications were accepted if they were established at 
greater than 99% probability with at least 2 unique peptides.252 The normalised total ion 
current (TIC) of MS/MS spectra of the peptides from the same protein was used for 
quantification. All data were exported to mzIdentML format using Scaffold and deposited 
to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD005726 and 10.6019/PXD005726. 
4.5.5 Generation of custom-made porcine ECM protein database 
To achieve the best peptide sequence coverage on database search, and identify as 
many proteins as possible, a search database containing a comprehensive list of porcine 
ECM proteins was generated. Previously reported cardiovascular ECM proteins identified 
in human, porcine and murine cardiovascular tissues170, 253, 254 were searched for their 
porcine sequences in the UniProt protein database (www.uniprot.org/). Porcine 
sequences of many of these proteins were found and retrieved from UniProt either as 
annotated proteins or after blasting the human sequence against non-annotated, 
uncharacterized porcine proteins. The remaining ECM proteins with no matching 
sequences in UniProt were deduced from public nucleotide databases (including mRNA 
annotated sequences and expressed sequence tags [EST]) using tBLASTtn. Exclusively 
the best matches (≥ 90% identity) were assigned to a protein sequence and retrieved for 
the database. The final database contained a total of 246 manually included porcine ECM 
protein sequences. All canonical human sequences were used as background in order to 
obtain a database suitable for search algorithms (i.e. Mascot). To avoid redundancies all 
human ECM proteins were manually removed and replaced by their porcine counterparts. 
The included porcine proteins are listed in Supplemental table 1 and the porcine 
sequence database is attached to the thesis in an electronic form.  
4.5.6 Data analysis: media vs. neointima 
The total spectral counts of all ECM proteins in all samples (BMS + DES) at day 28 
provide the total ECM count. This was calculated separately in both groups, neointima 
(n=14) and media (n=6). Then, the total spectral counts of each ECM protein across all 
samples were divided by the total ECM count within each group to calculate its 
percentage of the total ECM count in the media or neointima.  
4.6 Targeted proteomics for mice and human samples 
Targeted proteomics was applied to validate selected proteins of interest. Principles of this 
method were explained in section 1.3.8. Sample preparation prior to LC-MS analysis, 
namely in-solution protein digest upon protein extraction and C18 peptide clean-up were 
accomplished using the same methodology as described for pig samples above in 
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sections 4.5.1 and 4.5.2. Also the HPLC configurations and the eluting gradients were the 
same in the targeted method. 
4.6.1 PRM in SILAC mice tissue 
Samples were run in PRM mode (MS/MS resolution of 30,000 at 200 m/z) using the Q 
Exactive Plus mass spectrometer (Thermo Scientific), allowing to detect all generated 
fragment ions. Selection of proteotypic peptides and generation of scheduled PRM assays 
were based on previous untargeted experiments in our lab. All proteotypic peptides were 
lysine (K)-terminated to allow quantification of SILAC incorporation. Selected peptides are 
shown in (Table 2). 
 
Table 2. List of precursor ions for PRM in mouse tissue 
 
Skyline software (version 2.6, MacCoss Lab, University of Washington, Seattle) was used 
beforehand to generate the transition list with predicted collision energies and optimized 
retention times, and later after PRM to quantify peak areas for MS/MS fragment ions. The 
identity of a specific peptide was confirmed by the presence of multiple transitions within 
the same retention time. Retention time windows were set +/- 4 min. A mass tolerance of 
5 ppm was used as a minimum requirement for fragment ions. All peaks were manually 
reviewed and integrated. SILAC incorporation rates were derived from the proportion 
between ions derived from peptides containing either heavy (Lys+6) or light lysine using 
the following formula: Incorporation rate = [Heavy] / [Heavy + Light]. The intensities of 
heavy and light peptides were calculated using the peak areas of selected fragment ions 
after MS/MS. Because unique, proteotypic peptides were previously selected for each 
protein, the final protein incorporation rate was equivalent to that obtained for the 
proteotypic peptides. For proteins with more than one peptide the average value was 
considered. 
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4.6.2 PRM in human tissue 
For targeted proteomics analysis of the human aorta and saphenous vein GuHCl extracts 
same PRM methodology was applied as explained above except the SILAC specific data 
analysis and the following differences. Fragmentation was performed with a normalised 
collision energy (NCE) of 35 V for all precursor ions. As the retention time (RT) during the 
entire run has shifted slightly, RT given in the list below is the average RT of all samples. 
Total peak areas from selected fragment ions with high intensities were used for 
quantification. Then the values were normalized to the average of all values in each group 
to allow relative quantification between the different proteins (adjusted peak area). 
Monitored peptides and fragment ions in human tissue are shown in Table 3.  
 
Table 3. PRM fragment list used for human protein quantification 
 











Aggrecan C[+57]GGNLLGVR  45.0 473.2504 2 y3 331.21 
 
C318 - R326 
   
y4 444.29 
     
y5 557.38 
     
y6 671.42 
     
y7 728.44 
          y8 785.46 
Versican LATVGELQAAWR 124.6 657.8619 2 y4 503.27 
 
L277 - R288 
   
y5 631.33 
     
y6 744.42 
     
y7 873.46 
     
y8 930.48 
     
y9 1029.55 
     
y10 1130.60 
          y11 1201.63 
Decorin NLHALILVNNK 67.6 416.9189 3 y3 375.20 
 
N106 - K116 
   
y4 474.27 
     
y5 587.35 
     
y6 700.44 
 
4.7 Western blot 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) allows the separation of charged 
proteins in an electric field. Proteins are first solubilized with the negatively charged SDS 
molecules, which denature proteins and mask their intrinsic charge. This causes the 
proteins to migrate towards the positive electrode within the mesh of a polyacrylamide gel 
according to their molecular weight, but independent of their native charge state. In the 
subsequent western blot method, proteins of interest can be detected using specific 
antibodies, after transferring (‘blotting’) the separated proteins from the gel onto a sheet of 
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nitrocellulose paper. In this study, western blotting was applied for the detection of 
proteins of interest in the GuHCl extracts from porcine and human tissue. 
Porcine samples 
10 µg of deglycosylated (for aggrecan neo blots: GAG removal, for versican neo blots: 
pan-deglycosylation) GuHCl, NaCl or SDS extracts of stented porcine coronary artery 
media samples or 7 µg of non-deglycosylated neointima extracts were denatured and 
reduced in sample buffer (100 mM Tris, pH 6.8, 40% glycerol, 0.2% SDS, 2% b-
mercaptoethanol and 0.02% bromophenol blue) at 95 °C for 5 min. Protein samples were 
separated on precast 4-12% bis-tris gradient gels (NuPageÒ, Thermo Fisher Scientific, 
cat. no. EC60385BOX) in SDS running buffer (NuPageÒ Mops, Thermo Fisher Scientific, 
cat. no. NP0001) at 130 V until the tracking dye reached the bottom of the gel. 7 µl of pre-
stained protein standards (NovexÒ, Thermo Fisher Scientific, cat. no. LC5800) were used 
as a molecular weight marker. Subsequently proteins were blotted to a nitrocellulose 
membrane (GE healthcare, cat. no. RPN2020D) in ice-cold transfer buffer (25 mM Tris 
base, 200 mM glycine dissolved in 20% methanol) for 2 h at 350 mA constant current. 
Efficient transfer and equal loading was determined with reversible Ponceau S (Sigma-
Aldrich, Cat. no. P7170) staining. Next, membranes were incubated in 5% milk in PBS 
with 0.1% Tween (PBST) for 1 h on a horizontal shaker at room temperature. The 
rationale behind the incubation with milk proteins is to prevent unspecific antibody binding 
to the membrane later. After a brief wash in PBST, the membranes were incubated 
overnight in primary antibody solution at 1 µg/ml dilution (unless otherwise stated) in 5% 
bovine serum albumin (Sigma-Aldrich, cat. no. A2153) and 0.01% sodium azide (Sigma-
Aldrich, cat. no. S2002) in PBST at 4 °C. Primary antibodies were used to detect the 
aggrecan NITEGE neoepitope (Thermo Fisher, AF-PA1-1746), the versican DPEAAE 
neoepitope (Abcam, ab19345) and LRP1 (Abcam, ab92544; 0.046µg/ml). The following 
day, membranes were washed 3 x for 15 min each with PBST and treated with the 
appropriate horseradish peroxidase (HRP)-conjugated light chain-specific antibody 
(1:5000, Jackson ImmunoResearch, cat. no. 211-032-171) diluted in 5% milk in PBST for 
one hour. The membranes were washed again 3 times for 15 min each with PBST and 
developed using enhanced chemiluminescence detection reagent (ECL, GE Healthcare, 
cat. no. RPN2106) and X-ray films (FujiFilm) on a Xograph processor in 10-30 sec 
increments. Bands were quantified by densitometry using ImageJ software (v. 1.49, NIH, 
USA). Intensity is given in arbitrary units (A.U.) to compare abundance levels. 
Human samples 
Same protocol was applied for human sample western blots. 7 μg of GuHCl extracts of 
human aorta and saphenous vein were loaded per lane. Antibodies against the aggrecan 
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NITEGE neoepitope (Thermo, AF-PA1-1746), versican (Santa Cruz, sc-25831) and 
decorin (Thermo Fisher PA5-19151) were used. This western blot was run by Marc Lynch, 
MSc, of King’s College London. 
4.8 Silver staining 
Silver staining was performed based on a silver nitrate staining protocol for visualization of 
separated proteins in gel in order to investigate equal loading. 5 µg of porcine GuHCl 
extracts were loaded on each lane. Following electrophoresis proteins in gel were fixed in 
fixing solution (50% methanol, 5% acetic acid) for 30 min and subsequently incubated in 
distilled H2O overnight to re-expand the gel following methanol-induced shrinkage. Next, 
proteins were sensitized for 1 min with 0.8 M sodium thiosulphate pentahydrate, followed 
by 3 brief washes of 1 min each and silver staining in 6 mM silver nitrate for 30 min at 4 
°C. Again after 3 brief washes, gels were soaked in developing solution (180 mM sodium 
carbonate, 0.04% formaldehyde) and stop solution (5% acetic acid) was added, once the 
protein bands on gel became visible. After 5 min gels were immersed in distilled H2O and 
scanned with a calibrate scanner (GS-800, Bio-Rad). 
4.9 Gene expression analysis 
4.9.1 RNA extraction 
Total RNA from porcine tissue and cultured human cells was isolated using the 
miRNAeasy Mini kit (Qiagen, cat. no. 217004) according to the manufacturer’s 
instructions. First, porcine tissue was homogenized in 700 µl lysis buffer (QIAzol Lysis 
Reagent, Qiagen, cat. no. 79306) using ceramic spheres (Lysing Matrix D, MP 
Biomedicals) with a tissue homogenizer (Precellys®24, Bertin Corp., US). Homogenates 
were then incubated in lysis buffer for 5 min at room temperature. The lysis buffer 
contains the strong denaturant guanidinium thiocyanate, which immediately inactivates 
RNases preserving RNA. Next, homogenates were vigorously shaken with 140 µl of 
chloroform, which causes protein denaturation and leaves them soluble in the organic 
phase, while nucleic acids remain in the upper aqueous phase. After further 5 min 
incubation at room temperature, samples were centrifuged at 12000 rpm for 15 min at 4 
°C. Subsequently 280 µl of the upper aqueous phase were combined with 420 µl of 100% 
ethanol in a fresh tube. After thorough mixing samples were transferred to an RNeasy 
mini column to bind the RNA to a silica-based membrane. The remaining wash and 
centrifugation steps were carried out at room temperature according to the manufacturer’s 
protocol to wash away the contaminants. RNA was then eluted with 25 µl of RNase-free 
water by centrifugation at 12000 rpm for 1 min. 
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Determination of RNA concentration 
RNA concentration was determined using spectrophotometry at a wavelength of 260 nm 
with a NanoDrop device, relying on light absorption of RNA at this wavelength. 
Absorbance measurements at 280 nm allows determination of the protein concentration in 
the sample. Thus, protein contaminations of the sample can be estimated by calculating 
the OD260/OD280 ratio. For ‘pure’ RNA the ratio is around 2. Therefore, lower values 
indicate a contamination of the sample with proteins, or phenol or other contaminants 
absorbing light at 280 nm. After determining the RNA concentration samples were stored 
at -80 °C until further use. 
4.9.2 cDNA synthesis 
Complementary DNA (cDNA) was synthesized from extracted total RNA by the enzyme 
reverse transcriptase, an RNA-dependent DNA polymerase, using SuperScript® VILO 
MasterMix (Invitrogen, cat. no. 11755050). This kit contains all necessary components for 
the reverse transcription reaction including the reverse transcriptase, RNAse inhibitors, 
dNTPs, MgCl2 and random primers to ensure priming of total RNA. 2 µl of mastermix were 
combined with a fixed amount of total RNA for each sample (130 ng for porcine samples) 
and water to a total reaction volume of 10 µl. The reverse transcription (RT) reaction was 
performed in a Veriti Thermal Cycler (Applied Biosystems) using the following settings: 
initial incubation at 25 °C for 10 min, followed by incubation at 42 °C for 120 min. The 
reaction was terminated by heating the sample to 85 °C for 5 min and samples were 
stored at -20 °C for later use in quantitative polymerase chain reaction (qPCR). 
4.9.3 qPCR 
Relative expression levels of the genes of interest derived from proteomics studies were 
determined using qPCR. 
Principles of qPCR 
The gene amplification part of this method is not different from conventional PCR and 
relies on repetitive cycles of denaturation, annealing and elongation, exponentially 
amplifying the gene of interest, which is determined by the used primers. The quantitative 
part is retrieved from measured fluorescence signals, which are generated only when the 
dye is bound to double-stranded DNA products of the PCR reaction and are accumulated 
during amplification. The quantification is based on a direct relationship between the 
original cDNA concentration in the sample and the rate at which the PCR product is 
generated.255 This means, the more of a specific gene was present at the start of the 
reaction, the more fluorescence signal will be generated upon its exponential 
amplification. For better comparability across the samples and to overcome background 
signal interference a threshold for the fluorescence signal is set (just above background 
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fluorescence, in the linear phase of the amplification plot), at which the cycle number of 
the reaction is determined (Figure 14). This is known as the threshold cycle (Ct-value) and 
defines the number of cycles it takes in each reaction to detect the set threshold signal. 
The Ct-value is inversely proportional to the amount of the target gene in the sample. 
Thus, higher Ct values indicate low amounts of the target gene, while lower Ct values 
mean a higher expression of the target gene. Eventually, comparison of Ct-values for a 




Figure 14. Determination of the Ct-
value. Schematic illustration of the qPCR 
amplification curves for a gene of interest 
in two samples are shown. The spot 
where the reaction curve intersects the 
threshold line is defined as the Ct-value. 
The expression of the gene of interest in 
sample A is higher than in B, as it takes 




The RT product was diluted with nuclease-free water to obtain a cDNA concentration of 3 
ng/µl in each sample. Either TaqMan® or SYBRgreen assays were used to detect the 
genes of interest (Table 4). For TaqMan® assays the assay mix contained 2.5 µl of 2x 
TaqMan® Universal PCR Master Mix, no AmpErase® UNG (Applied Biosystems, cat. no. 
4324018) and 0.25 µl of the appropriate TaqMan® expression assay (20x). For 
SYBRgreen assays, primer pair sequences were obtained from PrimerBank and 
reconstituted in nuclease-free H2O at a concentration of 10 µM. Each SYBRgreen assay 
mix consisted of 2.5 µl of SYBR Select Master Mix (Life Technology, cat. no 4472908), 
0.1 µl of both the forward and reverse primer and 0.3 µl nuclease-free H2O. Assay mix 
(2.75 µl or 3 µl for TaqMan reaction or SYBRgreen reaction, respectively) and diluted 
sample (2.25 µl or 2 µl for TaqMan reaction or SYBRgreen reaction, respectively) were 
combined in a MicroAmp Optical 384-well reaction plate (Applied Biosystems) to a final 
volume of 5 µl using a Bravo Automated Liquid Handling Platform (Agilent Technologies 
Inc.). The plate was sealed, briefly centrifuged at 1000 rpm for 1 min and placed in a 
ViiATM 7 Real-Time PCR system (Applied Biosystems) and set to run under following 
conditions for the TaqMan reaction: incubation at 95 °C for 10 min for polymerase 
activation, followed by 40 cycles of 95 °C for 15 sec (denaturation yielding single-stranded 
DNA) and 60 °C for 1 min (annealing and elongation). The programme for SYBR green 
was set as follows: 50 °C for 2 min, then 95 °C for 2 min, followed by 40 reaction cycles 
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(same settings as for TaqMan). Data was analysed using ViiA 7 Software (Applied 
Biosystems) and Microsoft Excel. If the qPCR software reported undetermined values for 
individual replicates, a Ct-value of 40 was assumed. Expression levels were standardized 
to the expression of β-actin (ACTB). Relative amounts of the targets were quantified using 
the 2-ΔΔCT method.256 
 
Pre-amplification of cDNA 
As cadherin 5 gene expression levels were found to be relatively low, a pre-amplification 
reaction was performed for this cDNA prior to qPCR analysis. 2.5 µl of diluted cDNA 
sample (conc. 3 ng/µl) were mixed with 2.5 µl of 1:100 diluted cadherin 5 TaqMan® 
expression assay (0.2x) and 5 µl of TaqMan® PreAmp Master Mix (Applied Biosystems, 
cat. no. 4391128). The pre-amplification reaction was performed in a Veriti Thermal Cycler 
(Applied Biosystems) using the following settings: initial incubation at 95 °C for 10 min, 
followed by 12 cycles of 95 °C for 15 sec and 60 °C for 4 min, and terminated at 99 °C for 
10 min. The reaction product was diluted 1:10 for use in the qPCR reaction. 
 
Table 4. Primers used for qPCR analysis 
 
	 Gene TaqMan SYBRgreen 
 














Cadherin 5 Ss03378336_u1   
β-actin  Ss03376160_u1 
 
  
ADAMTS1   CGTGAACAAGACCGACAAGA AACTCCTCCACCACACGTTC 
ADAMTS4   CCCCATGTGCAACGTCAAG AGTCTCCACAAATCTGCTCAGTGA 












ADAMTS1 Hs00199608_m1  
 
  
ADAMTS4 Hs00192708_m1  
 
  




4.10 miRNA expression analysis 
miRNA expression was determined in porcine samples using the extracted RNA as 
described above in section 4.9.1. 
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4.10.1 RT reaction 
RT reaction was performed using the TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems, cat. no. 4366596) and was used at a final reaction volume of 10 µl 
as follows: 100 ng RNA in 4.3 μl H2O, 1 μl 10x RT buffer, 0.3 μl 100 mM dNTPs with 
dTTP, 1.2 μl 25 mM MgCl2, 0.2 μl RNase Inhibitor, 1 μl of 10x Megaplex RT Primers 
(Human Pool A version 2.1, Applied Biosystems, cat. no. 4399966) and 2 μl Multiscribe 
Reverse Transcriptase. The RT-PCR reaction was performed in a Veriti Thermal Cycler 
(Applied Biosystems) with the following settings: 40 cycles of 16 °C for 2 min, 42 °C for 1 
min and 50 °C for 1 sec, followed by incubation at 85 °C for 5 min to terminate the 
reaction.  
4.10.2 qPCR 
qPCR was conducted using TaqMan® assays according to the same protocol applied for 
gene expression analysis using the RT product in a concentration of 1 ng/µl. Used 
TaqMan® miRNA assays (life technologies) are listed in Table 5. U6 expression was used 
for normalisation. 
 
Table 5. TaqMan miRNA assays used for qPCR analysis 
 
Target miRNA Assay ID miRBase accession  
U6 snRNA 001973   
hsa-miR-21-5p 000397 MIMAT0000076 
hsa-miR-29b-3p  000413 MIMAT0000100 
hsa-miR-133a-3p 002246 MIMAT0000427 
hsa-miR-143-3p  002249 MIMAT0000435 
hsa-miR-145-5p 002278 MIMAT0000437 
hsa-miR-195-5p 000494 MIMAT0000461 
hsa-miR-221-3p 000524 MIMAT0000278 
   
4.11 Immunostaining 
4.11.1 Sample processing 
Human coronary arteries were collected under the Bristol Coronary Biobank ethical 
approval 08/H0107/48, which included both stented and unstented sections of coronary 
arteries and were provided for this study by Dr. Stephen J. White of the School of Clinical 
Sciences, University of Bristol.Human aorta and mice vessels (vein graft and inferior 
vena cava) were collected as described in section 4.3 and section 4.2, respectively. 
Tissues were immediately fixed in 10% formalin for 24 h at 4 °C to cross-link proteins and 
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prevent their degradation preserving the tissue architecture. Stented arteries were cut 
longitudinally and the stent was removed as careful as possible. Using an automated 
tissue processor tissues were dehydrated in graded ethanol baths and cleared in xylene, 
as both water and ethanol are largely immiscible with paraffin and were subsequently 
manually embedded in paraffin. Paraffin embedded samples were sectioned at 3 µm 
thickness (5 µm for human aorta) using a microtome and placed on adhesion glass slides. 
For the graft samples histological sectioning began at the centre of the graft to avoid cuff 
effects. Sections were baked at 37 °C in an oven overnight and subsequently stored at 
room temperature until staining. 
4.11.2 Immunohistochemistry (IHC) 
Sections were deparaffinised and rehydrated in graded ethanol baths with descending 
ethanol concentration. Next, sections were incubated in 0.3% H2O2 for 10 min to block 
endogenous peroxidases. Upon 3 wash steps with PBST for 5 min each, antigen retrieval 
was performed by incubating the slides in a boiling water bath in preheated 10 mM 
sodium citrate buffer (pH 6.0) for 30 min. The slides were allowed to cool down for further 
30 min, followed by further 3 wash steps with PBST for 5min each.  
Sections were blocked with either 20% goat (for rabbit primary antibody) or rabbit serum 
(for goat primary antibody) in PBS for 1 h at room temperature. The used blocking serum 
is derived from the same species as the secondary antibody to prevent its unspecific 
binding. The blocking solution was tipped-off and replaced with primary antibody or 
matched IgG control (5 µg/ml) in 1% goat/rabbit serum and incubated at 4 °C overnight. 
Applied primary antibodies and dilutions are listed below in Table 6.  
The following day, after 3 washes in PBST for 5 min each, the slides were incubated with 
biotinylated goat anti-rabbit (human tissue: 1:250; Sigma-Aldrich, B7389; mice tissue: 
1:400; Vector labs, BA-1000) or rabbit anti-goat (1:250; Dako, E0466) secondary 
antibodies for 1 h at room temperature. After further 3 wash steps sections were 
incubated with Extravidin-HRP (1:250, Sigma-Aldrich, E2886; mice tissue: Avidin D, 
1:400, Vector labs, A-2004) in PBS for 1 h. Upon 3 washes, detection was carried out 
using the diaminobenzidine (DAB) solution (Vector labs, SK-4100) for 10 min. Sections 
were washed in dH2O, counterstained for 15 sec in modified Harris Haematoxylin, 
dehydrated in graded ethanol baths and mounted in DPX. Histological slides with human 
sections were scanned using a digital scanning system (LEICA SCN400F) to provide a 
high resolution digital image. Images from mice sections were taken using a Leica 
DM2000 microscope interfaced to LAS software (version 4.3.0; Leica microsystems). IHC 
for the graft samples were performed by Marc Lynch, MSc, of King’s College London. 
  
MATERIALS AND METHODS 
 83 
Table 6. Antibodies and dilutions used for IHC in human and mice tissue samples 
 
Target protein Antibody ID Species Dilution 
human mouse  
aggrecan Abcam, ab36861 rabbit polyclonal 1:400 1:100 
aggrecan neo (NITEGE) Thermo, AF-PA11746 rabbit polyclonal 1:400 n/a 
HPLN1 Abcam, ab103455 rabbit polyclonal 1:200 n/a 
versican neo (DPEAAE) Abcam, ab19345 rabbit polyclonal 1:400 1:100 
MGP Abcam, ab86233 rabbit polyclonal 1:100 n/a 
SPP24 Santa Cruz, sc-169408 goat polyclonal 1:50 n/a 
Decorin Sigma-Aldrich, SAB2100539 rabbit polyclonal n/a 1:00 
 
4.11.3 Immunofluorescence 
Human coronary arteries and aorta samples were processed as described for 
immunohistochemistry. After deparaffinising, sections were incubated with 0.5 unit/ml 
chondroitinase ABC (Sigma-Aldrich, C3667) for 1 h at 37 °C to improve antibody 
recognition. After blocking with 10% donkey serum in PBS for 1 h, sections were co-
incubated with primary antibodies to aggrecan (1:10; Abcam, ab3778) and the aggrecan 
NITEGE neoepitope (1:200; Thermo, AF-PA11746) as well as matched isotope IgGs for 
negative controls. Following day, upon washing secondary antibodies (Alexa Fluor 647, 
cat. no. A31571 and Alexa Fluor 568, cat. no. A21069, Life technologies) were applied 
according to the primary antibody species for 1 hour at room temperature. After 3 washes 
cell nuclei were stained with DAPI (1:1000, Life Technology) for 10 minutes. Sections 
were visualized with a 20x CFI S Plan Fluor ELWD ADM objective or 60x Plan Apo VC NA 
1.40 Nikon using an inverted Nikon NI-E microscope equipped with a Yokogawa CSU-X1 
Spinning disk confocal unit and an Andor iXon 3 EM-CCD camera. Images were acquired 
using NIS-elements 4.0 software, and represent a maximum projection image of a Z-stack 
of 0.5 µm steps compassing 9 µm. Images were acquired at the Nikon Imaging Centre at 
King’s College London with the help of Dr. Chris Molenaar and Dr. Ruifang Lu, King’s 
College London. 
4.12 Cell culture 
4.12.1 SMC culture 
Human coronary artery SMCs (HCASMC) were obtained from PromoCell (C-12511) and 
grown in M199 medium (GibcoTM, cat. no 22340020) supplemented with 20% heat-
inactivated FBS (GibcoTM, cat no. 10500064) and antibiotics (100 U/ml penicillin and 100 
µg/ml streptomycin) (‘complete medium’) on 0.04% gelatine at 37 °C in a humidified 
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atmosphere of 95% air/5% CO2. The medium was changed every 2 days. For cell 
passaging upon 60-80% confluence the growth medium was removed and cells were 
washed 2 x with pre-warmed DMEM (GibcoTM, cat. no. 10938025). Cells were detached 
with trypsin-EDTA 0.05% (GibcoTM, cat. no.25300096) for few minutes at room 
temperature and trypsin activity was stopped by adding equal amounts of complete 
medium. The cell suspension was centrifuged at 1000 rpm for 5 min at room temperature 
and the supernatant was removed. Cells were resuspended in complete medium, counted 
and seeded at a density of 1x105 in 6-well plates coated with 0.04% gelatine. Cells were 
washed with cold PBS twice and scraped off the surface with 700 µl lysis buffer (QIAzol 
Lysis Reagent, Qiagen, cat. no. 79306) for RNA extraction. The experiments were carried 
out with cells at passage 7-11. 
4.12.2 EC culture 
Human endothelial cells from different vascular territories were obtained from PromoCell 
(Human aortic EC (HAoEC): C-12272; Human umbilical vein EC (HUVEC): C-12250; 
Human coronary artery EC (HCAEC): C-12222; Human saphenous vein EC (HSaVEC): 
C-12232). Cells were cultured to confluence in T25 flasks cells on 0.04% gelatine in 
appropriate Endothelial Cell Growth Medium (PromoCell C-22011, C-22010, C-22020, C-
22022, with the company provided SupplementMix) supplemented with antibiotics (100 
U/ml penicillin and 100 µg/ml streptomycin) at 37 °C in a humidified atmosphere of 95% 
air/5% CO2. For comparison analysis with SMCs, HCAECs were seeded at a density of 
1x105 in 6-well plates (Greiner bio-one) coated with 0.04% gelatine. Cells were washed 
with cold PBS twice and scraped off the surface with 700 µl lysis buffer (QIAzol Lysis 
Reagent, Qiagen, cat. no. 79306). The experiments were carried out with cells at passage 
4-9.  
4.12.3 Everolimus treatment 
Everolimus was a kind gift from Novartis, Switzerland and was shipped under a material 
transfer agreement with King’s College London. It was dissolved in dimethyl sulfoxide 
(DMSO) and aliquots with a stock concentration of 20 µM were prepared and kept at -20 
°C. 24 h after cells were seeded in complete medium (density of 1x105 in 6-well plates), 
cells were washed twice with DMEM and were cultured in either serum-free M199 medium 
for HCASMCs or HCAEC culture medium with growth factors (PromoCell, C-22020) 
supplemented with 20 nM everolimus or equivalent concentration of DMSO control for 48 
h. Each experiment was performed in triplicates. RNA was harvested as described above.   
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4.12.4 Cell counting 
To determine the cell number, 10 µl of a cell suspension were pipetted into a glass slip 
covered Neubauer counting chamber (AC1000). All cells within the 4 squares placed at 
the corners (each 1 mm2) were counted under a microscope. The average count was then 
multiplied by 104 to determine the number of cells in 1 ml.  
4.12.5  Viability and cell count  
Viability and cell count of HCAECs were determined using the Nucleo Counter® NC-
3000TM. This system enables automated cell counting. Cells were seeded in 6-well plates 
at a density of 1x105 and treated with everolimus or DMSO as described above for 24 h. 
To retrieve the total cells, cell medium was collected including the floating dead cells, and 
combined with the detached cells of each well. After centrifugation cells were 
resuspended in growth medium and ‘solution 18’ was added in a 1:20 ratio. ’Solution 18’ 
contains acridine orange, staining all living and dead cells, thus providing a total count. It 
further contains DAPI, which stains all dead cells. The cell suspension is then loaded on 
slides and analysed by the Nucleo Counter® NC-3000TM with the ‘Viability and Cell Count - 
Method 2 Assay’. The viability is calculated by the NucleoView NC-3000TM software as 
follows: %viability = !"#!$%!" 	x	100% . 
(Ct: concentration of total cells, Cnv: concentration of non-viable cells) 
4.13 Statistical analysis 
Data are shown as average (Av) ± standard error of the mean (SEM). If standard 
deviation (SD) is used, it is indicated. MS data of untargeted proteomics were quantified 
using normalized ion intensities (total ion current = TIC). IBM® SPSS® statistics software 
(version 22-24) and Microsoft® Excel® (version 15.20) were used for statistical 
calculations, GraphPad Prism® (version 6.0e) and Microsoft® Excel® (version 15.20) 
were used for data illustration. For OCT analysis, 2-way analysis of variance (ANOVA) 
was applied to assess neointimal volume, minimal lumen area and strut coverage 
between BMS and DES over time. 1-way ANOVA was applied for time-dependent 
changes in protein expression in BMS and DES. Unpaired Student’s t-test with unequal 
variance was applied for proteomics differences between neointimal BMS and DES, 
POBA early and late, for differences between BMS and DES at each time point as well as 
the comparison between BMS/DES day 28 and POBA late. T-test was not performed if a 
protein was undetectable in the majority of samples from 1 of the 2 groups compared, 
which is denoted as n/a (not applicable). Unpaired Student’s t-test with unequal variance 
was also used for targeted proteomics analysis between aorta and vein samples. 
MultiExperiment Viewer software (MeV, version 4.9) was applied using a Pearson 
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Correlation for protein clustering. For gene expression analysis of porcine tissue t-tests 
were applied for differences between BMS and DES and regression analysis for changes 
over time (P-value for trend). Differences in gene expression between different EC 
territories were assessed by 1-way ANOVA. Differences in gene expression between ECs 
and SMCs or treated and untreated cells respectively were determined using the 
Student’s t-test. Student’s t-test with unequal variance was also used for densitometry 





5.1 Porcine model of stent injury 
BMS or DES were implanted in porcine coronary arteries during coronary angioplasty 
under OCT guidance. Coronary arteries subjected to POBA alone without stent 
deployment served as controls. To prevent the risk of in-stent thrombosis pigs were 
treated with dual anti-platelet therapy daily. At five consecutive time points 1, 3, 7, 14 and 
28 days post-stent implantation, follow-up OCT was performed before harvesting the 
arteries for protein extraction. Macroscopically all stented arteries at day 28, regardless of 
the deployed stent type showed a neointima formation covering the stent struts. The 
evolved neointima was separated from the media and analysed in a separate proteomics 
analysis. The study design is summarized in Figure 15A and characteristics of all 
analysed samples are shown in Table 7. ECM proteins of the vascular media were 
sequentially extracted using a three-step extraction method as previously described114, 
while the more fragile neointima was extracted in a single step (Figure 15B). In total 45 
samples were analysed by proteomics (Figure 15C). A close-up of the separated 





Figure 15. Porcine model of stent injury. (A) Pigs underwent PCI with BMS/DES/POBA treatment. 
Following OCT analysis coronary arteries were harvested for proteomics analysis at 1, 3, 7, 14 and 28 
days after stent deployment. The evolved neointimal lesions at day 28 were analysed separately. (B) 
ECM proteins were obtained using our previously published extraction procedure in three steps for the 
media and in a single step for the neointima, followed by LC-MS/MS analysis of the deglycosylated 
tryptic peptides. (C) In total, 45 samples were analysed by proteomics. An overview of the conducted 
proteomics comparisons is shown: a) Media vs. neointima. b) Stent dependent changes in the 
neointima. c) Time dependent changes in BMS/DES/POBA. d) Stent vs. POBA at late stage. e) Stent 
dependent changes in the media at each day. (D) Close-up of the neointimal tissue (right) upon 
separation from the media (tissue including stent struts). Stent strut impressions are visible on the 
neointimal tissue. 
 
5.2 OCT findings 
OCT on follow-up was deployed for qualitative characterization of the neointima, 
classifying the neointimal patterns into homogenous with peristrut attenuation or with ring, 
heterogeneous or layered according to its backscatter and optical intensity (Figure 16A). 
At day 14 almost 80% of the neointima in both groups (BMS=78.3%, DES 78.5%) showed 
a homogenous pattern, for DES this increased to 98.5% at day 28. In contrast, no 
heterogeneous pattern was present at day 28 in both groups, while 39.8% for BMS had a 
layered pattern. In addition, OCT was used to assess differences in neointimal volume, 
minimal lumen area, stent strut coverage and apposition between BMS and DES stented 
arteries. OCT analysis revealed that up to 14 days post-stent implantation neointimal 
volume was higher in BMS compared to DES (P=0.025), but no difference was evident at 
day 28 (P=0.890) (Figure 16B). The minimal lumen area (P=0.894), malapposed struts 
(P=0.238) and stent strut coverage (P=0.778) were not different for BMS and DES during 
the 28 day follow-up. Thus, molecular differences for the clinically observed different 






Figure 16. OCT findings. (A) Neointimal patterns as characterized by OCT: representative images of 
homogenous with peristrut attenuation/ring, heterogeneous and layered. Percentage distribution of the 
three main patterns in BMS and DES at day 14 and day 28. (n=3 for each group, except BMS day 14 
n=2). (B) At 14 days post-stent implantation neointimal volume was higher in BMS compared to DES 
(*P=0.025) but showed no significant difference at day 28. P=0.89 (2-way ANOVA). The OCT data were 





Table 7. Sample characteristics 
Clinical characteristics of pigs (lifetime, sex, weight, age at intervention) and PCI specific parameters are 
shown, including used stent type, balloon/stent size at implantation, average vessel diameter (AVD) as 
measured by angiography before dilatation, final size of stent/balloon after expansion (target 
overstretch) as well as the applied inflation pressure. Macroscopically neointima formation was detected 























LAD M 35 3 3,5x15 3.4 4.1 22 
LCX dis M 35 3 3,5x15 3.0 3.5 12 
RCA prox F 38 3 3,5x15 3.0 3.6 12 
DES 
LAD F 38 3 3,0x15 3.0 3.5 23 
LCX prox F 38 3 3,5x15 3.1 3.7 12 
RCA M 35 3 3,0x15 3.0 3.6 24 
POBA early LCX prox M 35 3 3,5x15 3.0 3.5 28 RCA dis F 38 3 3,5x15 2.9 3.5 12 
3 
BMS 
LAD M 45 4 3,0x15 2.7 3.2 15 
LCX F 45 4 3,0x15 2.8 3.3 16 
RCA dis M 45 4 3,0x15 2.7 3.2 14 
DES 
LAD F 45 4 3,0x15 2.8 3.3 14 
LCX M 45 4 3,0x15 2.6 3.1 11 
RCA prox F 45 4 3,0x15 2.7 3.0 14 
POBA early RCA prox M 45 4 3,0x15 2.8 3.4 16 RCA dis F 45 4 3,0x15 2.5 3.0 14 
7 
BMS 
LAD prox M 32 3 3,5x15 3.1 3.7 14 
LCX prox F 33.5 3 3,5x15 2.9 3.4 10 
RCA prox F 33.5 3 3,0x15 2.8 3.4 18 
DES 
LAD prox F 33.5 3 3,5x15 3.0 3.5 9 
LCX prox M 32 3 3,5x15 3.0 3.6 9 
RCA prox M 32 3 3,0x15 2.4 2.9 10 
14 POBA late LCX prox M 33 3 3,0x15 2.5 2.9 14 
28 
BMS 
LAD prox F 29 3 3,5x15 2.9 3.5 10 
LCX prox F 28 3 3,0x15 2.5 3.0 10 
RCA prox F 28 3 3,0x15 2.0 2.4 10 
DES 
LCX prox F 29 3 3,5x15 3.0 3.5 9 
RCA medial F 29 3 3,5x15 3.1 3.5 9 
RCA dis F 28 3 3,0x15 2.0 2.4 9 






















LAD prox F 29 3 3,5x15 2.9 3.5 10 
LCX prox F 28 3 3,0x15 2.5 3.0 10 
RCA prox F 28 3 3,0x15 2.0 2.4 10 
RCA prox M 47 3.5 3,5x8 3.0 3.6 12 
RCA dis M 47 3.5 3,0x12 2.8 3.4 20 
RCA prox M 48 3.5 4,0x14 3.4 4.1 12 
LCX M 48 3.5 3,0x15 2.8 3.4 16 
DES 
LCX prox F 29 3 3,5x15 3.0 3.5 9 
RCA medial F 29 3 3,5x15 3.1 3.5 9 
RCA dis F 28 3 3,0x15 2.0 2.4 9 
LAD dis M 47 3.5 3,0x15 2.6 3.1 12 
LCX med M 47 3.5 3,5x18 3.2 3.9 18 
RCA dis M 48 3.5 3,5x15 2.9 3.8 12 
LAD med M 48 3.5 3,0x18 2.4 2.9 9 à12 
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5.3 miRNA changes in the vascular stent injury model 
Since previous studies had shown that miRNAs are critically involved in neointimal 
hyperplasia in proliferative vascular diseases76, 77, we aimed to investigate the changes of 
representative miRNAs associated with SMC proliferation (miR-21, miR-133, miR-143, -
145 and -221) and fibrosis (miR-21, miR-29b, miR-195) in our stent injury model (Figure 
17). Except for miR-133a and miR-145, other evaluated miRNAs were differentially 
expressed compared to controls at day 28, either for BMS/DES or for both. Especially the 
pro-fibrotic miRNA, miR-21, showed a remarkable increase in stented arteries similar to 
previous reports in stented arteries257 and vein grafts258. Also, miR-221, which is 
implicated in SMC phenotypic switch, showed a notable increase.  
Figure 17. miRNA changes upon stenting. Heat map for evaluated miRNA changes. Pearson 
correlation. Changes displayed in bar graphs, except for miR-133a, which was not significant (P for 
trend Control-BMS = 0.062, Control-DES = 0.859). n=3 per time point for stented arteries, except DES 
day 3: n=2. n=6 unstented control coronary arteries. miRNA expression values were normalized to 
unstented control arteries. Linear regression analysis for P-value for trend.  
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5.4 ECM proteins identified in the media and neointima 
5.4.1 Impact of custom-made porcine ECM database 
To improve the identification of ECM proteins upon LC-MS/MS analysis, a custom-made 
porcine ECM database was generated for database search. This database contained a 
comprehensive porcine sequence list of previously published ECM proteins on the 
background of a conventional human database. The commonly available porcine 
databases are incomplete, thus do not contain the whole sequence of all proteins. In 
addition, not every protein is well annotated in porcine databases. Despite highly 
conserved protein sequences in humans and pigs for many proteins, e.g. 90.3% similarity 
between porcine and human decorin, the remaining differences in the sequence prevent 
an optimal peptide match, thus lowering the proteomics quantification yields for affected 
proteins. Figure 18 shows the improvement in protein identification and quantification 
using the custom-made porcine database compared to the standard human, the standard 
pig and to the combination of both in a hybrid database. 
 
 
Figure 18. Impact of custom-made database on protein identification and quantification. The sum 
of total spectral counts in 5 samples are shown for selected proteins. Search with a hybrid database, 
which is the combination of a pig and human database is superior to a human database for protein 
identification and quantification due to a higher sequence coverage. For many ECM proteins, such as 
fibronectin and decorin, which are well annotated and fully sequenced, the custom-made database does 
not offer a major improvement. However, for other proteins, such as collagen alpha-1 (I) (CO1A1) and 
perlecan for example, which are not well annotated and fully sequenced, the custom-made database 









5.4.2 Comparison between media and neointima 
A total of 151 unique ECM proteins were identified overall in the media (Table 8) and 
neointima (Supplemental table 2) with a minimum of 2 high-confidence peptides (Figure 
19A). Proteins only identified in the media (n=11) or neointima (n=26) are marked with an 
asterisk in the table. Despite being plasma-derived, lipoproteins were included to the list 
due to their intimate relationship with proteoglycans and their obvious importance in 
cardiovascular pathology. While the 10 most abundant ECM proteins of the media made 
up more than half of the ECM content of the media, the same ECM proteins constituted 
less than a third of the neointima, indicating a more diverse ECM composition of the 
neointima compared to the media (Figure 19B). Fibrillar collagens and small leucine-rich 
proteoglycans (SLRPs) were increased in the vessel media, while basement membrane 
proteins were more abundant in the neointima. The difference in ECM composition is 
highlighted by the collagen alpha-1 (I) to fibronectin ratio in the media and neointima of 
stented vessels (P=0.003) (Figure 19C).  
Figure 19. ECM proteins identified in the media and neointima. (A) Overall in the media and 
neointima a total of 151 unique ECM proteins were identified. The Venn diagram depicts the distribution 
of the proteins in the media and neointima. (B) Pie charts illustrate the relative contribution of the top 10 
abundant ECM proteins in the media and neointima of stented vessels. (C) Collagen alpha-1 (I) 
(CO1A1) to fibronectin ratio in the media and neointima of stented vessels is shown. n=6 (media), n=14 
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P   
POBA 
Adipocyte enhancer-binding 
protein 1 F1SSF7_PIG 0.3±0.5 0.2±0.3 1.6±1.3 1.1±0.5 0.136 0.1±0.2 0.0±0.0 1.0±0.9 6.2±4.8 0.046 0.9±0.6 2.0±1.2 0.258 
Aggrecan  F1SKR0_PIG 6.5±2.3 2.7±0.9 18.0±11.4 28.2±9.0 0.010 5.2±2.1 10.9±9.3 18.3±7.6 52.5±11.1 0.000 5.3±3.0 17.3±10.7 0.187 
Agrin  I3LGD9_PIG 5.7±2.5 5.4±2.8 8.7±1.1 9.4±1.7 0.112 5.7±3.3 5.2±3.5 8.8±1.3 6.2±1.6 0.400 5.6±4.0 9.9±1.1 0.118 
Alpha-2-HS-glycoprotein  FETUA_PIG 1.4±1.4 1.6±1.5 2.6±1.9 5.2±8.5 0.717 4.0±2.1 3.7±2.4 3.7±3.7 7.8±7.5 0.623 3.7±2.2 1.9±1.4 0.232 
Annexin A1  ANXA1_PIG 1.8±0.8 2.3±1.0 1.7±0.6 2.0±2.2 0.943 2.4±1.1 3.7±1.6 3.7±2.9 3.7±0.9 0.765 3.1±0.8 0.5±0.2 0.005 
Annexin A2  ANXA2_PIG 10.8±1.8 14.2±4.7 24.3±4.3 37.2±31.9 0.265 9.5±1.5 12.7±7.0 20.8±4.3 28.1±7.7 0.016 14.2±10.5 14.9±2.9 0.898 
Antithrombin-III  Q7M364_PIG 2.5±1.3 0.8±0.5 0.0±0.0 0.7±0.8 0.028 1.4±0.7 14.2±17.7 2.1±1.1 1.7±0.7 0.289 2.5±1.8 0.3±0.5 n/a 
Apolipoprotein A-I  APOA1_PIG 18.7±4.3 11.0±8.0 21.2±12.5 25.6±16.3 0.484 17.5±2.2 26.8±13.5 19.1±13.2 24.8±10.0 0.686 19.5±7.7 12.7±5.6 0.231 
Apolipoprotein A-IV  APOA4_PIG 0.1±0.1 0.0±0.0 0.1±0.1 0.4±0.6 0.394 0.0±0.1 1.7±1.1 0.4±0.5 0.5±0.3 0.053 0.0±0.0 0.1±0.1 n/a 
Apolipoprotein C-III  APOC3_PIG 4.4±2.5 2.3±1.4 0.6±0.6 0.7±0.7 0.049 4.3±1.7 5.6±2.9 0.5±0.6 0.8±0.4 0.016 6.5±3.9 0.2±0.4 0.048 
Apolipoprotein E  APOE_PIG 15.7±4.0 11.3±7.0 1.8±1.7 1.6±0.7 0.006 8.9±4.2 82.2±70.2 8.9±6.2 1.9±2.4 0.071 26.2±20.3 1.2±0.3 n/a 
Apolipoprotein H  I3LGN5_PIG 21.7±6.2 20.3±5.4 18.7±2.7 29.4±18.3 0.603 26.7±5.1 36.6±27.2 29.3±14.7 59.5±10.6 0.139 23.1±4.4 19.5±8.5 0.551 
Apolipoprotein R  APOR_PIG 1.6±1.1 1.0±0.3 0.8±0.8 0.3±0.3 0.213 2.6±1.6 6.8±2.7 0.9±0.8 0.5±0.5 0.006 1.9±2.3 0.0±0.0 n/a 
Asporin  F1SUE4_PIG 78.2±16.2 62.0±11.9 86.2±17.1 150.3±37.5 0.007 77.5±16.5 81.7±37.1 90.1±30.2 157.3±43.8 0.059 61.0±14.8 87.4±40.2 0.375 
Biglycan  K7GP55_PIG 796.0±130.8 648.1±186.6 952.7±42.3 1503.4±443.4 0.014 748.6±200.3 750.0±367.0 1002.9±236.7 1972.6±202.2 0.001 659.9±210.4 971.4±110.9 0.056 
Carboxypeptidase-like 
protein X2 F1SEC6_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.4±0.2 n/a 0.0±0.0 0.0±0.0 n/a 
Cathepsin D  Q4U1U3_PIG 1.6±0.5 1.9±0.3 7.2±4.8 8.8±13.1 0.523 1.1±1.5 2.3±1.6 4.1±3.6 3.7±1.8 0.412 3.6±3.7 3.2±1.8 0.852 
Cathepsin G  F1SGS1_PIG 0.5±0.3 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.8±0.8 0.8±0.7 0.1±0.1 0.0±0.0 0.201 0.7±0.9 0.0±0.0 n/a 




HUMAN 0.1±0.1 0.0±0.0 0.3±0.5 0.0±0.0 0.415 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.1±0.2 0.0±0.0 n/a 
Clusterin  CLUS_PIG 98.2±51.7 59.8±17.0 45.6±16.8 16.4±10.7 0.048 59.0±19.6 273.4±202.6 61.0±24.0 21.2±10.8 0.060 95.9±46.7 19.7±8.5 0.044 
Collagen alpha-1 (I) CO1A1_PIG 2915.1±375.6 2913.2±993.1 4118.5±199.0 2622.2±1399.4 0.244 2749.1±797.9 1973.1±1213.2 3353.0±487.7 3996.0±273.1 0.062 2055.2±391.6 2088.2±468.7 0.926 
Collagen alpha-1 (II)* I3LSV6_PIG 108.4±22.4 127.9±54.4 149.6±3.8 68.4±34.1 0.090 100.9±39.9 77.0±38.5 122.7±62.7 116.6±15.0 0.584 82.5±12.5 67.2±16.1 0.248 
Collagen alpha-1 (III)  F1RYI8_PIG 332.8±111.3 571.8±520.0 454.4±127.6 472.3±201.4 0.797 302.2±59.7 185.0±119.2 318.7±83.5 480.3±67.1 0.019 252.0±85.1 431.9±112.0 0.087 
Collagen alpha-1 (IV) M3V819_PIG 3.1±2.1 5.7±1.9 7.5±2.2 8.8±3.3 0.091 2.5±0.4 4.2±2.5 6.6±0.9 4.3±1.2 0.055 4.3±2.7 5.2±1.7 0.628 
Collagen alpha-1 (V)  F1S021_PIG 81.8±19.0 108.4±42.0 181.5±36.4 174.3±88.5 0.128 82.2±11.7 109.9±66.9 126.0±20.7 251.3±25.0 0.003 75.2±29.8 96.9±37.1 0.453 
Collagen alpha-1 (VI) CO6A1_PIG 4.5±1.2 3.6±3.9 2.0±0.4 10.3±8.4 0.221 4.8±2.2 6.2±5.1 2.6±2.9 1.8±0.3 0.371 6.2±4.7 7.9±6.9 0.746 
Collagen alpha-1 (VIII)  F1SKX7_PIG 0.2±0.3 0.2±0.4 1.5±0.6 0.5±0.4 0.013 0.1±0.2 0.4±0.4 1.8±0.9 3.2±1.0 0.002 0.2±0.4 0.2±0.3 n/a 
Collagen alpha-1 (XI)  F1S571_PIG 48.9±9.7 50.3±22.3 111.5±27.7 103.7±54.7 0.088 45.9±2.4 62.4±36.9 60.7±17.8 190.8±17.9 0.000 42.1±14.8 56.5±23.0 0.408 
Collagen alpha-1 (XII) COCA1_PIG 7.1±0.5 3.4±2.9 17.2±16.6 46.9±52.0 0.273 5.7±0.7 3.8±1.8 14.2±10.6 53.7±15.8 0.001 6.1±2.5 3.4±3.6 0.338 
Collagen alpha-1 (XV) COFA1_PIG 3.2±1.0 2.5±0.9 9.0±2.7 9.5±4.8 0.028 2.3±1.8 2.1±1.2 10.0±2.2 14.1±3.8 0.001 4.4±3.8 6.8±4.6 0.491 





Collagen alpha-1 (XX) COKA1_PIG  14.6±12.5 5.7±4.3 22.3±9.2 60.8±43.8 0.081 8.2±2.6 4.0±2.6 24.8±9.2 22.2±2.9 0.003 12.5±4.4 21.3±4.4 0.053 
Collagen alpha-2 (I)  F1SFA7_PIG 2540.2±281.6 2097.8±569.3 3114.0±344.6 2616.7±1337.8 0.482 2441.6±563.3 1949.6±1173.6 2966.9±215.8 4329.5±613.6 0.019 1819.5±446.0 2184.2±434.5 0.332 
Collagen alpha-2 (IV)  F1RLL9_PIG 3.1±1.8 6.9±2.4 7.2±4.2 7.8±0.2 0.184 1.9±0.6 4.1±3.7 8.4±3.2 2.1±0.4 0.038 5.4±6.5 5.6±2.6 0.961 
Collagen alpha-2 (V)  Q59IP2_PIG 84.2±45.2 108.2±40.4 172.3±73.6 173.7±84.4 0.281 87.0±14.8 91.2±57.0 156.5±6.4 200.7±119.1 0.188 75.8±40.3 84.1±59.3 0.846 
Collagen alpha-2 (VI)  I3LQ84_PIG 13.4±3.9 15.3±15.9 7.1±1.6 41.7±41.5 0.309 14.8±5.6 23.3±24.5 10.3±4.8 8.5±3.2 0.534 24.5±16.6 31.7±22.6 0.669 
Collagen alpha-2 (XI)* A5D9K7_PIG 23.6±4.3 36.2±12.2 49.2±10.5 37.8±22.7 0.250 22.2±5.9 32.8±16.0 30.3±10.1 52.3±10.3 0.055 24.6±9.4 25.0±7.5 0.951 
Collagen alpha-3 (V)  Q59IP1_PIG 1.1±0.7 1.6±1.2 1.9±0.8 5.8±5.3 0.220 1.2±0.7 1.9±2.1 2.1±1.0 3.2±1.3 0.402 0.6±0.4 1.2±0.9 0.338 
Collagen alpha-3 (VI)  I3LUR7_PIG 42.7±11.3 38.2±40.2 16.2±6.8 92.4±98.5 0.411 32.6±15.3 41.5±39.4 21.3±16.8 18.4±11.3 0.624 58.0±38.7 63.2±66.2 0.911 
Collagen alpha-6 (VI) CO6A6_PIG 0.0±0.0 0.0±0.0 0.0±0.0 14.1±24.5 n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.2±0.3 0.0±0.0 n/a 
Complement C3  CO3_PIG 4.3±1.1 0.1±0.2 0.6±0.3 1.8±3.1 0.063 3.3±1.4 14.2±20.9 1.4±1.6 0.4±0.6 0.405 12.3±8.9 1.8±2.1 0.097 
Complement component 
C9  A0SEG9_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 1.0±1.7 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 n/a 
Connective tissue growth 
factor  CTGF_PIG 0.4±0.3 0.3±0.5 0.7±0.6 0.0±0.0 0.308 0.8±0.4 0.4±0.3 0.7±0.4 0.1±0.2 0.212 0.2±0.2 0.0±0.0 n/a 
Decorin  PGS2_PIG 581.1±67.5 418.8±208.1 411.1±91.6 1166.4±602.8 0.064 610.5±85.3 554.8±357.0 441.8±67.1 1145.6±50.6 0.008 369.9±68.6 569.0±248.3 0.298 
Dermatopontin  DERM_PIG 52.5±13.7 43.6±33.0 45.1±3.3 126.2±69.7 0.090 64.5±12.2 59.9±38.4 80.7±23.7 150.5±20.2 0.008 36.2±8.6 74.7±13.9 0.022 
Dystroglycan  I3LD20_PIG 1.2±1.1 0.6±0.5 0.7±0.2 0.7±0.6 0.729 0.9±0.6 0.8±1.1 0.6±0.2 0.8±0.5 0.945 0.5±0.3 2.2±0.6 0.026 
EMILIN-1 F1SDQ5_PIG 6.1±3.2 8.3±2.1 7.9±2.5 10.7±2.4 0.261 5.6±1.8 6.4±2.8 9.1±1.0 8.8±3.8 0.316 9.4±4.2 14.5±3.6 0.148 
Fibrillin-1  FBN1_PIG 0.2±0.4 0.8±1.4 0.0±0.0 0.0±0.0 0.519 0.2±0.3 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 n/a 
Fibrinogen beta chain  F1RX37_PIG 1240.6±374.6 268.9±219.0 49.0±38.0 3.3±0.7 0.000 1240.6±892.3 2814.7±3732.6 77.6±53.1 53.8±46.6 0.317 1514.5±1633.6 17.6±25.7 0.164 
Fibrinogen gamma chain  F1RX35_PIG 1124.9±400.8 267.0±197.3 43.8±31.0 8.0±0.7 0.001 994.9±674.2 2014.6±2519.2 69.7±42.6 39.7±31.3 0.277 1214.6±1333.0 16.2±19.1 0.170 
Fibromodulin  F1S6B5_PIG 144.8±77.4 73.5±29.1 200.7±36.9 299.2±28.4 0.002 135.1±50.9 62.4±47.7 185.0±36.5 598.9±175.3 0.001 76.2±40.4 273.4±67.2 0.019 
Fibronectin  F1SS24_PIG 557.8±157.1 983.5±206.3 1109.9±420.0 503.9±198.9 0.055 527.0±248.9 1237.2±357.0 870.3±360.6 925.0±188.5 0.104 996.9±285.9 314.4±116.2 0.011 
Fibronectin type III domain-
containing protein 1  F1SB59_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.2 n/a 0.0±0.0 0.0±0.0 0.0±0.0 1.0±1.5 n/a 0.0±0.0 0.0±0.1 n/a 
Fibulin-1  F1SM61_PIG 0.3±0.1 0.0±0.1 0.4±0.3 0.4±0.5 0.438 0.1±0.2 0.3±0.6 0.4±0.2 2.0±1.5 0.077 0.6±0.4 0.3±0.3 0.269 
Fibulin-2 FBLN2_PIG 0.0±0.0 0.2±0.3 0.3±0.3 0.3±0.4 0.634 0.0±0.0 0.0±0.0 1.5±1.4 4.0±2.0 0.011 0.2±0.3 0.2±0.4 n/a 
Fibulin-3 F8SIP2_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.3 n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 n/a 
Fibulin-5  F1SD87_PIG 11.3±1.8 4.4±1.7 7.6±1.1 17.7±13.6 0.185 9.5±2.7 7.4±3.1 7.3±3.9 7.8±1.5 0.772 10.0±5.2 14.0±8.2 0.511 
Galectin-1  LEG1_PIG 16.2±4.0 23.5±12.5 40.8±10.8 30.3±8.2 0.062 23.7±5.0 14.6±10.3 34.3±3.1 25.7±8.6 0.062 22.8±13.4 44.5±6.0 0.041 
Galectin-3 A3EX84_PIG 0.1±0.1 0.2±0.3 1.0±0.2 3.9±6.0 0.421 0.2±0.2 0.1±0.1 0.5±0.4 1.1±0.2 0.002 0.1±0.2 0.2±0.1 n/a 
Galectin-3-binding protein M3V7X9_PIG 0.4±0.8 2.4±3.2 4.1±1.5 0.7±0.6 0.127 0.0±0.0 1.3±2.0 1.8±1.5 1.3±0.9 0.475 4.7±7.0 0.0±0.0 n/a 
Gelsolin GELS_PIG 217.8±17.2 129.6±51.0 160.6±18.1 179.7±80.3 0.246 227.7±68.3 150.1±78.2 194.7±35.8 155.4±18.4 0.345 164.9±7.5 250.3±39.5 0.061 
Hyaluronan and 
proteoglycan link protein 1  HPLN1_PIG 2.6±2.2 3.5±2.7 7.1±2.5 3.4±0.7 0.128 4.4±2.5 9.6±2.5 10.9±6.5 0.9±0.8 0.036 6.1±3.8 9.8±4.3 0.302 
Hyaluronan and 
proteoglycan link protein 3* 
HPLN3_ 
HUMAN 0.2±0.3 0.4±0.8 0.6±0.7 0.0±0.0 0.552 0.7±0.6 0.6±1.0 1.0±1.1 0.1±0.2 0.604 1.6±0.7 0.8±1.1 0.367 
Hyaluronan and 
proteoglycan link protein 4* 
HPLN4_ 
HUMAN 0.0±0.0 0.0±0.0 0.2±0.3 0.0±0.0 n/a 0.0±0.0 0.6±0.6 0.0±0.0 0.0±0.0 n/a 0.3±0.6 0.0±0.0 n/a 
Insulin-like growth factor-





heavy chain H2  ITIH2_PIG 8.4±3.7 4.5±2.1 3.6±2.2 4.1±1.6 0.163 6.8±1.5 6.4±3.9 5.7±1.8 6.1±5.2 0.985 7.2±1.4 2.1±1.6 0.011 
Lactadherin  MFGM_PIG 7.9±4.8 11.7±5.7 17.8±9.7 19.1±15.3 0.499 4.8±3.8 9.3±7.2 19.7±5.5 6.1±0.6 0.022 13.5±7.6 11.8±2.5 0.686 
Laminin subunit alpha-4  F1RZM4_PIG 6.2±1.5 2.1±1.5 3.5±1.5 11.2±3.5 0.004 6.7±4.6 3.9±2.2 3.6±3.9 3.9±1.5 0.655 6.5±4.6 9.1±5.2 0.522 
Laminin subunit beta-1  F1SAE9_PIG 2.8±1.3 1.4±1.2 6.2±4.7 9.4±1.0 0.020 1.6±1.9 1.4±1.0 4.6±2.7 2.0±1.2 0.188 3.6±2.6 7.6±1.7 0.060 
Laminin subunit beta-2  F1SPT5_PIG 8.8±2.3 8.1±0.2 7.1±0.9 8.7±1.3 0.462 6.2±3.7 11.0±2.8 8.3±5.3 4.3±1.9 0.205 9.4±2.0 10.5±3.3 0.630 
Laminin subunit gamma-1  F1S663_PIG 41.7±11.2 35.9±1.9 38.7±5.3 47.8±8.8 0.330 36.6±21.7 39.7±6.9 42.7±18.6 16.7±4.9 0.213 41.1±7.8 51.6±4.7 0.080 
Latent-TGFß-binding 
protein 1  F1S405_PIG 0.7±0.7 0.4±0.1 0.3±0.2 0.2±0.2 0.526 0.3±0.1 0.5±0.5 0.6±0.5 0.0±0.0 0.285 0.5±0.5 0.2±0.3 0.272 
Latent-TGFß-binding 
protein 2  F1S2T5_PIG 2.5±1.3 2.9±2.0 5.5±1.0 2.7±2.4 0.213 2.4±1.1 2.4±1.8 10.2±0.8 9.1±1.6 0.000 3.3±2.5 2.3±1.5 0.558 
Latent-TGFß-binding 
protein 4 LTBP4_PIG 3.7±1.9 0.1±0.1 0.0±0.0 4.9±5.6 0.177 5.5±1.7 1.1±1.7 1.4±0.6 2.8±2.9 0.074 1.0±1.9 2.9±0.9 n/a 
Leukocyte elastase inhibitor  ILEU_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.1±0.2 n/a 1.0±0.4 1.6±2.8 0.0±0.0 0.0±0.0 0.463 1.3±1.7 0.0±0.0 n/a 
Lipoprotein lipase* LIPL_PIG 1.8±0.4 1.2±2.0 0.0±0.0 0.0±0.0 0.150 1.4±0.6 6.1±2.7 3.3±2.1 0.0±0.0 0.012 1.4±1.0 0.0±0.0 n/a 
Lumican  F1SQ09_PIG 288.9±36.6 204.3±53.9 312.6±49.2 431.5±212.7 0.188 257.0±73.7 277.8±152.9 282.2±61.7 405.1±59.0 0.286 201.5±83.1 274.7±84.1 0.310 
Lysyl oxidase homolog 1 F1SIC9_PIG 5.7±5.2 0.7±0.6 3.9±1.2 7.8±3.3 0.110 6.2±7.8 2.0±1.7 6.6±4.9 11.3±1.1 0.195 2.3±2.5 8.9±5.1 0.140 
Macrophage-capping 
protein  F1SVB0_PIG 0.0±0.0 0.0±0.0 0.1±0.1 0.6±1.0 n/a 0.1±0.1 0.0±0.0 0.2±0.2 0.4±0.2 0.060 0.0±0.0 0.1±0.1 n/a 
Matrix Gla protein  MGP_PIG 1.2±0.4 1.7±0.1 2.5±1.1 1.3±0.8 0.149 1.3±0.7 1.3±0.7 2.8±0.3 1.4±0.5 0.035 1.1±0.6 1.3±0.7 0.726 
Matrix-remodeling-
associated protein 5  F1RZ07_PIG 0.3±0.4 6.3±5.4 6.5±9.2 7.4±9.7 0.631 0.1±0.2 3.9±1.9 7.3±9.9 11.5±5.5 0.175 5.8±7.9 2.3±3.1 0.467 
Mimecan  I3L9T6_PIG 426.0±40.0 220.5±139.0 255.7±34.2 495.6±304.8 0.220 389.9±27.1 292.7±193.6 283.7±7.3 581.3±152.7 0.061 222.1±65.9 359.4±47.8 0.024 
Myeloperoxidase  K7GRV6_PIG 1.1±1.1 0.3±0.5 0.0±0.0 0.7±1.2 0.479 2.6±2.9 4.4±7.5 0.0±0.0 0.0±0.0 0.494 5.0±5.4 0.0±0.0 n/a 
Nidogen-1 NID1_PIG 1.5±0.8 2.2±2.2 4.3±1.7 6.1±2.5 0.070 2.0±0.7 3.8±2.2 5.3±2.6 8.1±2.7 0.049 1.3±0.3 2.2±0.6 0.095 
Nidogen-2  F1SFF3_PIG 109.6±14.8 137.7±31.0 155.9±5.2 173.2±56.0 0.187 104.0±32.6 157.8±56.4 161.3±12.5 96.8±25.8 0.109 107.0±40.5 191.0±42.9 0.055 
Papilin  F1S3J7_PIG 0.6±1.0 0.3±0.6 0.2±0.2 0.1±0.2 0.800 0.6±0.5 0.7±0.5 0.3±0.3 0.0±0.0 0.218 1.5±2.1 0.6±0.5 0.428 
Pentraxin-related protein 
PTX3* F1SJM0_PIG 0.9±0.8 1.2±1.1 0.0±0.0 0.1±0.1 0.138 0.8±0.3 0.5±0.9 1.4±1.1 0.0±0.0 0.234 1.6±0.5 0.0±0.0 n/a 
Peptidyl-prolyl cis-trans 
isomerase A  PPIA_PIG 2.2±1.0 1.5±0.7 4.3±1.5 6.2±8.1 0.536 3.8±1.8 3.6±2.5 5.8±4.0 7.3±2.8 0.385 3.5±2.1 3.2±0.8 0.780 
Periostin F1RS37_PIG 2.5±2.3 22.6±19.5 100.3±69.3 148.3±199.7 0.361 0.5±0.5 6.8±7.0 86.6±62.7 287.5±33.2 0.000 18.4±18.6 24.1±13.7 0.660 
Perlecan PGBM_PIG 210.9±42.8 188.9±59.9 245.7±21.6 384.9±98.0 0.019 215.7±38.4 237.8±121.6 321.6±78.5 336.2±111.9 0.359 223.6±75.7 314.7±59.1 0.134 
Peroxidasin homolog  I3LDA4_PIG 0.0±0.0 0.3±0.3 0.2±0.1 0.2±0.4 0.565 0.0±0.0 0.0±0.0 0.1±0.2 0.0±0.0 n/a 0.3±0.3 0.1±0.2 n/a 
Pigment epithelium-derived 
factor  Q0PM28_PIG 0.4±0.5 0.5±0.9 2.2±0.9 0.9±1.2 0.134 0.3±0.5 0.2±0.3 3.3±2.7 1.9±1.3 0.101 0.8±1.1 0.7±0.5 0.876 
Plasminogen  PLMN_PIG 57.8±54.2 79.7±55.9 10.7±5.6 2.1±1.8 0.114 34.6±16.9 146.3±54.8 11.2±6.5 2.6±1.8 0.001 28.7±24.0 0.4±0.6 0.099 
Podocan  I3LEB7_PIG 0.8±0.4 0.1±0.2 1.1±0.8 2.8±1.6 0.030 0.6±0.7 0.5±0.3 0.9±1.1 1.0±0.8 0.888 0.9±0.8 3.7±1.3 0.045 
Procollagen C-
endopeptidase enchancer 1  I3LEE6_PIG 0.2±0.1 0.1±0.1 0.8±0.5 0.7±0.3 0.069 0.2±0.2 0.1±0.1 2.7±3.8 1.1±0.5 0.366 0.4±0.5 0.9±0.7 0.373 
Prolargin  F1S6B4_PIG 269.7±21.2 200.2±42.2 300.6±54.5 608.6±187.3 0.005 263.7±49.7 255.3±109.7 341.3±134.5 995.5±337.7 0.004 203.8±44.9 319.0±81.4 0.117 
Prolow-density lipoprotein 





Properdin  K7GQR1_PIG 0.7±0.6 0.3±0.3 0.0±0.0 0.3±0.3 0.228 0.6±0.7 0.6±0.7 0.3±0.5 0.2±0.1 0.749 0.7±0.6 0.1±0.1 0.152 
Prophenin and tritrpticin  PF11_PIG 63.9±15.1 16.9±10.5 2.1±1.0 8.0±13.4 0.001 94.1±47.6 186.5±155.5 9.8±2.0 1.1±1.6 0.074 116.0±100.2 0.3±0.5 n/a 
Proteoglycan 4 I3L5Z3_PIG 0.5±0.2 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.1 0.1±0.2 0.0±0.0 0.0±0.0 0.554 0.0±0.0 0.0±0.0 n/a 
RPE-spondin RPESP_PIG 4.8±2.1 7.9±7.7 5.8±3.3 1.5±1.3 0.393 9.0±9.3 4.7±2.9 9.3±5.6 2.4±0.4 0.415 6.6±1.5 7.6±0.6 0.274 
Secreted frizzled-related 
protein 1  I3LB66_PIG 0.0±0.0 0.0±0.0 0.4±0.6 0.9±0.9 0.183 0.0±0.0 0.0±0.0 0.2±0.3 0.7±0.0 0.001 0.0±0.0 0.8±0.4 n/a 
Serine protease HTRA1  F1SEH4_PIG 7.0±1.7 10.8±4.9 46.7±13.0 45.6±41.4 0.100 5.5±2.7 6.5±3.8 37.4±17.4 37.2±21.0 0.029 5.9±3.4 24.5±17.8 0.208 
Serotransferrin  TRFE_PIG 0.4±0.4 2.3±0.7 1.7±1.8 3.2±5.6 0.710 3.0±2.3 6.0±2.7 1.6±2.0 6.6±9.7 0.624 3.3±3.0 0.2±0.3 n/a 
Serum amyloid P-
component  SAMP_PIG 0.1±0.1 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.1±0.1 0.0±0.0 0.0±0.0 0.0±0.1 0.713 0.2±0.3 0.0±0.0 n/a 
SPARC  SPRC_PIG 0.3±0.6 3.6±1.3 3.5±1.4 0.8±1.0 0.010 0.4±0.7 0.5±0.7 3.2±1.9 4.7±1.2 0.008 1.4±1.6 3.1±0.6 0.122 
Spondin-1 SPON1_PIG 0.0±0.0 0.1±0.1 0.5±0.5 0.4±0.7 0.449 0.1±0.1 0.1±0.2 0.5±0.3 0.9±0.8 0.187 0.2±0.4 0.5±0.4 n/a 
Sulfhydryl oxidase  F1S682_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.1±0.2 0.0±0.0 0.0±0.0 n/a 0.1±0.2 0.0±0.0 n/a 
Superoxide dismutase [Cu-
Zn]  Q007T6_PIG 1.1±0.4 0.2±0.2 1.6±0.6 1.3±0.7 0.042 1.8±1.5 0.2±0.2 1.3±0.3 2.1±0.6 0.098 0.9±1.0 3.2±1.9 0.156 
Target of Nesh-SH3* F1SL03_PIG 3.1±1.9 0.9±1.5 1.3±2.0 4.1±4.5 0.466 4.3±2.0 0.8±0.8 3.3±1.0 13.5±5.4 0.004 1.0±1.7 2.7±2.2 0.339 
Tenascin  TENA_PIG 64.2±20.0 52.4±13.9 257.6±39.4 168.2±84.9 0.003 44.9±12.4 82.6±47.7 168.9±41.0 106.5±33.4 0.017 81.9±36.9 36.0±30.0 0.131 
Tenascin XB*  A5A8W4_PIG 5.5±2.3 4.4±7.1 3.4±4.8 9.4±11.0 0.747 5.7±4.1 5.9±5.4 1.8±1.4 6.1±5.3 0.586 2.8±4.7 3.4±2.3 0.831 
Tetranectin  F1SRC8_PIG 1.6±0.5 0.9±0.8 2.5±2.0 2.3±0.4 0.324 1.7±0.8 2.2±2.0 3.5±2.6 6.7±2.1 0.059 1.1±1.0 1.4±0.7 0.698 
TGFß-1* TGFB1_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.2±0.3 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 n/a 
TGFß-3* K7GSJ9_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.6±0.9 n/a 0.0±0.0 0.0±0.0 n/a 
TGFß-induced protein ig-h3  BGH3_PIG 19.5±5.0 15.1±11.9 9.5±4.3 27.0±17.6 0.333 9.0±3.3 15.7±8.3 22.6±19.7 8.6±4.8 0.415 34.6±17.0 16.1±8.1 0.121 
Throbospondin-1 K7GPJ3_PIG 5.8±2.3 4.2±1.7 7.2±2.1 2.7±0.9 0.073 4.3±0.9 6.3±2.1 7.1±1.8 6.1±3.2 0.491 5.7±0.9 0.4±0.4 0.000 
Tryptase  TRYT_PIG 0.0±0.0 0.0±0.0 0.0±0.0 3.8±6.6 n/a 0.0±0.0 0.0±0.1 0.0±0.0 0.4±0.7 0.475 0.0±0.0 0.0±0.0 n/a 
Tubulointerstitial nephritis 
antigen-like  F1SVA2_PIG 83.0±10.1 56.6±25.4 53.2±6.7 65.1±9.5 0.142 71.7±13.9 67.8±36.6 69.5±11.8 43.5±5.7 0.364 58.3±3.7 67.8±14.1 0.362 
Versican  F1REZ2_PIG 70.2±5.8 103.0±18.5 153.5±7.9 148.5±26.1 0.001 112.2±54.7 81.1±31.6 231.4±38.8 398.1±137.4 0.004 106.1±58.1 142.6±42.5 0.381 
Vitamin D-binding protein  I3LN42_PIG 8.7±5.6 1.3±1.0 2.7±1.1 1.4±1.8 0.051 5.3±1.1 9.0±5.5 2.8±1.9 1.4±1.0 0.062 7.3±7.7 0.5±0.5 0.173 
Vitronectin  VTNC_PIG 298.1±250.1 239.7±90.3 148.2±65.3 87.3±94.7 0.352 202.6±40.6 694.9±156.0 235.4±154.0 82.8±48.1 0.001 149.0±66.3 43.5±29.8 0.043 
von Willebrand factor A 
domain-containing protein 1  F1RJE3_PIG 17.6±8.1 8.6±3.6 10.6±3.4 14.5±6.4 0.294 18.7±5.6 11.7±6.0 14.6±4.6 7.3±4.4 0.129 11.1±2.7 16.8±5.1 0.183 
WD repeat-containing 
protein 1  K9IVR7_PIG 0.0±0.0 0.1±0.2 0.1±0.1 0.1±0.2 0.537 0.0±0.0 0.0±0.0 0.0±0.1 0.0±0.1 0.595 0.0±0.1 0.1±0.0 0.598 
P values for changes in BMS and DES over time were identified for each stent type separately by one-way ANOVA (BMS: n=3 [BMS1/3/7/28], 1-way ANOVA; DES: n=3 
[DES 1/3/7/28], 1-way ANOVA). ANOVA was not applied if a protein was detected at only a single time point. P values for POBA are based on unpaired Student’s t-tests 
with unequal variance for changes between early (n=4 [day 1 + 3] and late (n=3 [day 14 + 28] stage. T-test was not performed if a protein was undetectable in the majority 
of samples from 1 of the 2 groups compared. ‘n/a’ denotes ‘not applicable’. Proteins only identified in the media are marked with*. Results in bold indicate P < 0.05. Values 




5.5 ECM remodelling in the neointima 
To study neointimal ECM composition in response to different stent types, the neointima 
lesions of coronary arteries 28 days post-stent implantation were analysed separately by 
proteomics. 
5.5.1 Method reproducibility 
The neointima samples were run in duplicates to test reproducibility for the LC-MS/MS 
analysis. Indeed, the method showed good reproducibility for spectral counts and 
sequence coverage as well as the number of identified peptides, as illustrated in Figure 
20A and B.  
 
Figure 20. Reproducibility of LC-MS/MS. The neointima samples were run in duplicates by LC-
MS/MS. (A) The total spectral counts (R=0.998) and the sequence coverage (R=0.969) for each ECM 
protein correlated well between technical replicates. n=140 proteins x 14 samples (Pearson correlation). 
The Venn diagram displays the unique peptides identified either in both or only in the 1st or 2nd analysis.  
 
5.5.2 Neointima comparison between DES and BMS 
The differentially expressed proteins between the neointimas of DES and BMS are shown 
in the heat map in Figure 21A. Compared to BMS, the neointima of arteries with DES 
implantation contained less structural ECM constituents like collagen type I, III, V as well 
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as regulatory ECM proteins such as biglycan, lumican, fibromodulin or periostin; in 
contrast, proteins involved in the regulation of calcification such as matrix Gla protein 
(MGP), secreted phosphoprotein 24 (SPP24) and bone morphogenetic protein 1 (BMP1) 
were increased in DES (Figure 21B). Immunohistochemistry localised MGP and SPP24 in 
human coronary arteries with atherosclerotic plaques with and without stent implantation 
(Figure 21C). Interestingly, proteomics also revealed the presence of chondroadherin in 
coronary arteries with DES (Figure 21B). This SLRP has not been previously reported in 
the vasculature.  
 
Figure 21. Comparison of neointimal BMS and DES. (A) Heat map of differentially expressed 
proteins. n=7 per group (t-test with unequal variance). Pearson correlation. (B) Proteins involved in the 
regulation of calcification (SPP24, MGP, BMP1) and chondroadherin were predominantly found in the 
DES group. *P<0.05. TIC = total ion current. BMP 1, chondroadherin and SPP24 were not detected in 
the control group, thus a t-test was not performed. (C) MGP and SPP24 in human stented and control 
coronary arteries detected by immunohistochemistry. Scale bars=1 mm. 
Normalized protein abundance 
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5.6 ECM remodelling in the media 
5.6.1 Temporal changes in the media post-stenting 
ECM remodelling in response to stent implantation was compared over a time course of 
28 days. Coronary arteries subject to POBA served as controls. Distinct clusters of 
differentially expressed proteins over time were observed (Figure 22A-C). At an early 
stage, proteins regulating haemostasis (e.g. plasminogen, fibrinogen, antithrombin-III, 
thrombospondin-1) and inflammation (e.g. pentraxin-related protein PTX3, prophenin and 
tritrpticin precursor) were increased. Similarly, apolipoproteins found on VLDL particles, 
including apoC-III, apoE and apoR259 showed an early rise, within the first few days upon 
intervention. They subsequently decreased with the increase of other ECM proteins. 
Proteins with a late response included large aggregating proteoglycans (aggrecan, 
versican) fibrillar collagens (e.g. type I, III and V), SLRPs (decorin, biglycan, fibromodulin, 
podocan, asporin) and matricellular proteins (e.g. periostin, tenascin, SPARC). Generally, 
fewer proteins significantly changed in POBA than in stented arteries and more 
pronounced changes were seen in DES compared to BMS. A comparison of POBA late 
versus BMS stented arteries at day 28 returned 5 differentially expressed proteins, while 
the comparison of POBA late with DES revealed significant changes in 29 proteins (Figure 
22D, Supplemental table 3). Differences between DES and BMS became most obvious at 
day 28. While up to 7 days only few proteins were differentially expressed between DES 
and BMS, significant differences were seen in 11 proteins at day 28 (Figure 22E, 
Supplemental table 4). Thus, DES affects the composition of the ECM.  
5.6.2 Media comparison between DES and BMS  
At day 28 basement membrane proteins such as collagen alpha-2 IV (CO4A2), collagen 
alpha-1 XVIII (COIA1), laminin beta-1 (LAMB1), laminin beta-2 (LAMB2) and laminin 
gamma-1 (LAMC1) were uniformly downregulated in arteries with DES compared to BMS 
(Figure 23A). Since DES inhibit cell proliferation, this finding likely reflects the reduced 
cellularity in arteries with DES. In contrast, the large aggregating proteoglycan aggrecan 
(PGCA) was upregulated after stenting, particularly in DES (Figure 23B). Aggrecan is the 
major proteoglycan in the articular cartilage and interacts with hyaluronic acid to form 
large aggregates. Its rise mirrored the increase of versican, the major large aggregating 
proteoglycan in the vasculature (Figure 23B). Aggregates of aggrecan and versican with 
hyaluronic acid are stabilized by hyaluronan and the proteoglycan link protein 1 (HPLN1). 






Figure 22. ECM remodelling in the media over time. (A-C) Heat maps of significantly differentially expressed ECM proteins over time in DES, BMS and the POBA 
group. BMS/DES: n=3 per time point. P<0.05 (1-way ANOVA). POBA: n=3-4 per group. P<0.05 (t-test with unequal variance). Pearson correlation. (D) Number of 
significant protein changes in POBA late compared to BMS/DES at day 28. (E) Number of differentially expressed proteins between DES vs. BMS over time. 
Abbreviations: ITI heavy chain H2, inter-alpha-trypsin inhibitor heavy chain H2; PTX3, pentraxin-related protein PTX3; sFRP-1, secreted frizzled-related protein 1; IGF, 
insulin-like growth factor; SD=superoxide dismutase; LTBP, latent-transforming growth factor beta-binding protein; AE, adipocyte enhancer. 
Normalized protein abundance 






Figure 23. Comparison of BMS vs. DES in the media. Volcano plot of differentially expressed proteins 
between DES and BMS at day 28. n=3 per group (t-test with unequal variance). PGCA, aggrecan; 
HPLN1, hyaluronan and the proteoglycan link protein 1 (B) Time- and stent-dependent changes in 
aggrecan, versican and HPLN1 protein levels. n=3 per group. *P<0.05 (t-test with unequal variance). 
TIC, total ion current. (C) Corresponding gene expression in stented (n=3 per time point, except DES 
day 3: n=2) and unstented control coronary arteries (n=6); Gene expression values were normalized to 
unstented control arteries. Linear regression analysis for P-value for trend. 
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5.7 Validation of proteomics findings 
5.7.1 Stent-induced changes in aggrecan and its fragments 
Due to its novelty in the vasculature and its significant time-dependent increase upon 
stenting, as well as its differential increase in DES over BMS at day 28, aggrecan was 
selected for further validation. For comparison, we used versican as it is structurally and 
functionally related to aggrecan, and which also showed a significant time-dependent 
increase upon stenting. Firstly, gene expression analysis was performed to validate the 
proteomics findings. However, samples of day 1 were excluded, due to the poor RNA 
yield in all DES day 1 samples, as also indicated by unreliable results for the measured 
housekeeping genes. It is likely that this was due to toxic drug effects as we have also 
observed decreased RNA levels and cell loss upon drug treatment of ECs in our in vitro 
studies (Figure 26C). Except for DES day 3 (n=2), again due to poor RNA yield, all 3 
biological replicates were analysed for the other stented groups. A temporal increase of 
both, aggrecan and versican expression after stenting was confirmed at the transcript 
level (Figure 23C). However, there was no difference in aggrecan expression in DES 
compared to BMS at the transcript level. Consistent with the proteomics findings, there 
was no increase in HPLN1 at day 28 on gene expression level.  
Besides gene expression, protein degradation determines the abundance of ECM 
proteins in the vessel wall. Degradation of aggrecan and versican in the vessel wall is 
regulated by members of the ADAMTS family, the so called aggrecanases. Thus, we used 
neoepitope antibodies that only recognize aggrecan and versican upon cleavage by 
ADAMTS proteases for western blot analysis in porcine GuHCl extracts (Figure 24A). For 
aggrecan, we probed for the signature cleavage at NITEGE373-ARGTV in the interglobular 
domain at the N-terminus. Western blot analysis showed that the rise in aggrecan as seen 
by proteomics was accompanied by increased detectability of the NITEGE neoepitope 
over time, however more pronounced in DES than BMS (Figure 24B). Similarly, an 
increase was seen for the ADAMTS-generated DPEAAE fragments of versican. When the 
fragment levels were compared in BMS and DES, again both were found to be higher in 
DES compared to BMS at day 28 in a second cohort of media samples, consistent with 
the increased levels of aggrecan observed in DES by proteomics (Figure 24C). 
Next, we evaluated the abundance of the proteoglycan fragments in BMS vs. DES 
in the different fractions and compared the intra- (SDS) and extracellular (NaCl and 
GuHCl) distribution of the fragments in BMS and DES. Aggrecan neoepitopes were not 
detectable in the NaCl and SDS extracts, while versican neoepitopes were detectable in 
all three extracts, indicating the lower abundance of aggrecan fragments. While the 
extracellular fractions (NaCl and GuHCl) showed an identical distribution pattern, 
RESULTS 
 104 
confirming the higher abundance of the versican fragments in DES compared to BMS 
stented arteries, in the intracellular fraction, no difference between BMS and DES was 
seen (Figure 24D). This finding may be indicative for differential extracellular degradation 
of the proteins in BMS and DES or differential internalization.  
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Figure 24. Aggrecan fragments in DES and BMS (A) The aggrecan neoepitope NITEGE and the 
versican neoepitope DPEAAE are generated by aggrecanase cleavage. Schematic illustration of the 
cleavage site by the red arrow. (B) Immunoblots for the aggrecan NITEGE and versican DPEAAE 
neoepitopes over time in BMS and DES stented arteries in GuHCl extracts. Ponceau stain below. 
Quantification by densitometry is shown below. n=3 per time point (except BMS day 3 and day 28: n=2). 
*P<0.05, **P<0.01, ***P<0.001 (1-way ANOVA [P<0.001] with Dunnett post hoc test to day 1) (C) 
Differences between BMS and DES at day 28 in the GuHCl extracts. Silver stain and densitometry 
below. n=4 per group (samples of a 2nd cohort of BMS/DES stented arteries at day 28). **P<0.01 (t-test 
with unequal variance). (D) Comparison of versican DPEAAE fragments between BMS and DES at day 
28 in all three extracts (NaCl, SDS, GuHCl). Densitometry is shown below. n=4 per group (samples of a 
2nd cohort of BMS/DES stented arteries at day 28). **P<0.01 (t-test with unequal variance). 
 
5.7.2 Aggrecanase changes in stented arteries  
Next, we assessed the expression levels of ADAMTS1 and ADAMTS4, the two 
predominant ADAMTS isoforms in men. Both, ADAMTS1 and ADAMTS4 were detectable 
in porcine coronary arteries, with significantly higher expression levels for ADAMTS1 in 
normal arteries (Figure 25A). Upon stenting, there was a notable loss of ADAMTS1, 
followed by a rise in ADAMTS4 expression. To evaluate the EC content of the tissue the 
endothelial specific marker cadherin 5 was measured (Figure 25B), as stenting induces 
EC injury. The re-expression of cadherin 5, possibly indicating re-endothelialisation, 
coincided with the shift in ADAMTS4 expression. 
Besides its expression levels, the extracellular activity of the ADAMTS enzymes is 
regulated by their endocytic clearance. Low density lipoprotein receptor-related protein 1 
(LRP1) was shown to be involved in the endocytic clearance of ADAMTS-4 and ADAMTS-
5.260, 261 Thus, we investigated the abundance levels of LRP1 in BMS and DES stented 
arteries at day 28, to evaluate its impact on ADAMTS activity and consequently on 
aggrecan and versican turn-over. We probed for the 85 kDa light beta-chain containing 
the transmembrane domain in the neointima samples to evaluate the contribution of both 
SMCs and ECs to extracellular ADAMTS clearance. Significantly higher LRP1 protein 
levels were found in DES stented samples (Figure 25C), possibly indicating an increased 




Figure 25. Aggrecanase changes in stented porcine coronary arteries. (A) Raw CT values of 
ADAMTS1 and ADAMTS4 in unstented control coronary arteries in pigs. n=6 per group. ***P<0.001 (t-
test with unequal variance). (B) Relative gene expression levels for ADAMTS1, ADAMTS4 and cadherin 
5 in porcine tissue upon stenting. n=3 per time point for BMS/DES; except DES day 3: n=2. n=6 for 
control coronary arteries. Gene expression values were normalized to unstented control arteries. Linear 
regression analysis for P-value for trend. (C) Comparison of LRP1 abundance between BMS and DES 
in the neointima at day 28. Silver stain below. Densitometry on the right. n=7 per group. *P<0.05 (t-test 
with unequal variance). 
5.7.3 Aggrecanase expression in cultured ECs and SMCs 
Since stenting induces endothelial injury and the changes in aggrecanases coincided with 
the EC marker, expression levels of ADAMTS1 and ADAMTS4 in human ECs from 
different vascular territories (umbilical vein ECs, saphenous vein ECs, aortic ECs and 
coronary ECs) were investigated. Human coronary artery ECs expressed high levels of 
ADAMTS1 (Figure 26A), indicating a more prominent role for ADAMTS-1 in coronary ECs 
compared to other vascular territories. Furthermore, we evaluated basal expression levels 
of the aggrecanases and their substrates, as well as HAPLN1 in cultured human coronary 
artery ECs and SMCs. Both, aggrecanases and aggrecan are expressed in HCASMCs, 
however HCAECs express only the aggrecanases (Figure 26B), but not aggrecan or 
HAPLN1. To investigate whether a direct drug effect could be responsible for the changes 
seen in the ADAMTS enzymes, we cultured HCASMCs and HCAECs in the presence of 
everolimus, the drug eluted from the stents used in our porcine model. Upon drug 
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treatment ECs showed a substantial decrease in RNA levels, indicating a limited tolerance 
to the drug. This was confirmed by significantly reduced cell count and viability of 
everolimus treated ECs as assessed by automated cell counting of total and dead cells 
(Figure 26C). Thus, all proteases were reduced in treated ECs (data not shown). 
However, in SMCs, which better tolerated the drug, an effect was only seen in ADAMTS4, 
while the expression levels for ADAMTS1 remained unchanged (Figure 26D).  
Figure 26. Validation of findings in cultured cells. (A) Gene expression of ADAMTS1 and 4 in arterial 
and venous ECs. n=4, 2 independent cell passages of 2 different cell lines, except HSaVEC: n=3 
independent cell passages of 1 cell line. P-values were derived from 1-way ANOVA. HUVEC, human 
umbilical vein ECs; HSaVEC, human saphenous vein EC; HAoEC, human aortic ECs; HCAEC, human 
coronary artery ECs. (B) Raw CT values of ADAMTS1 and 4 as well as versican, aggrecan and 
HAPLN1 in ECs and SMCs of coronary arteries. n=triplicates of 3 independent cell passages. HCASMC 
(p7,9,11), HCAECs (p7,8,9). ***P<0.001 (t-test with unequal variance). (C) Viability and cell count of 
HCAECs treated with everolimus or DMSO (controls) as determined by Nucleo Counter® NC-3000TM. 
n=6 per group. ** P<0.01, ***P<0.001 (t-test with unequal variance). (D)  Relative gene expression 
levels of ADAMTS1 and ADAMTS4 in control and everolimus treated HCASMCs. n=triplicates of 3 
independent cell passages. HCASMCs (p7, p9, p11) ***P<0.001 (t-test with unequal variance). Gene 
expression values were normalized to the control group in each passage. 
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5.8 Aggrecan in human vasculature 
5.8.1 Aggrecan in human stented arteries 
To confirm the presence of aggrecan and its fragments also in stented human coronary 
arteries immunostaining was used. Aggrecan and ADAMTS-generated aggrecan 
fragments were co-localized in the coronary arteries. Again, as for the validation of 
neointimal changes, coronary arteries with atherosclerotic plaques but without stents 
served as a reference control. Aggrecan and HPLN1 co-localized in the media of control 
arteries (Figure 27A). In stented coronary arteries, staining for the aggrecan NITEGE 
neoepitope was observed predominantly in the intimal and medial layer at the contacts of 
the stent struts with the artery as demonstrated by immunofluorescence (Figure 27B; all 
images in appropriate channels and corresponding IgG controls are shown in Figure 28). 
5.8.2 Aggrecan in human aorta and vein 
Since the major role of aggrecan in cartilage is to confer resistance to pressure, we 
assumed a similar function in the vasculature. Thus, to further investigate the role of 
aggrecan in the human vasculature we compared specimens of human thoracic aorta and 
human saphenous veins, as representatives of the high- and low-pressure system, 
respectively. Targeted proteomics analysis revealed that similar to versican, aggrecan 
was more abundant in the aorta than in veins (Figure 29A). The SLRP decorin served as 
a control. Likewise, by western blotting it was shown that the ADAMTS-generated 
aggrecan NITEGE neoepitope was more abundant in the aorta (Figure 29B). Aggrecan 
and aggrecan cleavage was found throughout the media of the human aorta as confirmed 




Figure 27. Immunostaining on human coronary arteries. (A) Localization of aggrecan, the aggrecan NITEGE and versican DPEAAE neoepitopes (neo), and HPLN1 
in stented and control human coronary arteries with presence of atherosclerosis (*). Arrows mark the contacts of the stent struts with the coronary artery. Scale bars=1 
mm. (B) Co-localization of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE neoepitope (Alexa 568, displayed in red) in human stented coronary 
arteries by immunofluorescence is displayed on a magnified section as marked in (A). Note the presence of aggrecan fragments at the contacts of the stent struts with 
the artery and in the subendothelial layer (zoomed-in areas). Overview image 20x, scale bar=500 µm; Zoomed-in areas 60x, scale bar=25 µm. Sections were provided 
by Dr. Steve White of University of Bristol. Fluorescence images were taken with Dr. Chris Molenaar of King’s College London.  
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Figure 28. Aggrecan in human stented coronary artery. Detail images to figure 25B. Co-localization 
of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE neoepitope (Alexa 568, displayed in 
red) in human stented coronary artery visualized by immunofluorescence. Overview image 20x, scale 




Figure 29. Aggrecan in human vessels. (A) Adjusted peak area for aggrecan, versican and decorin in 
the human thoracic aorta and saphenous veins as determined by targeted proteomics. n=7 per group. 
*P<0.05, **P<0.01 (t-test with unequal variance). (B) Immunoblots for the aggrecan NITEGE neoepitope 
and versican in the human thoracic aorta and saphenous veins. The SLRP decorin served as a loading 
control. Quantification by densitometry is shown on the right. n=4 per group. *P<0.05 (t-test with unequal 
variance). (C) Co-localization of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE 
neoepitope (Alexa 568, displayed in red) in human aorta visualized by immunofluorescence. Elastin 
fibres in white (autofluoresence with 488nm laser excitation captured in the green emission channel). 
Control sections stained with matching isotope IgGs. Magnification 60x, scale bars=20 µm.  
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5.9 Aggrecan in a mouse model of venous bypass graft 
5.9.1 Role of mechanical forces in aggrecan expression 
The higher abundance of aggrecan in stented coronary arteries and aorta compared to 
veins and its role in the cartilage to absorb pressure, let us hypothesize that mechanical 
stretch might induce aggrecan expression in the vasculature, similar to its role in the 
cartilage. In order to explore this potential mechanism, veins were grafted into carotid 
arteries of mice (Figure 30A). After grafting, mice were fed a diet of stable isotope labelled 
amino acids for 28 days to label all newly synthesized proteins (Figure 30B). Using 
targeted LC-MS/MS analysis, the incorporation of the stable isotope labelled amino acids 
was compared between ECM proteins in veins, vein grafts and arteries (Figure 30C). 60% 
of aggrecan peptides were found to be labelled in the murine aorta, demonstrating active 
synthesis of this proteoglycan in the arterial wall. In contrast, labelled aggrecan peptides 
were undetectable in veins, thus no aggrecan was produced in the normal vein. The 
incorporation ratio in vein grafts, however, was comparable with the aorta. Thus, aggrecan 
synthesis was inducible in veins by exposure to arterial blood pressure. Representative 
histological sections of mice fed a normal chow are shown in Figure 30D, where aggrecan 
was markedly elevated after grafting. The upregulation coincided with cleavage of the 
versican core as indicated by staining for the ADAMTS-specific DPEAAE neoepitope. 
Thus, besides its role in cartilage, aggrecan might be an important contributor to ECM 




Figure 30. Aggrecan induction upon mechanical forces. (A) Isogenic venae cavae of donor mice 
were grafted to carotid arteries of receptor mice. (B) Upon grafting, mice were fed a diet with stable 
isotope labelled amino acids for 28 days with subsequent analysis of the vessels by targeted MS. (C) 
Incorporation ratios for aggrecan, versican and decorin in interposition grafts, vena cava inferior and 
aortas are plotted. n=8-9 per group. N.D.=not detectable. (D) Immunostaining for aggrecan, the versican 
DPEAAE neoepitope and decorin. Magnification 10x, scale bars=200 µm. Mice graft surgery was carried 




The vascular ECM plays a critical role in providing structural support to the vessel wall 
and influences cell behaviour and signalling. In ISR, a complication of stent implantation in 
coronary arteries, the ECM constitutes over 50% of the tissue.155 However, to date, the 
composition of the ECM and the functional importance of ECM remodelling post coronary 
artery stenting are only poorly characterised at a molecular level. Our current knowledge 
of ECM changes after stent injury and during neointima formation is mainly based on 
histopathological analysis. To gain a more profound understanding of the ECM 
composition, we have applied proteomics analysis to stented porcine coronary arteries. 
This study is a significant advance over the published literature as it provides the first 
proteomics analysis of ECM remodelling in stented coronary arteries over time and a 
comparison of the effects of DES versus BMS on the vascular ECM. It revealed a 
previously unrecognized expression and cleavage of aggrecan during ECM remodelling 
upon stent implantation. Findings in the large animal model were validated in human 
specimen and followed-up in a small animal model. Diverging from the traditional ECM 
focus on collagens and MMPs, this study highlights the contribution of aggrecan and 
aggrecanases to vascular remodelling after stent implantation. Thus far, little is known 
about the role of aggrecan in the vasculature and stimuli that induce its expression.262 We 
have demonstrated that aggrecan synthesis is higher in arteries than in veins and that it is 
inducible upon grafting a vein into arterial circulation, which might be related to high 
circulatory pressure. However, this needs to be confirmed with further experiments, such 
as comparing the aggrecan content in the aorta of a hypertensive animal model to a non-
treated animal. 
Our findings provide a blue-print of the healing process in the coronary vasculature, which 
may lay the foundations for a better understanding of complications, such as ISR including 
neoatherosclerosis and thrombosis and suggest potential new drug targets to alter ECM 
remodelling in the vasculature. 
6.1 Porcine animal model of stent injury 
Animal models are essential to investigate temporal changes post stent implantation. Pigs 
are ideal, since the stages of the healing process closely resemble human disease.263 The 
time course, however, is notably different: stent healing in pigs occurs approximately six 
times faster than in humans.264 In the porcine model, peak neointima growth is observed 
at 28 days after stent deployment corresponding to six months in human. Few changes 
occur beyond this time point, with the exception of slight neointima thinning later on.264 
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Obvious reasons for the more rapid healing process in pigs are the absence of 
atherosclerotic lesions. In human samples, it has been shown that stent struts with an 
underlying necrotic core heal slower than stents in close proximity to areas with adaptive 
intimal thickening containing many SMCs.265 A slower healing response also applies to 
stents overlying calcified and densely fibrotic and hypocellular plaques. Notably, the 
presence of a lipid core of the underlying atherosclerotic lesions in human, likely 
influences drug retention and therefore further delaying healing and re-
endothelialization.60  The lack of a realistic atherosclerosis model is trying to be addressed 
by using pigs with metabolic syndrome or genetically modified models, particularly PCSK9 
engineered minimpigs.85 A further explanation for the rapid healing of stented pig coronary 
arteries is their young age. At the same time these are the shortcomings of our animal 
model: unlike patients, juvenile pigs are free of atherosclerosis.  This might also be the 
reason for the rather unexpected OCT findings. In our study the neointima of DES showed 
almost entirely a homogenous pattern at day 28, while this pattern was seen at only about 
60% of the BMS neointima. 39.8% of the neointima in BMS displayed a layered pattern at 
day 28. On the other hand, histopathological studies of atherosclerotic human arteries 
related a layered and heterogeneous OCT pattern rather to DES in-stent restenosis, while 
homogenous was typical for BMS.50 A previous study correlating OCT patterns of 
neointima formation to histopathologic findings using a healthy pig model similar to our 
study, found that heterogeneous and layered patterns had significantly thicker neointima 
compared to homogenous patterns.266 Further, peri-strut inflammation was less frequently 
found in the homogeneous pattern. Thus, for a more in-depth molecular characterization 
of the neointima formation upon stenting we have used proteomics. 
6.2 miRNA changes in the stent injury model 
Previous studies demonstrated a role for miRNAs in vascular disease.77 To complement 
the protein measurements in the large animal model, we have measured the expression 
of few selected miRNAs known to be involved in the proliferative response upon stent 
injury. Indeed, pronounced changes were observed between control and stented arteries, 
especially for miR-21 and miR-221, which were significantly upregulated upon stenting in 
our model. Both miRNAs are highly expressed in SMCs as well as ECs, indicating their 
important role in vascular remodelling.267 miR-21 and miR-221 are known to promote the 
synthetic phenotype of SMCs and induce their proliferation.77, 81 miR-221 was found to 
play a critical role in vascular SMC proliferation and neointima formation after angioplasty 
in a rat model.81 In contrast, antiproliferative effects have been reported on ECs via c-kit 
inhibition for miR-221.268 Thus, the upregulation of both miRNAs upon stenting in our 
model is likely associated with proliferative vascular SMCs, whereas their increase may 
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be a cause or effect of the proliferation. In addition, our observation for miR-21 is in line 
with previous reports of a prominent miR-21 upregulation after stent injury.257, 269 Wang et 
al. found that anti-miR-21 coated stents implanted in a humanized myointimal hyperplasia 
model in rats, were effective in decreasing ISR without interfering with re-
endothelialisation.269 Similarly, McDonald et al, demonstrated that an inhibition of miR-21 
attenuated neointimal formation in mice post-stenting.257 
Unlike miR-21 and miR-221, miRNAs, which inhibit SMC proliferation (miR-133a, 
miR-143, miR-145 and miR-195)267 were initially down-regulated upon stenting, consistent 
with the proliferative state of SMCs upon vascular injury. Both, miR-143 and miR-145 
maintain SMCs in a differentiated state, and it was shown that miR-145 overexpression 
inhibits neointimal growth76.  
6.3 Strengths and caveats of the proteomics approach 
Proteomics provides a valuable tool to comprehensively characterize the ECM 
composition of cardiovascular tissues.114, 253, 270 As proteins are the actual effector 
molecules carrying out cellular functions, proteomics is better suited than transcriptomics 
to analyse the ECM composition. The untargeted discovery-based proteomics approach, 
allowed an unbiased identification and relative quantification of ECM protein changes 
upon stenting.271 In contrast, conventional methods such as immunohistochemistry or 
western blotting, require a priori knowledge on the proteins of interest and tend to focus 
only on single proteins at a time. In addition, they rely on the availability of good 
antibodies. Besides notorious limitations of antibodies such as epitope masking or non-
specific binding, the abundance of the same protein can only be relatively quantified 
across different samples; however, the abundances of different proteins cannot be reliably 
compared, since the sensitivity and specificity of antibodies may differ. On the other hand, 
a caveat of data-dependent LC-MS/MS analysis is that low abundant proteins often 
escape detection in complex samples. Thus, to overcome this limitation, we have 
subfractionated the tissue and enriched for ECM proteins as previously described by our 
group.170 
The initial hypothesis-generating proteomics approach allowed us to identify 
candidate proteins, in particular aggrecan, which we have further investigated using a 
targeted MS approach and other independent techniques. In addition to validating the 
proteomics findings, techniques such as immunostaining, complemented the proteomics 
data by providing insights into protein localization, and this spatial information helped to 
further elucidate the potential role of aggrecan in the vasculature. 
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6.4 The role of databases in proteomics data analysis 
Improvements in MS instrumentation and database software have immensely contributed 
to the advances made in proteomics. However, the availability of complete and accurately 
annotated sequence databases for many species are equally important.199 For humans, 
several databases exist, with different degrees of completeness, redundancy and 
annotations.272 When peptide spectra are assigned to the database search, the potential 
peptide assignments are matched and thus limited to those sequences present in the 
database. For pigs, well-annotated and comprehensive protein databases are not yet 
available. Thus, we have generated a custom-made database that included as many 
known ECM proteins as possible to improve protein identification and quantification. For 
example, for perlecan, the database search with the combined human and porcine 
database returned only two thirds of the spectra that were identified using our custom-
made database. With our expanded database, the coverage of the identified proteins as 
well as the accuracy of our protein expression analysis increased. Thus, the output of 
proteomics studies depends on the comprehensiveness of the available databases. 
6.5 Identification of ECM proteins using discovery-based proteomics 
Porcine coronary arteries were stented with BMS/DES or were subjected to POBA serving 
as control. The arteries were analysed 1, 3, 7, 14 and 28 days post-stenting by 
proteomics. At day 28, the evolved neointimal tissue on top of the stent struts was 
separated and subjected to a separate proteomics analysis.  
6.5.1 ECM changes in the neointima 
Our proteomics comparison of the neointima revealed the following findings:  
• First, a more diverse composition of the neointima compared to the media of the 
same stented vessel at day 28 was observed. Further, basement membrane 
proteins were more abundant in the neointima than in the media. This observation 
is likely due to the higher cellularity in the neointima, since SMCs proliferate and 
migrate from the media towards the intima followed by ECM production.60 BM 
proteins including fibronectin are responsible for cellular anchorage, thus their 
abundance is tightly linked to tissue cellularity. 
• Secondly, a more organized and structured ECM assembly in the neointima 
forming over BMS compared to DES was seen. This was indicated by the 
increased abundance of fibrillar collagens and SLRPs, which contribute to collagen 
fibril formation and organization such as lumican, biglycan or fibromodulin in BMS 
stented arteries. Presumably, ECM organization indicating healing occurs at an 
earlier stage in arteries treated with BMS compared to DES. 
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• Thirdly, an upregulation of proteins associated with the regulation of calcification in 
neointimal lesions of arteries treated with DES became apparent.  
 
Vascular calcification generally refers to the accumulation of calcium phosphate crystals 
in vascular medial and intimal layers. Vascular intimal calcification associated with 
atherosclerosis is the most common form of calcific vasculopathy and different from 
medial Mönckeberg calcification, which can occur independently from intimal 
calcification.273 Intimal calcification is suggested to be similar to the process observed in 
bone formation.144, 274 Upon triggers such as inflammatory cytokines and mineral 
imbalance as prominently seen in chronic kidney disease vascular SMCs undergo 
chondrocyte and osteoblast-like differentiation. An osteogenic signalling pathway for 
example involves the BMP2/4 induced activation of the transcription factor Runx2, which 
is involved in osteoblastic differentiation.275 This transformation is characterized by the 
release of matrix vesicles, containing calcium and phosphate in form of hydroxyapatite 
crystals. Further, apoptotic SMCs releasing apoptotic bodies may serve to nucleate 
hydroxyapatites. Notably, vascular calcification is efficiently prevented by the calcification 
inhibitor MGP, either directly or by inhibiting BMP2 induced osteogenic differentiation.144 
The importance of MGP in calcification inhibition is stressed in studies showing that MGP 
deficient mice develop spontaneous vascular calcification.275, 276 
In our study, we observed an upregulation of the calcification inhibitor MGP277 and 
SPP24 in the neointima of DES treated arteries. Similarly, SPP24 is anti-osteogenic as its 
C-terminal fragment binds to and inhibits the activity of BMP2.278 The upregulation of 
these proteins may be a protective response of the vasculature as demonstrated by the 
presence of MGP and SPP24 in human control arteries. However, it is unclear whether 
their predominant abundance in the neointima of DES is due to a compensatory 
mechanism to a potentially increased calcification tendency or a primary inhibition of 
calcification. As neoatherosclerosis with or without calcification, is more frequently and 
rapidly observed in DES than BMS, a higher calcification tendency in DES is plausible.56 
On the other hand, recently it was shown that mTOR signalling inhibition decreases 
phosphate-induced vascular calcification via the upregulation of the Klotho gene 
expression.279 In the latter study the observed inhibition of calcification in aortas of chronic 
renal failure rats with mTOR inhibitors was independent of autophagy or apoptosis. In vitro 
calcification assays with everolimus treated cells might be a useful model to further 
elucidate the role mTOR inhibitors and consequently of DES in vascular calcification. In 
summary, the observed changes for these proteins in DES may also be due to the effects 
of the drug on phenotypic modulation of SMCs280, as these genes are modulated in the 
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transition. This may also explain why they appear increased in normal vessels vs stented 
human vessels. 
Finally, we observed chondroadherin in DES stented arteries. This SLRP is mainly 
expressed in cartilaginous tissue281 and its fragmentation has been previously associated 
with disc degeneration,282 but its expression in the vasculature at the protein level has - to 
our knowledge - never been reported. Yet, there is evidence for an association of 
chondroadherin with vascular pathology, since its transcription was found to be 
specifically induced in atherosclerotic plaques of femoral arteries in the Tampere Vascular 
Study.283 It remains to be elucidated, if chondroadherin might provide a link to the 
increased incidence or accelerated course of de novo atherosclerosis within DES-stented 
vessels.73 
6.5.2 Early changes upon vascular stent/balloon injury 
The early response to injury was independent of the deployed stent type. Similar protein 
changes were also observed after POBA in the early phase. Thus, their up-regulation 
indicates primarily a response to vascular injury, including balloon dilatation, rather than 
stenting. We have identified three different functional classes among these “early” 
proteins: 
• Proteins involved in haemostasis such as fibrinogen, plasminogen, antithrombin III 
and thrombospondin were increased. This is in line with findings in 
histopathological studies of platelet activation and thrombosis formation during the 
early stage of vascular healing.284  
• Furthermore, inflammatory proteins associated with innate immunity such as 
PTX3285 or prophenin and tritrpticin (C6)286 were increased. Also Cathepsin G was 
only detected at day 1 of BMS stented arteries. Cathepsin G, for example, has 
also important effects in regulating chemotaxis.287 An explanation for their 
upregulation is the recruitment of inflammatory cells to the site of vascular injury. 
Clinical studies reported a rise of inflammatory markers following PCI.288 
Lactadherin expression peaked around 7 days post-stent implantation in the DES 
group. Lactadherin plays an important role in the promotion of mucosal healing 
and contributes to phagocytic removal of apoptotic cells.289, 290 
• Finally, various apolipoproteins, such as apolipoproteins E, C-III and R259 and also 
lipoprotein lipase were retained in all groups. It is noteworthy that these are VLDL-
associated apolipoproteins. Apolipoprotein R is pig-specific.259 Their upregulation 
likely resulted from the disruption of the endothelial lining with subsequent 
exposure of the vascular ECM. This endothelial injury may have allowed VLDL-
associated apolipoproteins to bind to vascular proteoglycans, such as versican 
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and biglycan, that are known to retain apolipoproteins in the vessel wall.14 
However, apolipoproteins also contribute to innate immune responses, as carriers 
of proinflammatory oxidation by-products.291 Clearly, the lack of detection of other 
apolipoproteins does not exclude their contribution to the vascular injury response.  
• Apart from insulin-like growth factor-binding protein 7, cytokines and growth factors 
were barely detected in our proteomics analysis of the GuHCl extracts. This is 
likely due to their very low abundance compared to other proteins, thus they may 
escape detection by LC-MS/MS without further enrichment steps.  
6.5.3 ECM changes in the media 
In the early phase upon stent insertion, most ECM proteins showed no significant change. 
ECM changes were observed predominantly after 28 days. Notably, in our study the pigs 
used for the time point day 28 were all female compared to the groups of the other time 
points, which had an equal distribution of the two sexes. In addition, the pigs of day 28 
weighed on an average 9.6 kg less than their counterparts of other time points. In general, 
for this study both female and castrated male pigs were used, which is in line with other 
studies from major pathology labs deploying the porcine vascular injury model.86, 292 Thus, 
from this aspect no major impacts of male sexual hormones should be expected on our 
findings. Moreover, the fact that all pigs were female at day 28 is not based on any 
selection bias, as the pigs were distributed randomly into the groups as they were 
available from the supplier regardless of their sex but with similar age. The similar age 
would presuppose a similar stage of growth in all pigs. However, it is a fact that the day 28 
pigs were significantly smaller, for which we cannot provide an obvious explanation, as all 
animals were on the same diet. On a positive note, there were no significant weight or sex 
differences within the group, especially excluding an impact with regard to the BMS vs. 
DES comparison. Taken together, we cannot exclude any impact of the smaller animal 
size by the time of stent implantation on the vascular remodeling process. However, it 
appears more plausible, that the ECM changes predominantly observed at day 28 were 
due to the time it takes SMCs to lay down enough new ECM, rather than their size at stent 
implantation. 
Significant increase at day 28 were seen in fibrillar collagens, such as type I, III and V, 
the structural ECM components, but also in matricellular proteins (periostin, tenascin, 
SPARC) and SLRPs (decorin, biglycan, fibromodulin, podocan, asporin).  
• As highlighted in the introduction, SLRPs are important regulatory proteins, 
involved in a variety of cellular functions such as collagen fibril assembly, 
inflammation, cell proliferation, adhesion, migration as well as fibrosis.108, 117 
Decorin for example was found to negatively regulate fibrosis in cardiac tissue via 
DISCUSSION 
 121 
its inhibition of the TGF-b pathway.293 Despite high sequence and structural 
homology between decorin and biglycan, they were found to have distinct kinetics 
during neointima formation after arterial stent injury.294 Unlike biglycan, decorin did 
not occur in the neointima of control, non-atherosclerotic rabbit aortas, but 
appeared in the atherosclerotic aortas in the confined area of SMCs surrounding 
macrophages around stent struts.294 
• Like the SLRPs, matricellular proteins have important regulatory functions. The 
term ‘matricellular’ refers to their ability to modulate cell-matrix interactions and cell 
functions.116 SPARC, for example, facilitates collagen crosslinking and is therefore 
needed for proper healing after myocardial infarction.295 It has been shown that the 
absence of SPARC in mice caused increased cardiac rupture and dysfunction 
after myocardial infarction. Similarly, the upregulation of SPARC found in our study 
might indicate its importance in proper vascular healing post stent injury.  
• Interestingly, we have also found the lecticans aggrecan and versican increased at 
late stage. Aggrecan and its functionally related ECM protein, the link protein or 
hyaluronan and proteoglycan link protein 1 (HPLN1) were also among the 
differentially expressed proteins between BMS and DES at day 28. However, 
HPLN1, serves as the stabilizing link protein by binding to both lecticans and 
hyaluronan296, and was found to be downregulated in the DES group unlike 
aggrecan. 
 
To conclude the results of the identified ECM proteins, proteomics uncovered a 
coordinated ECM remodelling in response to vascular injury, including proteins such as 
aggrecan, which have not been described in the vasculature in connection with stent 
injury to date. Generally, more proteins showed a significant change in the DES compared 
to BMS group, with the differences being more pronounced at later stages. In DES, a 
uniform down-regulation of basement membrane proteins, indicative of a reduced 
cellularity, was accompanied by an increase in aggrecan. 
6.6 Aggrecan: more than just a cartilage protein 
6.6.1 Aggrecan structure and function 
Aggrecan is above all known for its role as the major proteoglycan in cartilage. It is 
characterized by its ability to bind hyaluronan, a large carbohydrate polymer, to form even 
larger aggregates, stabilized by the link protein (Figure 31A).109 The aggrecan gene, 
ACAN, in human is found on chromosome 15q26.1 and is composed of 19 exons. Exons 
1 and 9 are non-coding and exons 2-18 code for the core protein with around 2450 amino 
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acids, with a calculated molecular mass of approximately 250 kDa. Aggrecan is a 
multimodular protein consisting of three globular domains, two located at the N-terminus 
(G1 and G2) and one at the C-terminus (G3).297, 298 Thus, it is reminiscent of a barbell like 
shape with globular domains at either end (Figure 31B). The G1 domain has the same 
structural motif as link proteins and functionally anchors aggrecan to hyaluronan and link 
protein, forming a stable ternary complex in the ECM. The G2 domain is unique to 
aggrecan among the lecticans and is homologous to the tandem repeats of G1. However, 
no interaction with hyaluronan, link protein or other ECM proteins were described for this 
domain. It has been suggested that the G2 domain is involved in regulating protein 
processing through the secretory pathway in order to produce a mature functional 
molecule.299 Its C-terminal G3 domain consists of different structural motifs: two epidermal 
growth factor (EGF)-like repeats, a C-type lectin domain (CLD) and a complement 
regulatory protein (CRP, also known as sushi) repeat.297 The G3 domain links the 
aggrecan aggregates to other ECM proteins such as tenascins, fibulins or fibrillin-1. An 
interglobular domain (IGD) of approximately 150 amino acids separates G1 from G2. The 
central and largest part of aggrecan lies between its G2 and G3 domains and carries 
numerous GAGs, namely keratan sulfate (around 30) and chondroitin sulfate (around 100) 
chains, which give the protein its enormous amount of fixed negative charges. In fact, its 
glycosylation increases its molecular weight from around 250 kDa for its core protein to 
around 2.5 MD.297 These highly negatively charged GAGs attract counter-ions and draw 
water into the tissue providing the basis for the viscoelastic properties of cartilage. 
However, the numerous GAG side chains of aggrecan are not only important for cartilage 
resilience. It has also been shown that aggrecan is an important component of the 
perineuronal net, a matrix substructure in the central nervous system, involved in 
regulating brain synaptic plasticity and in glial scar formation after brain injury.109, 297 In 
addition, aggrecan in perineuronal nets was shown to exert neuroprotective actions by 
reducing oxidative stress through scavenging redox-active cations.300 
6.6.2 Aggrecan cleavage 
Aggrecan is known to be extensively degraded in tissue and aggrecan aggregates 
constantly undergo turnover in cartilage.301 Aggrecan degradation and its consequent loss 
from the cartilage for example, is one of the earliest events that occurs in association with 
osteoarthritis.302, 303 Especially cleavage of aggrecan in its interglobular domain between 
G1 and G2 is known to be of central importance for the pathology, as this releases the C-
terminal GAG carrying region of aggrecan from the cartilage, which is responsible for its 
water-entrapping function. Aggrecan was shown to be cleaved by multiple proteolytic 
enzymes, including MMP3 (also at its IGD generating a fragment terminating in DIPEN341) 
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and the ADAMTS enzymes.304 In fact, previously, there has been an active debate over 
the relative importance of the different enzymes responsible for cartilage aggrecan 
degradation.305 However, it is now well established that ADAMTS - the aggrecanases - 
are the primary enzymes responsible for aggrecan cleavage in cartilage.306 Although 
aggrecanases cleave aggrecan at multiple sites307 (even more efficiently within its C-
terminus) (Figure 31B), the aggrecanase cleavage at the NITEGE373 and ARGSV374 bond 
is the most relevant for pathology, as the loss of the GAG-rich region compromises its 
function. 
While ADAMTS-5 (aggrecanase-2) was found to be the major aggrecanase in 
mouse cartilage308, in human ADAMTS-4 (aggrecanase-1) and ADAMTS-5 are suggested 
to be equally important in aggrecan cleavage in osteoarthritis.309 With only a single 
thrombospondin motif ADAMTS-4 is the shortest member of the ADAMTS family, while 
ADAMTS-5 is ranked second with two thrombospondin motifs (Figure 7). Moreover, it has 
been suggested that ADAMTS-4 expression is inducible, while ADAMTS-5 is constitutively 
expressed in human – for example, ADAMTS-4 was induced following stimulation with 
TGF-b, however ADAMTS-5 was not and neither by IL-1 nor TNF-a.310 Thus, expression 
of these aggrecanases seem to be differentially regulated. Also, ADAMTS-1 was shown to 





Figure 31. Schematic structure of aggrecan and its cleavage sites (A) Illustration of large aggrecan 
aggregates with hyaluronan. HPLN1 (black dots) stabilizes the binding. (B) Domain structure of 
aggrecan core protein with attached GAG side chains is shown. G2 domain is unique to aggrecan 
among the lecticans. Aggrecanase cleavage sites and neoepitopes in the aggrecan core protein are 
shown for their human sequence. The critical cleavage site within the IGD is marked with red arrow (the 
NITEGE373 ARGSV). 
 
6.7 Aggrecan in the vasculature 
Aggrecan turnover is altered in disease such as osteoarthritis and is well-studied herein303, 
313, but its expression and function in the vasculature has only recently begun to be 
appreciated. Proteoglycans with their GAG side chains are known to present growth 
factors and cytokines to the surrounding tissue for cell differentiation.104 Also their multiple 
interactions with other ECM components modulate a wide range of cellular responses, 
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including inflammation.314 Fibulin-2 for example, is a high-affinity ligand for the C-type 
lectin motif in the G3 domain of aggrecan, which links aggrecan aggregates to the 
ECM.315 Fibulin-2 was also found to be increased upon DES stenting in our study. These 
functions of proteoglycans might contribute to vascular healing after stenting.  
On the other hand, it has also been suggested that lipoprotein binding to 
negatively charged GAG side chains might contribute to atherosclerosis.316, 317 While this 
has been repeatedly shown for versican in several studies14, 262, as it is a major structural 
component of the vessel wall, there is also evidence for aggrecan contributing to 
atherogenesis. Aggrecan expression was demonstrated in advanced lesions of 
atherosclerotic aortas of ApoE/LDLr deficient mice by immunohistochemistry, further 
supporting that cartilage-associated ECM proteins may be involved in the pathogenesis of 
atherosclerosis.318 Similarly, we have observed staining for aggrecan in the 
atherosclerotic lesion of the human control coronary artery (Figure 27A, *indicates plaque 
location). Furthermore, a previous proteomics analysis discovered aggrecan in vascular 
intimal hyperplasia.319 Finally, aggrecan deposition was reported in leptomeningeal 
arteries of hereditary brain haemorrhage with amyloidosis.320 
Our proteomics study provides evidence for an upregulation of aggrecan after 
stenting. This unexpected finding in the porcine stent model was substantiated by findings 
in mice upon grafting veins from a low- to a high-pressure environment. Similarly, 
aggrecan was more abundant in the high-pressure environment of the human aorta, than 
in veins. Also, aggrecan and its fragments were co-localized in the media of the human 
thoracic aorta. These findings may suggest, that due to its water-attracting property that 
confers resistance to compression, aggrecan may be part of an adaptive response of the 
vasculature to absorb increased mechanical forces – similar to its function in cartilage. 
Though increased mechanical stretch seems to be a plausible mechanism for the 
induction of aggrecan upon grafting a vein into a high-pressure environment, other factors 
also remain eligible to have induced aggrecan synthesis in our model. For example, 
surgical or ischemic injury may be partly responsible for triggering inflammation in the 
graft model and the consequent release of cytokines and growth factors initiating SMC 
proliferation and aggrecan synthesis. To confirm that mechanical force induces aggrecan 
synthesis, an animal model of hypertension would be a useful tool. Finally, the exact 
mechanisms and the stimuli leading to aggrecan synthesis remain to be further 
elucidated. 
6.8 Aggrecanases in the vasculature 
Besides aggrecan, we have detected the aggrecan NITEGE neoepitope in porcine 
coronary arteries upon stenting as well as in stented human arteries and the aorta. This 
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aggrecan neoepitope is generated upon proteolytic cleavage by aggrecanases. 
Importantly, neoepitope antibodies fail to recognize the same sequence in the undigested 
protein, thus their detection provides a signature for enzyme activity.127 However, the 
detectability is equally dependent on substrate availability, thus more substrates result in 
increased fragment detection. We have probed for the critical site at NITEGE373 within the 
IGD, due to the functional importance of this cleavage site. Indeed, as observed in 
proteomics and in gene expression analysis, aggrecan increases upon stenting. However, 
at the protein level the increase is more pronounced in DES. Similarly, the aggrecan 
neoepitopes become detectable by day 28 in DES, suggesting increased aggrecan build-
up. Likewise, the deglycosylated versican DPEAAE fragment of the V1 isoform showed an 
increase upon stent injury corresponding to the versican induction. However, unlike 
aggrecan, the versican fragment is already detectable at baseline. This is consistent with 
the much higher abundance of versican compared to aggrecan, especially in normal 
arteries. As expected, at day 28 the fragments in DES stented arteries were increased 
compared to BMS. This observed difference at day 28 was in line with the proteomics 
findings and suggested that differential degradation/turn-over of aggrecan in BMS and 
DES might explain the difference between protein abundance and gene expression. 
Aggrecan and versican mRNA levels at day 28 were similar in both groups. Aggrecan and 
versican protein levels, however, were higher in DES, both in the proteomics analysis and 
the western blots using neoepitope antibodies to visualise the smaller fragments that are 
readily separated on a gel.  
Thus, we compared the expression levels of the aggrecanases ADAMTS-1 and 
ADAMTS-4. The involvement of ADAMTS-4 in vascular pathology has been highlighted in 
the introduction. Very recently Kumar et al. reported that loss of ADAMTS-4 reduced 
atherosclerosis in a high fat diet-induced atherosclerosis mouse model.321 Notably, this 
was associated with reduced aggrecan cleavage and decreased macrophage infiltration. 
Though ADAMTS-1 is not considered as important in the cartilage field, we investigated 
ADAMTS-1 in our study, as important roles were attributed to ADAMTS-1 in the 
vasculature, in particular in atherogenesis129, 152 and plaque instability153. Further, 
ADAMTS-1 is known to be involved in versican proteolysis in the human aorta322 and in 
angiogenesis.323 However, the reports on the role of ADAMTS-1 in angiogenesis are 
contradictive: ADAMTS-1 was reported to be a potent inhibitor of angiogenesis as it 
inhibits EC proliferation by sequestering VEGF.324 It directly binds VEGF and 
consequently interferes with the binding of VEGF to its receptor. On the other hand, also a 
proangiogenic role for ADAMTS-1 has been implicated, as it was shown that VEGF-A can 
induce ADAMTS-1 expression to cleave versican at its DPEAAE site, which facilitates 
mother vessel formation.325 These reports highlight the fine balance required for the 
DISCUSSION 
 127 
regulation of angiogenesis. Moreover, a very recent study highlighted a role for ADAMTS-
1 as a major mediator of vascular homeostasis, as the decrease of the protease induced 
thoracic aortic aneurysms in mice.326 This effect was found to be induced by an increase 
in NO due to activation of the inducible nitric oxide synthase (NOS2) by ADAMTS-1 
deficiency, suggesting a previously underexplored ADAMTS1-NOS2 axis. The authors 
proposed that NOS2 activation was mediated by Akt and NF-kB, which again where 
activated by increased syndecan 4 levels327, which is a substrate of ADAMTS-1. Thus, the 
accumulation of ADAMTS-1 targets, including aggrecan, upon ADAMTS-1 loss, might 
contribute to vascular pathology. Notably, as mTOR is an upstream target of this axis, its 
inhibition by drugs also reverts the NOS2 induction. 
Indeed, in pig coronary arteries, like in human SMCs, we have found ADAMTS1 to 
be highly expressed. Upon stenting, ADAMTS1 was markedly reduced. 
6.8.1 Shift in vascular aggrecanase activity 
The two aggrecanases ADAMTS-1 and ADAMTS-4 showed a notable shift in expression 
in stented arteries, which likely coincided with impaired/delayed re-endothelialisation in 
DES and faster SMC recovery in BMS. Previous studies have shown that the initial 
regenerated endothelium in stented regions is incompetent in regard to its functionality 
(i.e. reduced expression of eNOS and antithrombotic molecules) but also to its barrier 
function (i.e. poorly formed cell-to-cell junctions)328, particularly in DES.329 In rabbit iliac 
arteries transmission electron microscopy has shown poorly formed cell contacts upon 
DES deployment. Furthermore, the expression of the antithrombotic cofactor 
thrombomodulin was absent or reduced in ECs of DES compared to BMS. In particular, 
several clinical studies demonstrated that regenerated endothelium in DES is more 
affected by dysfunctionality than in BMS, by assessing the endothelium-dependent 
vasodilation: vasoconstriction was observed in response to acetylcholine or exercise at six 
months after DES implantation, while the same stimuli induced the expected vasodilation 
in BMS stented arteries.330, 331 Despite the high-resolution images of OCT, recognition of 
EC structure of the coronary arterial endothelium remains difficult. As observed in our 
study, at day 14, the neointimal volume was higher in BMS compared to DES, whereas no 
difference was seen at day 28. However, it is the EC function rather than the coverage 
which is crucial, but cannot be optimally assessed by OCT. 
In our study, ADATMS-1 expression was high in coronary arteries, but was 
markedly reduced upon stent implantation. We observed high levels of ADAMTS1 
expression especially in coronary artery ECs (compared to ECs of other vascular 
territories), suggesting that the loss of competent coronary artery ECs may contribute to 
the decrease of ADAMTS-1 upon stenting. Similarly, ECs treated with everolimus showed 
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a loss of both enzymes. However, this effect is not limited to ADAMTS enzymes, as other 
proteases including MMPs showed a significant decrease upon everolimus treatment 
(data not shown) and is likely explained by general inhibition of protein synthesis or even 
toxic drug effects as demonstrated by the cell counting and viability assay. Instead, 
ADAMTS4 expression was increased, in particular in BMS, which could be due to their 
faster re-endothelialisation and/or uninhibited SMC proliferation, as SMCs are also an 
important source of ADAMTS-4. There is further support for the contribution of ECs to 
ADAMTS4 expression as it coincided with the re-expression of the endothelial specific 
marker cadherin 5. Our in vivo finding was complemented by in vitro data showing that 
everolimus treated SMCs had a significant reduction of ADAMTS4, while ADAMTS1 
expression was unaffected. Thus, a drug effect might contribute to the repression of 
ADAMTS-4 in DES. However, also macrophages have been shown as an important 
source of the pro-inflammatory cytokine inducible aggrecanase ADAMTS-4.154 Thus, all 
three cell types could be involved in the more pronounced increase of ADAMTS-4 in BMS.  
Both, aggrecanases and aggrecan are expressed in human coronary artery SMCs, 
but human coronary artery ECs express only the aggrecanases. This finding suggests that 
ECs influence aggrecanase activity and aggrecan levels without producing aggrecan. 
Further, we have seen that in stented human arteries staining for aggrecan neoepitopes 
was particularly pronounced at the contact points of the stent struts (Figure 27A, arrow 
marks), suggesting again either increased aggrecan production and/or increased 
aggrecanase activity at sites of mechanical injury. Besides ECs, both SMCs and 
macrophages are likely contributors to this injury response. Taken together, these findings 
suggest that a loss of functional arterial ECs upon stenting might contribute to reduced 
aggrecanase expression and activity in the vessel wall. Moreover, delayed/impaired re-
endothelialisation and reduced aggrecanase secretion i.e. by DES, would facilitate the 
accumulation of large aggregating proteoglycans in the vessel wall. Notably, both the 
detectability of versican and aggrecan neoepitopes in the western blots predominantly 
correlated with substrate availability rather than ADAMTS expression. 
6.8.2 Regulation of aggrecanase activity  
Our findings of altered aggrecanase levels suggest their import contribution to the build-up 
of large aggregating proteoglycans upon stenting. Especially, as enzymes are responsible 
for potent effects even in small amounts, due to their catalytic activity speeding up 
biochemical reactions. However, our current picture is incomplete and may not reflect the 
actual aggrecanase activity, as enzyme levels and activity are regulated on various levels: 
on mRNA as well as protein levels.  
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Besides aggrecanase synthesis, (Figure32, 1), which we have investigated in this 
study by measuring mRNA levels, ADAMTS secretion and activation (Figure32, 2) 
determines enzyme activity. Aggrecanases are synthesized as inactive zymogens and the 
cleavage of the propeptide is required for enzymatic activity. This control mechanism 
allows the ADAMTS enzymes to exert their activity at precise locations. Proprotein 
convertases (PC) such as furin, paired basic amino acid cleaving enzyme 4 (PACE4), 
PC5/6 or PC7 were shown to activate aggrecanases.332 Activation can either take place at 
the trans-Golgi network by membrane-bound PCs, as shown for ADAMTS-1333 and 
ADAMTS-4334 or extracellularly by constitutively secreted PCs, as demonstrated for 
ADAMTS-5 processing335. However, ADAMTS-4 activation also occurs extracellularly by 
PACE4. PACE4 is thought to be vital for aggrecanase activation in cartilage, and its 
expression was found to be increased in osteoarthritis.336 Also, the authors demonstrated 
an inhibition of the aggrecanase activity by reducing PACE4 expression with siRNA. 
These studies highlight the important contribution of PCs to aggrecanase activity. Thus, to 
gain a better understanding of enzyme activity, mRNA expression in tissue can only be an 
indication and further studies are required determining the levels of PCs or their 
regulation. 
Moreover, aggrecanase activity is regulated by inhibitors (Figure32, 3). As 
mentioned in the introduction the small protein TIMP-3 is a potent endogenous inhibitor of 
the aggrecanases, which inhibits ADATMS-1311 as well as very potently ADAMTS-4 and 
ADAMTS-5337. Due to its aggrecanase inhibition, it is not surprising that TIMP-3 is 
suggested to play a chondroprotective role.338, 339 Evidence for this role was further 
supported by the finding that Timp3-knockout mice showed increased aggrecanase and 
collagenase activity and developed early cartilage degradation as seen in osteoarthritis.340 
However, effects of TIMP-3 were also postulated for vascular remodelling and 
hypertension341, as well as for atherosclerosis342. However, it is unclear whether these 
TIMP-3 effects on the vasculature are also mediated by aggrecanase inhibition, as TIMP-
3 is known to inhibit multiple enzymes, including members of the MMP family, which play 
a critical role in atherosclerosis and plaque stability.136  
Finally, extracellular levels and activity of aggrecanases are regulated by 
endocytosis (Figure 32, 4). Recently, the large integral protein LRP1 was shown to be 
responsible for ADAMTS-5261, as well as ADAMTS-4 clearance260 in cartilage (‘protease 
sink’) and loss of LRP1 has been associated with osteoarthritis. These studies 
demonstrated that siRNA-mediated knockdown of LRP1 in chondrocytes markedly 
reduced the cellular uptake of aggrecanases. LRP1 is an endocytic transmembrane 
receptor consisting of an extracellular 515 kDa heavy or alpha chain and the 85 kDa light 
or beta chain containing the transmembrane and cytoplasmic domain. It is involved in the 
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internalization of multiple other ligands including lipoproteins and proteinases. Notably, 
LRP1 was reported to modulate atherogenesis, as deletion of macrophage LRP1 was 
associated with increased atherosclerosis and increased MMP9 levels.343 
In our study, we have found the light chain of LRP1 in the neointima samples of 
the porcine arteries, indicating that LRP1-induced endocytosis of aggrecanases might 
also contribute to reduced aggrecanase levels in DES as LRP1 was more abundant in 
DES compared to BMS samples. A consequent increased uptake of proteases in DES 
would contribute to the build-up of aggrecan and versican in DES stented arteries. But 
again, the increase in aggrecan neoepitopes as observed in DES, might be the 
consequence of increased substrate levels. On the other hand, it was also shown that the 
aggrecanase inhibitor TIMP-3 is endocytosed by LRP1.344 However, aggrecanase and 
TIMP-3 internalization are not dependent of each other.261 Even though TIMP-3 
endocytosis would suggest an increase of aggrecanase activity, the authors have shown 
in addition that the LRP1 – TIMP3 complex can also shed from the cell surface, whereby 
TIMP-3 remains its inhibitory function. Moreover, in LRP1 null mice increased proteolytic 
activity was observed in the aorta alongside increased fragmentation of ECM proteins.345 
Thus, LRP1 rather inhibits protease activity. Also, two very recent studies have targeted 
LRP1 mediated TIMP-3 internalization to increase extracellular TIMP-3 activity for a 
chondroprotective effect. The approach of the first study was to ‘trap’ TIMP-3 
extracellularly by generating a soluble minireceptor (a distinct binding cluster of LRP1) 
blocking its internalization.346 The other study mutated TIMP-3 in a way, which reduced 
binding to LRP1 but remained an unaltered inhibitory activity.347  
In summary, aggrecanase activity is determined at multiple levels, which need to 
be taken into consideration collectively to describe the net effect of aggrecanase activity.  
 
 
Figure 32. Regulation of aggrecanase activity. ADAMTS activity is determined at multiple levels. 
Besides the mRNA level (1), posttranslational regulation on protein level by enzyme secretion and 
activation (2) by proprotein convertases (PC) such as furin determine activity levels. Furthermore, the 
inhibition (3) of aggrecanases by TIMP3 and the LRP1 mediated internalization (4) of ADAMTS are 
crucial to consider for aggrecanase activity.  
DISCUSSION 
 131 
6.8.3 Differential aggrecan turnover in DES and BMS 
Stenting and vascular mechanical stretch induce a vascular remodelling with increased 
large aggregating proteoglycans in BMS as well as DES stented arteries. However, in 
DES stented arteries aggrecan and versican accumulation was more pronounced than in 
BMS. This could, at least in part, be explained by the loss of aggrecanases in DES. Loss 
of aggrecanase activity is associated with the impaired and delayed re-endothelialisation 
with incompetent EC function as well as a direct drug effect on SMCs (Summary figure 
33). The increased aggrecan and versican neoepitopes in DES compared to BMS at day 
28 are consistent with the build-up of the substrate and not necessarily indicative of higher 
enzymatic activity. Even at lower enzymatic activity, more substrate may result in more 
neoepitope staining. This would be supported by our finding that the aggrecanase shift 
seen for ADAMTS-4 in BMS did not result in more detectable neoepitopes in BMS. In 
addition, as explained above in detail the aggrecanase activity is regulated at multiple 
levels, which we have not taken into account at the current state of the study. Thus, it is 
not unlikely that drug induced expression differences in proprotein convertases or TIMP-3 
activity levels, might contribute to different enzyme activity in BMS and DES - similar to 
what we have observed for LRP1 abundance in BMS and DES neointima. Moreover, it is 
possible that there is increased internalization of the fragments by vascular cells in BMS 
stented arteries. Even though we were not able to show aggrecan fragments in the SDS 
extracts, the intracellular fraction, presumably due to its low concentrations, versican 
fragments were detected in all three fractions. The two extracellular fractions (NaCl and 
GuHCl) showed an increase for the fragments in DES compared to BMS, while no 
difference was detected intracellularly. This might be a result of differential extracellular 
degradation, by equal intracellular synthesis. However, it is also possible that the 
intracellular difference was compensated due to increased internalization of the fragments 
in BMS stented arteries. There is further support for this theory in the literature. It has 
been shown, that aggrecan NITEGE fragments as well as the link protein bound to 
hyaluronan are internalized by cells via a mechanism that requires CD44.348 In fact, this 
study showed that CD44 mediated endocytosis represents a major mechanism for the 
clearance of G1 domains after aggrecanolysis. Moreover, a further study demonstrated 
that aggrecan degradation was required to allow for hyaluronan internalization via 
CD44.301 This implicates that hyaluronan endocytosis is regulated mainly by extracellular 
processing of hyaluronan-bound proteoglycans. The processing requirement for 
internalization would explain, why less fragments are found in BMS, despite higher 
aggrecanases and consequent fragmentation. Finally, a further mechanism might be 
involved: HPLN1 is critical for locking aggrecan (and versican) onto hyaluronic acid. 
Aggrecan diffuses from the cartilage in mice that lack HPLN1.349 Thus, the relative 
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reduction of HPLN1 in DES as observed in the proteomics analysis might release the 
NITEGE fragment from hyaluronan and contribute to its increased detection and at the 
same time prevent its internalization with hyaluronan. However, the reason for HPLN1 
decrease in DES at day 28 is currently unclear.  
Taken together, the detectability of neoepitopes is influenced by enzymatic activity, 
substrate availability and the intracellular uptake of the proteolytic fragments, i.e. via 
CD44. Whether the increased accumulation of aggrecan in DES can explain the clinically 
observed increased neoatherosclerosis findings in DES56 due to increased lipoprotein 




Figure 33. Induction of large aggregating proteoglycans upon stenting. Our results showed a loss 
of ADAMTS expression upon stenting and a corresponding increase of the large aggregating 
proteoglycans both in BMS and DES stented arteries. However, in DES stented arteries aggrecan and 
versican accumulation was more pronounced than in BMS. The latter showed an increase of ADAMTS-
4, which was absent in DES. In cultured HCASMCs, everolimus inhibited expression of ADAMTS-4. 
Moreover, impaired re-endothelialization in DES likely contributes to loss of aggrecanases. Thus, 




6.9 Strengths and limitations 
A particular strength of our study is the combination of proteomics with a clinically relevant 
large animal model of human disease. The majority of studies in cardiovascular research 
are conducted in mice despite the notorious limitations regarding their translational 
potential of models in rodents.350 Due to higher similarity to human, pigs are better suited 
to explore basic pathophysiological mechanisms granting a higher translational potential. 
However, unlike in human, our pigs were young and free of atherosclerosis. Another main 
limitation of using pigs is that they are expensive, hence the relatively smaller sample 
size. Despite the smaller sample size, significant differences were observed for 
proteoglycans and basement membrane proteins in stented arteries. Moreover, the study 
was not limited to a single time point, but samples were collected at multiple time points to 
obtain an accurate description of ECM remodelling over time. A caveat of working with 
porcine tissue is the limited availability of antibodies, limiting the possibilities for validation 
studies. Thus, proteomics was key for a comprehensive protein analysis without 




7 FUTURE WORK 
One objective of our future research is to delineate the mechanisms responsible for the 
observed ECM protein changes, i.e. the regulation of aggrecan, aggrecanases and 
HAPLN1 during vascular remodelling. Especially the significance of the cartilage protein 
aggrecan in arteries is of interest; its presence in arteries is a relatively new discovery. It 
remains to be elucidated, whether aggrecan exerts a protective and beneficial role in the 
vasculature or contributes to the pathogenesis of atherosclerosis. However, it is more 
likely to be involved in both as these are not mutually exclusive. Notably, prominent 
staining of aggrecan is observed in the media of the human aorta. Aggrecan is barely 
detectable in the normal coronary artery, but clearly visible in atherosclerosis and upon 
stenting. We will evaluate aggrecan levels in other vascular territories and relate its 
expression to haemodynamic stress. Another objective will be to elucidate the changes 
seen in calcification regulatory proteins and whether these findings might provide a 
mechanistic link to the increased incidence or accelerated course of neoatherosclerosis in 
DES-stented vessels. 
 
Significance of aggrecan in the vasculature  
Based on our findings of aggrecan changes in stented arteries and high-pressure 
exposed vein grafts we postulate that aggrecan absorbs increased mechanical forces in 
the vasculature due to its water-attracting properties. Thus, aggrecan expression could be 
important for arterial stiffness and we will pursue the validation of this hypothesis by 
measuring the levels of aggrecan and fragments in aortic tissue of patients with different 
degrees of arterial stiffness as assessed by pulse wave velocity (PWV). As PWV is a 
strong predictor of cardiovascular events and all-cause mortality351, the latest European 
guidelines for managing arterial hypertension recommend arterial stiffness measurement 
for the evaluation of target organ damage.352 PWV will be measured in consented patients 
prior to coronary artery bypass grafting (CABG) surgery. The small aortic tissue, which is 
routinely excised during the CABG procedure to establish the anastomosis between the 
aorta and the bypass vein will be used for targeted proteomics analysis. Similarly, serum 
samples will be collected from the patients to correlate the tissue proteomics changes with 
their concentrations in systemic circulation as potential biomarkers.  
 
Role of aggrecan in stented arteries 
Even though we have demonstrated that aggrecan is an essential component of arteries 
and provided evidence for its induction upon stenting, it remains unclear whether the 
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observed changes in aggrecan between BMS and DES could be linked to pathologies 
such as ISR and neoatherosclerosis. Therefore, it is of interest to investigate the biological 
function of aggrecan degradation in neointimal lesions of BMS and DES stented arteries 
in larger patient cohorts. Maybe akin to its prominent role in osteoarthritis, aggrecan 
degradation contributes to inflammation in arteries exposed to abnormal mechanical 
stress. 
In order to investigate the intracellular effects in BMS and DES treated arteries the 
SDS extracts of the pig coronary arteries, the second step of our three-step protein 
extraction method, will be analysed. SDS induces decellularization releasing the 
intracellular proteins. A focus will be especially on LRP1, since this protein is involved in 
the endocytic clearance of ADAMTS-4 and -5.  
In our neointima comparison of BMS vs. DES stented arteries at day 28, we have 
seen an upregulation of proteins involved in the regulation of calcification for DES. We 
want to investigate whether direct drug effects may interfere with calcification regulatory 
proteins as downstream targets. For this reason, we will perform calcification assays. 
Cresolphthalein assays will be performed in HCASMC treated with everolimus or DMSO 
as a control and calcification levels for both conditions will be compared. Moreover, we will 
look for effects of everolimus on apoptosis, since apoptosis is known to induce 
calcification.  
 
Effects of miRNAs for differential expression of ECM proteins 
Previous studies have shown that miRNAs are critically involved in neointimal hyperplasia 
in proliferative vascular diseases.76, 77 Also in our study we saw pronounced changes for 
anti-fibrotic miRNAs between unstented controls and stented arteries. Thus, we aim to 
expand our miRNA studies to investigate miRNA regulation of target ECM proteins, similar 
to our previous publications.353, 354 Different miRNA prediction algorithms will be employed 
to identify miRNA binding sites responsive to the ECM proteins of interest. Promising 
candidates will then be measured in our porcine samples. We will then go on to explore 
whether there is interdependency between the miRNAs that change and the ECM proteins 
that show differential expression. However, this will become a separate line of 




We have provided the first proteomics characterization of ECM remodelling in response to 
vascular stenting in a large animal model. The remodelling response was different 
between BMS and DES as well as POBA. The most pronounced changes occurred in 
DES stented arteries. Our findings imply that the effects of DES go beyond inhibition of 
SMC proliferation, but have a wider impact on vascular remodelling by altering the 
composition of the ECM. The antiproliferative effect of DES was evident by a reduction in 
basement membrane proteins. Moreover, the decreased cellularity was accompanied by 
increased production of large proteoglycans like aggrecan and versican and attenuated 
aggrecanase expression. These in vivo observations were supported by our in vitro 
findings that HCAECs express high levels of ADAMTS-1 and that everolimus suppresses 
ADAMTS-4, but not ADAMTS-1 in HCASMCs. 
The importance of aggrecan as an integral component of the arterial wall was 
demonstrated by its evidence in the arterial over the venous vessel as well as its induction 
upon grafting veins into a high-pressure environment. Our novel observation that 
aggrecan is induced and aggrecanases are altered during ECM remodelling after stent 
implantation may open novel therapeutic avenues to improve vascular healing and 




9 SUPPLEMENTAL TABLES 




Protein name UniProt ID Length  UniProt ID Length  Genebank ID 
A disintegrin and metalloproteinase with thrombospondin motifs 1  ATS1_HUMAN 967 Q2N1I7_PIG 947 
 A disintegrin and metalloproteinase with thrombospondin motifs 15 ATS15_HUMAN 950 F1S6D2_PIG 956 
 A disintegrin and metalloproteinase with thrombospondin motifs 20  ATS20_HUMAN 1910 H9BR48_PIG 1915 
 A disintegrin and metalloproteinase with thrombospondin motifs 3 ATS3_HUMAN 1205 F1RUN5_PIG 338 XM_003129104.4 
A disintegrin and metalloproteinase with thrombospondin motifs 4 ATS4_HUMAN 837 F1S1A7_PIG 836 
 A disintegrin and metalloproteinase with thrombospondin motifs 5 ATS5_HUMAN 930 F1SHP0_PIG 923 
 A disintegrin and metalloproteinase with thrombospondin motifs 8 ATS8_HUMAN 889 F1S6D3_PIG 1020 
 A disintegrin and metalloproteinase with thrombospondin motifs 8 ATS8_HUMAN 889 F1S6D3_PIG 1020 
 A disintegrin and metalloproteinase with thrombospondin motifs 9 ATS9_HUMAN 1935 F1SFS3_PIG 1936 
 Adipocyte enhancer-binding protein 1 AEBP1_HUMAN 1158 F1SSF7_PIG 1140 
 Aggrecan PGCA_HUMAN 2415 F1SKR0_PIG 2,284 
 Agrin  AGRIN_HUMAN 2067 I3LGD9_PIG 2039 
 Alpha-1-antitrypsin A1AT_HUMAN 418 A1AT_PIG 421 
 Alpha-2-HS-glycoprotein  FETUA_HUMAN 367 FETUA_PIG 362 
 Ameloblastin  AMBN_HUMAN 447 AMBN_PIG 421 
 Anionic trypsin-2  TRY2_HUMAN 247 C6L245_PIG 247 
 Annexin A1  ANXA1_HUMAN 346 ANXA1_PIG 346 
 Annexin A2  ANXA2_HUMAN 339 ANXA2_PIG 339 
 Antileukoproteinase SLPI_HUMAN 132 SLPI_PIG 129 
 Antithrombin-III  ANT3_HUMAN 464 Q7M364_PIG 431 
 Apolipoprotein A-I  APOA1_HUMAN 267 APOA1_PIG 265 




Apolipoprotein A-IV APOA4_HUMAN 396 APOA4_PIG 382 
 Apolipoprotein B-100 APOB_HUMAN 4563 Q29021_PIG 2629 
 Apolipoprotein C-III APOC3_HUMAN 99 APOC3_PIG 96 
 Apolipoprotein D APOD_HUMAN 189 F1SQX9_PIG 190 
 Apolipoprotein E  APOE_HUMAN 317 APOE_PIG 317 
 Apolipoprotein H APOH_HUMAN 345 I3LGN5_PIG 268 
 Apolipoprotein L4 APOL4_HUMAN 351 F1SPT9_PIG 336 
 Apolipoprotein M APOM_HUMAN 188 APOM_PIG 188 
 Apolipoprotein O  APOO_HUMAN 198 K7GPW3_PIG 198 
 Apolipoprotein O-like  APOOL_HUMAN 268 K7GNC6_PIG 268 
 Apolipoprotein R n/a n/a APOR_PIG 202 
 Asporin  ASPN_HUMAN 380 F1SUE4_PIG 370 
 Biglycan  PGS1_HUMAN 368 K7GP55_PIG 369 
 Bone morphogenetic protein 1  BMP1_HUMAN 986 F1RMB2_PIG 1009 
 Cadherin-13  CAD13_HUMAN 713 A8D737_PIG 713 
 Carboxypeptidase A1 CBPA1_HUMAN 419 CBPA1_PIG 419 
 Carboxypeptidase-like protein X2 CPXM2_HUMAN 756 F1SEC6_PIG 761 
 Cartilage intermediate layer protein 1 CILP1_HUMAN 1184 F1SJL4_PIG 1189 
 Cartilage intermediate layer protein 2 CILP2_HUMAN 1156 F1S6Q3_PIG 1157 
 Cartilage oligomeric matrix protein COMP_HUMAN 757 F1S902_PIG 756 
 Cathepsin D CATD_HUMAN 412 Q4U1U3_PIG 410 
 Cathepsin F  CATF_HUMAN 484 F1RU48_PIG 460 
 Cathepsin G CATG_HUMAN 255 F1SGS1_PIG 255 
 Cathepsin Z CATZ_HUMAN 303 A5GFX7_PIG 304 
 Chitinase-3-like protein 1 CH3L1_HUMAN 383 CH3L1_PIG 383 
 Chondroadherin-like protein CHADL_HUMAN 762 F1SRC2_PIG 757 
 Chymase CMA1_HUMAN 247 I3LDA9_PIG 255 
 Clusterin  CLUS_HUMAN 449 CLUS_PIG 446 




Coatomer subunit alpha  COPA_HUMAN 1224 F1RJX8_PIG 1224 
 Collagen alpha-1 (I)   CO1A1_HUMAN 1464 n/a n/a XM_005668928.1 
Collagen alpha-1 (II)   CO2A1_HUMAN 1487 I3LSV6_PIG 1365 
 Collagen alpha-1 (III)   CO3A1_HUMAN 1466 F1RYI8_PIG 1466 
 Collagen alpha-1 (IV) CO4A1_HUMAN 1669 M3V819_PIG 1669 
 Collagen alpha-1 (V)   CO5A1_HUMAN 1838 F1S021_PIG 1826 
 Collagen alpha-1 (VI)   CO6A1_HUMAN 1028 I3LS72_PIG  435 XM_005659047.1 
Collagen alpha-1 (VII) CO7A1_HUMAN 2944 F1SKM1_PIG 2939 
 Collagen alpha-1 (VIII) CO8A1_HUMAN 744 F1SKX7_PIG 745 
 Collagen alpha-1 (XI)   COBA1_HUMAN 1806 F1S571_PIG 1607 
 Collagen alpha-1 (XII)   COCA1_HUMAN 3063 F1RQI0_PIG  960 XM_005659436.1 
Collagen alpha-1 (XIII) CODA1_HUMAN 717 F1SUE9_PIG 635 
 Collagen alpha-1 (XIV) COEA1_HUMAN 1796 F1S285_PIG 1790 
 Collagen alpha-1 (XIX)   COJA1_HUMAN 1142 F1RTT4_PIG 1142 
 Collagen alpha-1 (XV)   COFA1_HUMAN 1388 F1SSE7_PIG  192 XM_005660284.1 
Collagen alpha-1 (XVI) COGA1_HUMAN 1604 F1SV99_PIG 1594 
 Collagen alpha-1 (XVII)   COHA1_HUMAN 1497 F1S5P1_PIG 1081 
 Collagen alpha-1 (XVIII) COIA1_HUMAN 1754 n/a n/a XR_299377.1 
Collagen alpha-1 (XX) COKA1_HUMAN 1284 F1S285_PIG  1790 XM_005662881.1 
Collagen alpha-1 (XXII) COMA1_HUMAN 1626 n/a n/a XM_005674527.1 
Collagen alpha-1 (XXVII) CO27A1_HUMAN 1714 n/a n/a XM_005660374.1 
Collagen alpha-1 (XXVIII)   COSA1_HUMAN 1125 F1SF83_PIG 1034 
 Collagen alpha-2 (I)   CO1A2_HUMAN 1366 F1SFA7_PIG 1366 
 Collagen alpha-2 (IV)   CO4A2_HUMAN 1712 F1RLL9_PIG 1654 
 Collagen alpha-2 (IX) CO9A2_HUMAN 689 I3L8B2_PIG 688 
 Collagen alpha-2 (V)   CO5A2_HUMAN 1499 Q59IP2_PIG 1499 
 Collagen alpha-2 (VI)   CO6A2_HUMAN 1019 I3LQ84_PIG 989 
 Collagen alpha-2 (VIII) CO8A2_HUMAN 703 F1SV48_PIG 705 




Collagen alpha-3 (IV) CO4A3_HUMAN 1670 F1SNP0_PIG  807 XM_005658969.1 
Collagen alpha-3 (V) CO5A3_HUMAN 1745 Q59IP1_PIG 1748 
 Collagen alpha-3 (VI) CO6A3_HUMAN 3177 I3LUR7_PIG 3170 
 Collagen alpha-4 (IV)   CO4A4_HUMAN 1690 F1SNP1_PIG 1711 
 Collagen alpha-4 (VI)   n/a n/a n/a n/a XM_005669267.1 
Collagen alpha-5 (VI)   CO6A5_HUMAN 2615 F1RS99_PIG 2599 
 Collagen alpha-6 (VI)   CO6A6_HUMAN 2263 F1RS99_PIG  2599 XM_005669265.1 
Complement C1q tumor necrosis factor-related protein 9  C1QT9_HUMAN 333 F1RTM0_PIG 333 
 Complement C3  CO3_HUMAN 1663 CO3_PIG 1661 
 Complement component C8 beta chain  CO8B_HUMAN 591 A0SEH2_PIG 611 
 Complement component C9  CO9_HUMAN 559 A0SEG9_PIG 543 
 Connective tissue growth factor CTGF_PIG 349 CTGF_PIG 349 
 Cysteine-rich protein 2 CRIP2_HUMAN 208 K7ZMG1_PIG 198 
 Decorin  PGS2_HUMAN 359 PGS2_PIG 360 
 Dehydrogenase/reductase SDR family member 7C  DRS7C_HUMAN 312 F1SS86_PIG 311 
 Dermatopontin  DERM_HUMAN 201 DERM_PIG 183 
 Disintegrin and metalloproteinase domain-containing protein 11 ADA11_HUMAN 769 F1RQZ7_PIG 770 
 Disintegrin and metalloproteinase domain-containing protein 28 ADA28_HUMAN 775 F1RM87_PIG 777 
 Dystroglycan  DAG1_HUMAN 895 I3LD20_PIG 877 
 EMILIN-1  EMIL1_HUMAN 1016 F1SDQ5_PIG 1018 
 EMILIN-2 EMIL2_HUMAN 1053 F1SBC8_PIG 967 
 EMILIN-3 EMIL3_HUMAN 766 F1SDV5_PIG 765 
 Endonuclease domain-containing 1 protein  ENDD1_HUMAN 500 F1STI9_PIG 500 
 Endoplasmic reticulum aminopeptidase 1  ERAP1_HUMAN 941 K9J6I5_PIG 942 
 Estradiol 17-beta-dehydrogenase 11  DHB11_HUMAN 300 F1S3H8_PIG 312 
 Extracellular matrix protein FRAS1  FRAS1_HUMAN 4008 F1RYS0_PIG 3985 
 Extracellular superoxide dismutase SODE_HUMAN 240 Q007T6_PIG 244 
 Fibrillin-1  FBN1_HUMAN 2871 FBN1_PIG 2871 




Fibrinogen beta chain  FIBB_HUMAN 491 F1RX37_PIG 495 
 Fibrinogen gamma chain  FIBG_HUMAN 453 F1RX35_PIG 438 
 Fibroblast growth factor 1  FGF1_HUMAN 155 FGF1_PIG 152 
 Fibroblast growth factor 11 FGF11_HUMAN 225 I3L7I1_PIG 225 
 Fibroblast growth factor 23 FGF23_HUMAN 251 F1SKZ1_PIG 244 
 Fibromodulin  FMOD_HUMAN 376 F1S6B5_PIG 379 
 Fibronectin  FINC_HUMAN 2386 F1SS24_PIG 2478 
 Fibronectin type III domain-containing protein 1 FNDC1_HUMAN 1894 F1SB59_PIG 1885 
 Fibulin-1 FBLN1_HUMAN 703 F1SM61_PIG 709 
 Fibulin-2 FBLN2_HUMAN 1184 n/a n/a AK346749.1 
Fibulin-3 FBLN3_HUMAN 493 F8SIP2_PIG 490 
 Fibulin-4 FBLN4_HUMAN 443 F1RU22_PIG 443 
 Fibulin-5  FBLN5_HUMAN 448 F1SD87_PIG 448 
 Filamin-A  FLNA_HUMAN 2647 Q2YHQ3_PIG  167 XM_003134702.2 
FRAS1-related extracellular matrix protein 2  FREM2_HUMAN 3169 F1RS31_PIG 3167 
 FRAS1-related extracellular matrix protein 3 FREM3_HUMAN 2139 n/a n/a XM_005656529.1 
Galectin-1  LEG1_HUMAN 135 LEG1_PIG 135 
 Galectin-3 LEG3_HUMAN 250 A3EX84_PIG 260 
 Galectin-3-bining protein LG3BP_HUMAN 585 M3V7X9_PIG 552 
 Galectin-8  LEG8_HUMAN 317 F1RGZ0_PIG 317 
 Galectin-9  LEG9_HUMAN 355 F1RJ33_PIG 355 
 Gelsolin  GELS_HUMAN 782 GELS_PIG 772 
 Glypican-1 GPC1_HUMAN 558 F1SIQ5_PIG 552 
 Glypican-2 GPC2_HUMAN 579 F1RNM8_PIG 578 
 Glypican-3 GPC3_HUMAN 580 F1RTE0_PIG 501 
 Glypican-4 GPC4_HUMAN 556 F1RTE1_PIG 503 
 Glypican-6 GPC6_HUMAN 555 A3KDL8_PIG 171 XM_001925471.5 
Granzyme A  GRAA_HUMAN 262 E3VSK1_PIG 259 




Growth/differentiation factor 7  GDF7_HUMAN 450 I3LB35_PIG 449 
 Hemicentin-1 HMCN1_HUMAN 5635 n/a n/a XM_005653746.1 
Hemicentin-2 HMCN2_HUMAN 5059 F1S0Y1_PIG 4061 
 Hyaluronan and proteoglycan link protein 1 HPLN1_HUMAN 354 HPLN1_PIG 354 
 Insulin-degrading enzyme  IDE_HUMAN 1019 F1SC98_PIG 990 
 Insulin-like growth factor 1 receptor IGF1R_HUMAN 1367 IGF1R_PIG 304 
 Insulin-like growth factor I IGF1_HUMAN 195 IGF1_PIG 153 
 Insulin-like growth factor-binding protein 7  IBP7_HUMAN 282 C7EDN1_PIG 282 
 Inter-alpha-trypsin inhibitor heavy chain H1  ITIH1_HUMAN 911 ITIH1_PIG 902 
 Inter-alpha-trypsin inhibitor heavy chain H2  ITIH2_HUMAN 946 ITIH2_PIG 935 
 Intercellular adhesion molecule 1  ICAM1_HUMAN 532 F1S3J9_PIG 537 
 Kallistatin KAIN_HUMAN 427 n/a n/a XM_003356792.2 
Kininogen-1  KNG1_HUMAN 644 F1SFI4_PIG  385 AK233327.1 
Lactadherin  MFGM_HUMAN 387 MFGM_PIG 409 
 Laminin subunit alpha-1 LAMA1_HUMAN 3075 I3LCP3_PIG  517 XM_005658563.1 
Laminin subunit alpha-2  LAMA2_HUMAN 3122 F1S2Z4_PIG  925 XM_005659200.1 
Laminin subunit alpha-3  LAMA3_HUMAN 3333 F1SBB3_PIG  1724 XM_003482045.2 
Laminin subunit alpha-4  LAMA4_HUMAN 1823 F1RZM4_PIG 1471 
 Laminin subunit beta-1  LAMB1_HUMAN 1786 F1SAE9_PIG 1799 
 Laminin subunit beta-2  LAMB2_HUMAN 1798 F1SPT5_PIG 1642 
 Laminin subunit beta-3 LAMB3_HUMAN 1172 I3LI99_PIG 959 
 Laminin subunit gamma-1  LAMC1_HUMAN 1609 F1S663_PIG 1606 
 Laminin subunit gamma-3  LAMC3_HUMAN 1575 F1S0X0_PIG 1583 
 Latent-TGFβ-binding protein 1 LTBP1_HUMAN 1721 F1S405_PIG 1343 
 Latent-TGFβ-binding protein 2 LTBP2_HUMAN 1821 F1S2T5_PIG 1821 
 Latent-TGFβ-binding protein 3 LTBP3_HUMAN 1303 F1RRJ9_PIG 1244 
 Latent-TGFβ-binding protein 4 LTBP4_HUMAN 1624 n/a n/a XM_005674643.1 
Leukocyte elastase inhibitor ILEU_HUMAN 379 ILEU_PIG 378 




Low-density lipoprotein receptor-related protein 2  LRP2_HUMAN 4655 K9IVL7_PIG 4544 
 Low-density lipoprotein receptor-related protein 6  LRP6_HUMAN 1613 F1SQ65_PIG 1470 
 Lumican  LUM_HUMAN 338 F1SQ09_PIG 341 
 Lysyl oxidase homolog 1 LOXL1_HUMAN 574 F1SIC9_PIG 591 
 Macrophage-capping protein  CAPG_HUMAN 348 F1SVB0_PIG 349 
 Mast/stem cell growth factor receptor  KIT_HUMAN 976 KIT_PIG 972 
 Matrilin-2  MATN2_HUMAN 956 F1S0M0_PIG  303 AK234298.1 
Matrilin-4 MATN4_HUMAN 622 F1SDQ7_PIG 627 
 Matrix Gla protein MGP_HUMAN 103 MGP_PIG 103 
 Matrix metalloproteinase-2 MMP2_HUMAN 660 Q95JA4_PIG 661 
 Matrix remodeling-associated protein 5 MXRA5_HUMAN 2828 F1RZ07_PIG 2830 
 Melanotransferrin  TRFM_HUMAN 738 F1SQX4_PIG 736 
 Metalloproteinase inhibitor 1 TIMP1_HUMAN 207 TIMP1_PIG 207 
 Metalloproteinase inhibitor 3 TIMP3_HUMAN 211 F1SPS4_PIG 172 
 Microfibril-associated glycoprotein 4 MFAP4_HUMAN 255 F1S0X3_PIG 461 
 Microfibrillar-associated protein 1  MFAP1_HUMAN 439 n/a n/a AK397307.1 
Mimecan  MIME_HUMAN 298 I3L9T6_PIG 216 
 Myeloperoxidase  PERM_HUMAN 745 K7GRV6_PIG 743 
 Neural cell adhesion molecule 1  NCAM1_HUMAN 858 K7GMV4_PIG 839 
 Neural cell adhesion molecule L1-like protein  CHL1_HUMAN 1208 F1SFM3_PIG 1210 
 Nidogen-1  NID1_HUMAN 1247 I3LJT1_PIG  381 XM_005658402.1 
Nidogen-2  NID2_HUMAN 1375 F1SFF3_PIG 1385 
 Osteoclast-stimulating factor 1 OSTF1_HUMAN 214 OSTF1_PIG 214 
 Osteopontin OSTP_PIG 314 OSTP_PIG 303 
 Papilin  PPN_HUMAN 1278 F1S3J7_PIG 1301 
 Pentraxin-related protein PTX3  PTX3_HUMAN 381 F1SJM0_PIG 382 
 Peptidyl-prolyl cis-trans isomerase A  PPIA_HUMAN 165 PPIA_PIG 164 
 Periostin POSTN_HUMAN 836 F1RS37_PIG 836 
 Perlecan PGBM_HUMAN 4391 F1SU03_PIG  1848 XM_005656042.1 
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Peroxidasin homolog  PXDN_HUMAN 1479 I3LDA4_PIG 1479 
 Pigment epithelium-derived factor PEDF_HUMAN 418 Q0PM28_PIG 413 
 Pikachurin EGFLA_HUMAN 1,017 I3LEG7_PIG 1020 
 Plasma glutamate carboxypeptidase PGCP_HUMAN 472 F1S0L6_PIG  283 AK392015.1 
Plasminogen  PLMN_HUMAN 810 PLMN_PIG 809 
 Podocan PODN_HUMAN 613 I3LEB7_PIG 642 
 Proactivator polypeptide SAP_HUMAN 524 F1SU97_PIG 524 
 Procollagen C-endopeptidase enhancer 1 PCOC1_HUMAN 449 I3LEE6_PIG 470 
 Prolargin  PRELP_HUMAN 382 F1S6B4_PIG 375 
 Properdin PROP_HUMAN 469 K7GQR1_PIG 463 
 Prophenin and tritrpticin n/a n/a PF11_PIG 212 
 Protein ELFN1 ELFN1_HUMAN 828 I3LFQ3_PIG 806 
 Proteoglycan 4  PRG4_HUMAN 1404 I3L5Z3_PIG 1383 
 Reticulon-3  RTN3_HUMAN 1032 F1RPY3_PIG 236 XM_005660769.1 
Retinol-binding protein 3  RET3_HUMAN 1247 F1SEL7_PIG 1282 
 RPE-spondin RPESP_HUMAN 264 F1RWI4_PIG  193 XM_003125598.4 
Sclerostin SOST_HUMAN 213 F1S1H5_PIG 212 
 SCO-spondin SSPO_HUMAN 5147 n/a n/a XM_005658106.1 
Secreted frizzled-related protein 1 SFRP1_HUMAN 314 I3LB66_PIG 315 
 Secreted frizzled-related protein 3 SFRP3_HUMAN 325 F1RYL4_PIG 325 
 Secreted phosphoprotein 24 SPP24_HUMAN 211 SPP24_PIG 204 
 Serine protease HTRA1 HTRA1_HUMAN 480 F1SEH4_PIG 524 
 Serotransferrin  TRFE_HUMAN 698 TRFE_PIG 696 
 Serum amyloid P-component SAMP_HUMAN 223 SAMP_PIG 224 
 SPARC SPRC_HUMAN 303 SPRC_PIG 300 
 Spondin-1 SPON1_HUMAN 807 F1S981_PIG  281 XM_003122966.4 
Target of Nesh-SH3 TARSH_HUMAN 1075 F1SL03_PIG 952 
 Tenascin TENA_HUMAN 2201 TENA_PIG 1746 




Tetranectin TETN_HUMAN 202 F1SRC8_PIG 202 
 TGFβ receptor type 1 TGFR1_HUMAN 503 Q19ML9_PIG 503 
 TGFβ receptor type 3 TGBR3_HUMAN 851 TGBR3_PIG 848 
 TGFβ-1 TGFB1_HUMAN 390 TGFB1_PIG 390 
 TGFβ-2 TGFB2_HUMAN 414 F1S9L0_PIG 436 
 TGFβ-3 TGFB3_HUMAN 412 K7GSJ9_PIG 456 
 TGFβ-induced protein ig-h3  BGH3_HUMAN 683 BGH3_PIG 683 
 Thrombospondin type-1 domain-containing protein 7A THS7A_HUMAN 1657 I3L9B1_PIG 1593 
 Thrombospondin-1 TSP1_HUMAN 1170 K7GPJ3_PIG 1085 
 Thrombospondin-4 TSP4_HUMAN 961 F1RF28_PIG 944 
 Transferrin receptor protein 1  TFR1_HUMAN 760 TFR1_PIG 768 
 Tryptase-1 TRYB1_HUMAN 275 TRYT_PIG 275 
 Tubulointerstitial nephritis antigen-like  TINAL_HUMAN 467 F1SVA2_PIG 467 
 Uncharacterized aarF domain-containing protein kinase 1  ADCK1_HUMAN 530 K9J4Q5_PIG 523 
 Usherin  USH2A_HUMAN 5202 n/a n/a XM_003130490.4 
Versican CSPG2_HUMAN 3396 F1REZ2_PIG 3382 
 Vitamin D-binding protein  VTDB_HUMAN 474 I3LN42_PIG 476 
 Vitronectin  VTNC_HUMAN 478 VTNC_PIG 459 
 von Willebrand factor A domain-containing protein 1  VWA1_HUMAN 445 F1RJE3_PIG 413 
 von Willebrand factor A domain-containing protein 8 VWA8_HUMAN 1905 I3LI96_PIG  419 XM_005668452.1 
WD repeat-containing protein 1  WDR1_HUMAN 606 K9IVR7_PIG 606 
  
Extracellular proteins for which the porcine sequences were included in the protein database for proteomics search. The UniProt IDs for the human and their porcine 
counterparts are shown. For protein sequences, which were deduced from public nucleotide databases the used Genebank ID is given. The length indicates the 
number of amino acids for each entry in UniProt. n/a denotes not applicable. The porcine ECM database with the amino acid sequences of the porcine proteins are 




Supplemental table 2. Extracellular proteins identified by proteomics analysis in the 
neointima of stented porcine coronary arteries. 
 
   
BMS             DES              
  
Identified Proteins  UniProt ID  
MW 
(kDa) Total ion current x 10
6 Av±SD P 
FC 
DES/BMS 
Adipocyte enhancer-binding  
protein 1 F1SSF7_PIG 128 165.6±93.4 142.4±32.5 0.554 0.9 
Aggrecan F1SKR0_PIG 238 41.2±69.5 70.8±34.1 0.338 1.7 
Agrin I3LGD9_PIG 216 116.6±65.1 128.5±40.2 0.688 1.1 
Alpha-1-antitrypsin*  A1AT_PIG 47 33.6±30.2 11.8±8.0 0.109 0.4 
Alpha-2-HS-glycoprotein FETUA_PIG 38 472.0±223.6 263.1±75.3 0.050 0.6 
Annexin A1  ANXA1_PIG 39 231.1±142.4 129.4±45.3 0.113 0.6 
Annexin A2  ANXA2_PIG 39 571.0±247.8 430.9±65.4 0.192 0.8 
Antithrombin-III  Q7M364_PIG 49 92.2±38.7 71.2±18.1 0.228 0.8 
Apolipoprotein A-I  APOA1_PIG 30 619.6±234.8 549.4±270.4 0.614 0.9 
Apolipoprotein A-IV  APOA4_PIG 43 7.6±4.0 10.9±8.3 0.362 1.4 
Apolipoprotein B* Q29021_PIG 300 27.7±33.0 11.8±15.5 0.278 0.4 
Apolipoprotein C-III  APOC3_PIG 11 16.2±9.2 18.8±11.9 0.658 1.2 
Apolipoprotein E  APOE_PIG 37 76.6±73.2 63.8±70.2 0.745 0.8 
Apolipoprotein H I3LGN5_PIG 29 141.2±84.9 128.0±131.6 0.827 0.9 
Apolipoprotein R  APOR_PIG 23 27.0±17.6 40.8±22.6 0.228 1.5 
Asporin F1SUE4_PIG 42 137.6±70.1 80.2±33.0 0.083 0.6 
Biglycan  K7GP55_PIG 41 1767.1±214.9 1130.6±169.0 0.000 0.6 
Bone morphogenic protein 1* F1RMB2_PIG 114 0.0±0.0 4.9±5.6 n/a n/a 
Carboxypeptidase-like protein X2 F1SEC6_PIG 86 24.9±26.1 15.8±5.3 0.397 0.6 
Cathepsin D  Q4U1U3_PIG 44 79.6±46.1 34.5±24.3 0.047 0.4 
Cathepsin G F1SGS1_PIG 29 0.4±1.0 0.0±0.0 n/a 0.0 
Cathepsin Z* A5GFX7_PIG 34 2.9±5.6 0.0±0.0 n/a 0.0 
Chitinase-3-like protein 1  CH3L1_PIG 43 31.8±39.8 2.6±4.6 n/a 0.1 
Chondroadherin* CHAD_HUMAN 40 0.8±1.3 35.6±25.3 n/a 46.5 
Clusterin  CLUS_PIG 52 149.6±28.5 301.7±99.0 0.006 2.0 
Coatomer subunit alpha* F1RJX8_PIG 138 16.3±14.7 14.6±7.2 0.796 0.9 
Collagen alpha-1 (I) CO1A1_PIG 100 2798.6±873.9 1842.9±504.6 0.032 0.7 
Collagen alpha-1 (III) F1RYI8_PIG 139 698.6±329.3 224.0±93.9 0.008 0.3 
Collagen alpha-1 (IV) M3V819_PIG 160 49.1±20.8 47.8±10.7 0.887 1.0 
Collagen alpha-1 (V) F1S021_PIG 182 205.5±64.2 137.6±35.9 0.036 0.7 
Collagen alpha-1 (VI) CO6A1_PIG 43 36.4±27.4 19.2±7.1 0.155 0.5 
Collagen alpha-1 (VIII) F1SKX7_PIG 73 14.1±5.2 19.8±5.7 0.075 1.4 
Collagen alpha-1 (XI) F1S571_PIG 159 19.4±20.4 10.9±12.2 0.369 0.6 
Collagen alpha-1 (XII) COCA1_PIG 229 484.1±151.0 218.6±50.9 0.003 0.5 
Collagen alpha-1 (XV) COFA1_PIG 27 68.8±36.2 137.6±20.6 0.002 2.0 
Collagen alpha-1 (XVIII) COIA1_PIG 62 216.1±61.8 248.4±36.7 0.263 1.1 
Collagen alpha-1 (XX) COKA1_PIG 192 1190.7±613.9 440.1±145.6 0.017 0.4 
Collagen alpha-2 (I) F1SFA7_PIG 129 1305.6±466.3 845.6±261.8 0.048 0.6 
Collagen alpha-2 (IV) F1RLL9_PIG 161 89.9±26.6 82.8±13.2 0.542 0.9 
Collagen alpha-2 (V)  Q59IP2_PIG 145 134.8±55.5 66.7±26.4 0.018 0.5 
Collagen alpha-2 (VI) I3LQ84_PIG 106 124.7±110.6 57.2±29.7 0.163 0.5 
Collagen alpha-3 (V)  Q59IP1_PIG 172 2.1±5.5 0.0±0.0 n/a 0.0 
Collagen alpha-3 (VI) I3LUR7_PIG 342 371.3±357.3 92.9±63.2 0.086 0.3 
Collagen alpha-6 (VI) CO6A6_PIG 250 8.1±12.9 0.0±0.0 n/a 0.0 
Complement C3  CO3_PIG 187 805.6±730.5 687.7±404.2 0.717 0.9 
Complement component C8B* A0SEH2_PIG 69 23.1±18.9 27.3±18.4 0.682 1.2 
Complement component C9  A0SEG9_PIG 62 2.4±1.5 6.9±6.4 0.115 2.9 
Connective tissue growth factor  CTGF_PIG 38 1.2±3.1 6.3±7.4 n/a 5.4 
Decorin  PGS2_PIG 40 185.4±59.1 104.5±81.3 0.057 0.6 
Dermatopontin  DERM_PIG 22 55.8±23.6 38.1±14.2 0.121 0.7 
Dystroglycan  I3LD20_PIG 95 3.3±4.4 1.7±2.5 n/a 0.5 
EMILIN-1 F1SDQ5_PIG 107 64.1±34.1 62.4±12.4 0.905 1.0 
EMILIN-2* F1SBC8_PIG 106 0.5±1.2 0.0±0.0 n/a 0.0 
Fibrillin-1  FBN1_PIG 313 23.8±28.1 10.4±10.8 0.274 0.4 
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Fibrinogen beta chain  F1RX37_PIG 56 5135.7±4558.0 4487.1±2656.8 0.752 0.9 
Fibrinogen gamma chain F1RX35_PIG 50 4287.0±3582.2 3875.7±2485.5 0.808 0.9 
Fibromodulin F1S6B5_PIG 44 549.7±94.2 350.4±115.8 0.004 0.6 
Fibronectin F1SS24_PIG 272 10317.1±3240.8 11617.1±2173.3 0.398 1.1 
Fibronectin type III domain- 
containing protein 1 F1SB59_PIG 204 26.8±41.2 11.7±9.9 n/a 0.4 
Fibulin-1  F1SM61_PIG 78 120.4±47.0 149.3±43.4 0.255 1.2 
Fibulin-2 FBLN2_PIG 54 20.9±22.8 16.5±14.2 0.670 0.8 
Fibulin-3 F8SIP2_PIG 54 190.2±94.1 155.0±53.8 0.412 0.8 
Fibulin-4* F1RU22_PIG 49 36.2±11.8 38.3±7.7 0.694 1.1 
Fibulin-5 F1SD87_PIG 50 300.0±137.6 351.1±84.6 0.422 1.2 
Filamin-C* F1SMN5_PIG  290 310.9±151.2 387.0±102.9 0.295 1.2 
Galectin-1  LEG1_PIG 15 353.4±61.5 265.0±52.4 0.014 0.7 
Galectin-3  A3EX84_PIG 27 87.2±91.7 29.8±14.2 0.151 0.3 
Galectin-3-binding protein M3V7X9_PIG 61 14.3±11.8 52.4±42.3 0.056 3.7 
Galectin-9* F1RJ33_PIG 40 1.3±1.7 0.3±0.6 n/a 0.3 
Gelatinase A*  Q95JA4_PIG 74 6.6±8.5 0.5±0.9 n/a 0.1 
Gelsolin  GELS_PIG 85 1242.1±295.1 1123.4±194.5 0.394 0.9 
Hemicentin-1* HMCN1_PIG 180 1.3±2.2 0.7±1.8 n/a 0.5 
Hyaluronan and proteoglycan link 
protein 1  HPLN1_PIG 40 7.7±10.8 16.2±15.4 0.257 2.1 
Insulin-like growth factor-binding 
protein 7  C7EDN1_PIG 29 395.2±201.4 468.1±122.0 0.432 1.2 
Inter-alpha-trypsin inhibitor heavy 
chain H1* ITIH1_PIG 100 145.1±77.4 143.1±46.0 0.955 1.0 
Inter-alpha-trypsin inhibitor heavy 
chain H2  ITIH2_PIG 105 95.1±63.8 63.5±16.7 0.247 0.7 
Intercellular adhesion molecule 1*  F1S3J9_PIG 58 0.8±2.2 0.0±0.0 n/a 0.0 
Kininogen-1* KNG1_PIG 48 20.6±15.8 14.8±11.8 0.450 0.7 
Lactadherin  MFGM_PIG 46 253.9±104.7 407.3±57.5 0.008 1.6 
Laminin subunit alpha-4 F1RZM4_PIG 164 75.8±28.8 74.4±31.8 0.933 1.0 
Laminin subunit beta-1 F1SAE9_PIG 199 246.4±69.2 265.6±65.1 0.604 1.1 
Laminin subunit beta-2 F1SPT5_PIG 179 39.4±46.5 39.7±31.1 0.987 1.0 
Laminin subunit gamma-1 F1S663_PIG 177 406.9±140.2 440.3±100.8 0.619 1.1 
Latent TGFβ-binding protein 1 F1S405_PIG 148 28.3±9.3 19.5±6.9 0.068 0.7 
Latent TGFβ-binding protein 2 F1S2T5_PIG 196 174.6±79.5 198.0±58.4 0.544 1.1 
Latent TGFβ-binding protein 4 LTBP4_PIG 112 38.5±26.7 35.6±14.9 0.811 0.9 
Leukocyte elastase inhibitor  ILEU_PIG 43 27.5±31.0 7.0±5.3 0.134 0.3 
Lumican F1SQ09_PIG 39 490.7±128.7 145.1±44.0 0.000 0.3 
Lysyl oxidase homolog 1 F1SIC9_PIG 65 68.5±29.0 63.0±19.0 0.687 0.9 
Macrophage capping protein F1SVB0_PIG 39 109.4±87.6 62.1±38.0 0.226 0.6 
Matrilin-4* F1SDQ7_PIG 69 0.5±1.2 0.7±1.9 n/a 1.5 
Matrix Gla protein  MGP_PIG 12 27.1±5.8 61.9±31.1 0.025 2.3 
Matrix-remodeling-associated  
protein 5 F1RZ07_PIG 308 47.9±48.7 13.7±8.9 0.114 0.3 
Metalloproteinase inhibitor 1* TIMP1_PIG 23 0.4±0.9 0.0±0.0 n/a 0.0 
Mimecan I3L9T6_PIG 25 108.2±29.8 96.8±26.8 0.467 0.9 
Myeloperoxidase K7GRV6_PIG 84 4.5±8.1 0.0±0.0 n/a 0.0 
Nidogen-1  NID1_PIG 50 29.1±17.4 76.6±35.8 0.012 2.6 
Nidogen-2 F1SFF3_PIG 152 948.4±283.4 713.1±127.3 0.079 0.8 
Osteoclast-stimulating factor 1* OSTF1_PIG 24 13.8±11.9 6.3±5.4 0.166 0.5 
Papilin F1S3J7_PIG 141 0.1±0.2 0.7±1.8 n/a 9.3 
Peptidyl-prolyl cis-trans isomerase 
A  PPIA_PIG 18 732.6±221.5 646.6±224.5 0.484 0.9 
Periostin F1RS37_PIG 93 2380.0±652.6 1489.0±573.9 0.019 0.6 
Perlecan PGBM_PIG 365 3168.6±652.1 3467.1±535.4 0.368 1.1 
Peroxidasin homolog I3LDA4_PIG 164 13.3±8.3 31.7±10.6 0.004 2.4 
Pigment epithelium-derived factor  Q0PM28_PIG 46 264.7±46.4 314.9±70.6 0.146 1.2 
Plasma glutamate 
carboxypeptidase* PGCP_PIG 52 2.3±3.2 1.3±1.7 n/a 0.6 
Plasminogen  PLMN_PIG 91 272.3±106.8 514.1±199.6 0.019 1.9 
Podocan I3LEB7_PIG 72 60.1±38.7 23.4±10.0 0.047 0.4 
Procollagen C-endopeptidase 
enhancer 1 I3LEE6_PIG 50 40.2±10.6 41.9±11.6 0.778 1.0 
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Prolargin F1S6B4_PIG 43 451.1±102.9 351.1±138.2 0.153 0.8 
Prolow-density lipoprotein 
receptor-related protein 1  K9IVL7_PIG 505 30.4±26.2 20.5±7.4 0.372 0.7 
Properdin K7GQR1_PIG 51 57.9±29.3 117.1±61.8 0.049 2.0 
Prophenin and tritrpticin  PF11_PIG 24 230.0±297.6 7.5±8.9 0.095 0.0 
Proteoglycan 4 I3L5Z3_PIG 149 0.9±1.5 0.0±0.0 n/a 0.0 
Reticulon-3* RTN3_PIG 105 0.0±0.0 0.6±1.5 n/a n/a 
RPE-spondin RPESP_PIG 32 1.1±3.0 1.9±3.3 n/a 1.6 
Secreted frizzled-related protein 1 I3LB66_PIG 35 12.1±6.0 9.2±6.4 0.400 0.8 
Secreted frizzled-related protein 
3* F1RYL4_PIG 36 3.3±3.6 2.5±1.1 0.591 0.8 
Secreted phosphoprotein 24*  SPP24_PIG 23 0.0±0.0 12.4±9.1 n/a n/a 
Serine protease HTRA1 F1SEH4_PIG 56 138.2±102.9 348.3±183.4 0.026 2.5 
Serotransferrin  TRFE_PIG 77 3167.4±2227.2 1765.1±729.6 0.156 0.6 
Serum amyloid P-component  SAMP_PIG 26 3.2±6.3 14.2±14.9 n/a 4.4 
SPARC  SPRC_PIG 34 128.6±37.6 154.1±75.8 0.448 1.2 
Spondin-1 SPON1_PIG 66 5.7±4.8 0.7±1.0 0.033 0.1 
Sulfhydryl oxidase  F1S682_PIG 81 19.2±11.1 11.8±6.2 0.154 0.6 
Superoxide dismutase [Cu-Zn]  Q007T6_PIG 26 236.2±133.9 155.7±49.9 0.176 0.7 
T-cadherin* A8D737_PIG 78 22.0±12.0 13.9±6.9 0.153 0.6 
Tenascin  TENA_PIG 191 861.4±309.9 1192.9±318.3 0.072 1.4 
Tetranectin F1SRC8_PIG 22 156.6±34.1 171.5±75.3 0.644 1.1 
TGFβ-induced protein ig-h3  BGH3_PIG 74 64.8±20.5 55.1±13.0 0.317 0.9 
Thrombospondin-1 K7GPJ3_PIG 120 344.4±124.1 565.3±195.2 0.030 1.6 
Thrombospondin-4* F1RF28_PIG 104 8.9±7.9 33.3±26.4 0.051 3.7 
Translationally-controlled tumor 
protein* TCTP_PIG 20 50.9±23.5 49.1±19.5 0.874 1.0 
Tryptase  TRYT_PIG 30 0.1±0.3 0.0±0.0 n/a 0.0 
Tubulointerstitial nephritis antigen-
like F1SVA2_PIG 52 98.8±33.3 128.6±24.4 0.083 1.3 
Versican F1REZ2_PIG 369 1073.4±242.9 797.6±234.6 0.052 0.7 
Vitamin D-binding protein I3LN42_PIG 53 143.0±62.4 106.4±38.1 0.215 0.7 
Vitronectin  VTNC_PIG 53 419.9±72.3 1038.1±338.7 0.003 2.5 
von Willebrand factor A domain-
containing protein 1 F1RJE3_PIG 44 8.3±6.4 10.0±7.6 0.660 1.2 
WD repeat-containing protein 1  K9IVR7_PIG 66 288.7±36.1 297.6±112.3 0.848 1.0 
P values for differential expression between neointimal DES and BMS are based on unpaired Student’s 
t-tests with unequal variance (n=7 [BMS] and n=7 [DES]). T-test was not performed if a protein was 
undetectable in the majority of samples from 1 of the 2 groups compared. n/a denotes not applicable, 
FC denotes fold change. Proteins only identified in the neointima are marked with*. Results in bold 




Supplemental table 3. Significant extracellular protein changes between BMS/DES 
day 28 vs. POBA late 
 
   MW  BMS/POBA DES/POBA 
Identified Proteins  UniProt ID  (kDa) P FC  P FC 
RPE-spondin RPESP_PIG 32 0.006 0.2 <0.001 0.3 
Laminin subunit gamma-1  F1S663_PIG 177 0.562 0.9 <0.001 0.3 
Galectin-3 A3EX84_PIG 27 0.395 23.4 0.002 6.8 
Collagen alpha-1 (XI)  F1S571_PIG 159 0.272 1.8 0.002 3.4 
Periostin F1RS37_PIG 93 0.394 6.1 0.002 11.9 
Biglycan  K7GP55_PIG 41 0.167 1.5 0.004 2.0 
Collagen alpha-1 (V)  F1S021_PIG 182 0.267 1.8 0.006 2.6 
Latent-TGFß-binding protein 2  F1S2T5_PIG 196 0.833 1.2 0.006 3.9 
Collagen alpha-1 (XVIII) COIA1_PIG 62 0.027 0.6 0.007 0.2 
Collagen alpha-1 (I) CO1A1_PIG 100 0.584 1.3 0.007 1.9 
Apolipoprotein H  I3LGN5_PIG 29 0.463 1.5 0.008 3.1 
Dermatopontin  DERM_PIG 22 0.328 1.7 0.008 2.0 
Collagen alpha-2 (I)  F1SFA7_PIG 129 0.639 1.2 0.010 2.0 
Laminin subunit beta-1  F1SAE9_PIG 199 0.197 1.2 0.013 0.3 
Fibronectin  F1SS24_PIG 272 0.243 1.6 0.014 2.9 
Aggrecan  F1SKR0_PIG 238 0.250 1.6 0.017 3.0 
Collagen alpha-1 (II)  I3LSV6_PIG 130 0.961 1.0 0.018 1.7 
Annexin A1  ANXA1_PIG 39 0.364 4.0 0.022 7.4 
Collagen alpha-2 (XI) A5D9K7_PIG 162 0.436 1.5 0.024 2.1 
Collagen alpha-1 (XII) COCA1_PIG 229 0.284 13.7 0.026 15.7 
Collagen alpha-1 (VIII)  F1SKX7_PIG 73 0.301 2.6 0.028 15.3 
Tetranectin  F1SRC8_PIG 22 0.118 1.7 0.036 4.9 
Gelsolin GELS_PIG 85 0.267 0.7 0.036 0.6 
Agrin  I3LGD9_PIG 216 0.693 0.9 0.040 0.6 
Nidogen-2  F1SFF3_PIG 152 0.687 0.9 0.042 0.5 
Galectin-1  LEG1_PIG 15 0.080 0.7 0.042 0.6 
Dystroglycan  I3LD20_PIG 95 0.046 0.3 0.043 0.4 
Podocan  I3LEB7_PIG 72 0.502 0.8 0.049 0.3 
Lactadherin  MFGM_PIG 46 0.498 1.6 0.050 0.5 
Throbospondin-1 K7GPJ3_PIG 120 0.031 6.5 0.090 14.8 
SPARC  SPRC_PIG 34 0.033 0.3 0.144 1.5 
P values and FC for changes between BMS/DES day 28 and POBA late are shown. P values are based 
on unpaired Student’s t-tests with unequal variance (n=3 [BMS day 28]/ n=3 [DES day 28], n=3 [POBA 
late]). T-test was not performed if a protein was undetectable in the majority of samples from 1 of the 2 




Supplemental table 4. Differentially expressed proteins between DES and BMS over time 
 
  
MW Day1 Day3  Day7 Day28  
Identified Proteins UniProt ID  (kDa) P FC P FC P FC P FC 
Collagen alpha-2 (IV)  F1RLL9_PIG 161 0.362 0.6 0.338 0.6 0.707 1.2 <0.001 0.3 
Laminin subunit beta-1  F1SAE9_PIG 199 0.432 0.6 0.975 1.0 0.639 0.7 0.001 0.2 
Laminin subunit gamma-1  F1S663_PIG 177 0.741 0.9 0.440 1.1 0.753 1.1 0.011 0.3 
SPARC  SPRC_PIG 34 n/a 1.3 0.036 0.1 0.802 0.9 0.014 5.6 
Hyaluronan and proteoglycan link protein 1  HPLN1_PIG 40 0.427 1.7 0.043 2.8 0.419 1.5 0.019 0.3 
Collagen alpha-1 (XVIII) COIA1_PIG 62 0.540 0.8 0.921 1.0 0.788 1.1 0.020 0.2 
Latent-TGFß-binding protein 2  F1S2T5_PIG 196 0.952 1.0 0.753 0.8 0.003 1.9 0.026 3.3 
Collagen alpha-1 (VIII)  F1SKX7_PIG 73 n/a 0.6 n/a 2.0 0.645 1.2 0.029 5.9 
Laminin subunit beta-2  F1SPT5_PIG 179 0.364 0.7 0.201 1.4 0.728 1.2 0.038 0.5 
Tubulointerstitial nephritis antigen-like  F1SVA2_PIG 52 0.326 0.9 0.686 1.2 0.125 1.3 0.038 0.7 
Aggrecan  F1SKR0_PIG 238 0.523 0.8 0.263 4.1 0.971 1.0 0.044 1.9 
TGFß-induced protein ig-h3  BGH3_PIG 74 0.045 0.5 0.950 1.0 0.368 2.4 0.206 0.3 
Prophenin and tritrpticin  PF11_PIG 24 0.388 1.5 0.199 11.1 0.010 4.6 0.467 0.1 
Collagen alpha-1 (XII) COCA1_PIG 229 0.045 0.8 0.849 1.1 0.810 0.8 0.846 1.1 
Vitronectin  VTNC_PIG 53 0.578 0.7 0.019 2.9 0.440 1.6 0.947 0.9 
P values between DES and BMS at each time point are based on unpaired t-tests with unequal variance (n=3 [BMS day 1/3/7/28], n=3 [DES 1/3/7/28]). T-test was not 
performed if a protein was undetectable in the majority of samples from 1 of the 2 groups compared. Only proteins with at least one significant result at any time point 
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